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The current public health strategy for the containment of influenza is annual 
vaccination. However, due to a lack of efficacy of current influenza vaccines in some 
populations, research is needed on improving the immune response to vaccination 
with the use of adjuvants. This thesis describes investigations of the adjuvant effect 
of two nanoparticle systems for influenza subunit vaccine: cationic liposomes and 
peptide-based nanoparticles. 
1.1. Influenza virus and flu 
Seasonal outbreaks of influenza infections (also known as “seasonal flu”) are 
caused by influenza viruses. Although influenza can affect people of all ages, 
hospitalization and death are more frequent in the elderly and in populations with 
chronic diseases or immune-deficiency. Thereby influenza viruses are a substantial 
cause of morbidity and mortality worldwide each year, with three to five million 
cases of annual hospitalization and up to 500,000 annual deaths worldwide [1] [2] 
[3]. 
In temperate climates, influenza exhibits a seasonal pattern with a peak activity 
during the winter months (December through March), which is less apparent in 
tropical countries. The virus is stable at low humidity and at low temperatures, 
conditions that favor its transmission, and it grows in respiratory secretions [4]. 
The virus belongs to the Orthomyxoviridae family (single-stranded RNA viruses). 
The viral core consists of eight single stranded RNA segments, and nucleoproteins 
(PB1, PB2, PA, NP) surrounded by a capsid composed of the M1 protein. This core is 
enveloped by an outer lipid membrane in which several viral glycoproteins are 
inserted: hemagglutinin (HA), neuraminidase (NA) and matrix proteins (M) (Fig. 
1).2. The virus is roughly spherical, with a size between 80 to 120 nm. The different 
influenza virus types (A, B, and C) are characterized by important antigenic 
differences [5] [6]. 
HA is the major influenza envelope glycoprotein. This trimeric protein forms 
spikes at the virus surface and facilitates viral entry and exit from human 
respiratory epithelial cells. More precisely, HA is responsible for the attachment of 
the virus to sialic acid-containing proteins on the host cell surface, the fusion with 
the endosomal membranes and the release of viral RNA into the cytoplasm. NA also 
plays a strong role in viral proliferation, as its enzymatic activity results in cleavage 
of the sialic acid residues on the host cell surface to facilitate release and spread of 
newly formed virus particles [7]. 
Sixteen HA and nine NA subtypes have been identified in influenza A, which helps 
to characterize the circulating viruses and the causes of human infections. Most 
seasonal local outbreaks in humans are caused by influenza A and B, and H1-3 and 






Fig. 1: Schematic representation of the structure of influenza A virus with viral proteins. 
 
These viral proteins are recognized as foreign by a host's immune system, thus 
eliciting an immune response. However, each of these viruses undergoes antigenic 
modifications through the accumulation of point mutations in the surface proteins, 
allowing the virus to escape from the host’s existing immunity. This phenomenon is 
referred to as antigenic drift [8]. This mechanism allows the influenza viruses to 
evade from adaptive immune responses, which consequently results in reduced 
clearing of the virus and virus-infected cells, and more severe infection. It is the 
main cause of the yearly seasonal influenza outbreaks. 
In addition, a second mechanism of variation, known as antigenic shift [9], is less 
frequent but more dramatic and can occur either through cross-species 
transmission (e.g., poultry to humans) or by mixing of viral genes when there is 
simultaneous infection by more than one strain of influenza in a single human or 
nonhuman host. This is the main origin of influenza pandemics and cause of 
important morbidity and mortality among persons of all ages worldwide. 
 
1.2. Immune response against influenza virus 
The understanding of immunity induced by seasonal influenza viruses, not only 
helps to define the needs for a better protection against an influenza infection, but 
also the requirements for more potent vaccines. The immune system can be divided 
into innate and acquired parts. The innate immune system can be described as the 
non-specific and rapid response to infection but the results are short lived and non-
protective against future infection. In contrast, the acquired immune system is 






1.2.1. Innate immune response 
The targets for influenza virus are the epithelial cells from the respiratory tract. 
Therefore, the primary line of defense is formed by the physical barrier (mucus, 
epithelium) and the innate cellular immune response. 
The presence of influenza viruses is sensed by receptors of the innate immune 
system through recognition of pathogen-associated molecular patterns (PAMPs) of 
influenza A viruses by pattern-recognition receptors (PRRs) that initiate antiviral 
signaling cascades, resulting in the production of interferons, cytokines and 
chemokines. The PRRs involved in the recognition of influenza viruses are toll like 
receptors (TLRs), retinoic acid inducible gene-I (RIG-I) and the nucleotide 
oligomerization domain (NOD)-like receptor family pyrin domain containing 3 
(NLRP3) protein. The TLR ligands that recognize the influenza virus are: TLR7, an 
intracellular receptor which binds single-stranded viral RNA; TLR3, another 
intracellular receptor that recognizes double stranded viral RNA; and TLR2 & TLR4, 
which are able to recognize viral surface glycoproteins and lipoproteins. The 
activation of these receptors induces the production of proinflammatory cytokines 
and type I interferons.  
Innate immune cells such as alveolar macrophages and monocytes are attracted 
by the infected cells. They enhance the pro-inflammatory response and also play a 
direct role in the phagocytosis of apoptotic infected cells and opsonized viral 
particles. Furthermore, the dendritic cells (DCs), which are professional antigen-
presenting cells, are a link between the innate and the adaptive immune system. 
They initiate an adaptive immune response after infection by presenting viral 
antigens to B and T lymphocytes. In case of influenza infection, DCs can be infected 
either directly or by phagocytosis of viral particles or apoptotic infected cells. Viral 
proteins can be processed intracellularly and the derived peptides can then be 
presented to CD8+ T-cells or CD4+ T cells by MHC I or MHC II complexes, 
respectively. Moreover, type I interferons stimulate the DCs and enhance the antigen 
presentation to CD4+ and CD8+ T cells. 
 
1.2.2. Adaptive immune response 
The adaptive immune response against influenza is based on virus specific 
antibodies produced by B cells (humoral response) and virus specific CD4+ and 
CD8+ T cells (cellular response). This response is faster and stronger after the 
second encounter with the same pathogen, and contributes to the clearance of the 








1.2.2.1. Humoral response 
Following an influenza virus infection, specific antibodies against the two surface 
glycoproteins HA and NA are produced by the host, which enable virus 
neutralization. The HA-specific antibodies inhibit virus attachment and entry into 
the host cell; and antibodies against NA have protective potential as they limit 
spreading of the virus. However, most antibodies directed against HA are influenza 
virus strain-specific and fail to neutralize intrasubtypic drift variants and viruses of 
other subtypes [9], due to the high variability of the HA globular head. Antibodies 
are also induced against other viral proteins, such as the highly conserved NP, which 
could potentially contribute to heterosubtypic immunity [10]. 
 
1.2.2.2. Cellular response 
DCs degrade viral proteins and the derived peptides are presented on their 
surface by MHC class I or class II molecules. For MHC class II presentation, viral 
proteins are degraded in endosomes/lysosomes and the resulting peptides associate 
with MHC class II molecules. These complexes are then transported to the cell 
membrane for recognition by CD4+ T helper (Th) cells. For class I presentation, the 
influenza virus-derived peptides are liberated in the cytosol and transported to the 
endoplasmic reticulum where they associate with MHC class I molecules. Then the 
complexes are transported to the cell membrane for recognition by specific CD8+ T 
cells (CTLs).  
Some CD4+ T cells display cytolytic activity to infected cells [11]. However, the 
most important phenotype of these cells is that of T helper (Th) cells. Different 
subsets of Th cells are distinguished based on their cytokine expression profiles. Th2 
cells produce interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) and 
stimulate B cells, resulting in antibody secretion (predominantly IgG1 subtype in 
mice). Besides, Th1 cells produce interferon gamma (IFN-γ) and interleukin 2 (IL-2), 
are involved mainly in promoting cellular immune responses (CTL), and are 
essential for memory CD8+ T cells. In addition, the production of IgG2a/c antibodies 
in mice is dependent on the presence of IFN-γ. Therefore, higher IgG2a/c or IgG1 
antibody secretion suggests the induction of Th1 or Th2 response, respectively. 
After activation of the CD8+ T cells in the draining lymph nodes and 
differentiation into CTLs, they migrate to the site of infection where they recognize 
and eliminate influenza infected cells. However, little is known about the specific 
role played by CTLs response in protection of human individuals against influenza 
infection. 
1.3. Influenza vaccines 
The aim of a flu vaccine is to induce an immune response similar to that after a 




elicit a strong immune memory response to protect the host upon future infection 
[12]. As mentioned above, the circulating influenza viruses undergo antigenic drift 
through the accumulation of point mutations in the surface proteins, allowing the 
virus to escape from the host’s existing immunity. Thereby, the seasonal influenza 
vaccine requires yearly modification, based on a mix of the three most current 
influenza strains (mostly: two viruses type A, and one virus type B). 
1.3.1. Inactivated influenza vaccines 
The different kinds of parenteral seasonal flu vaccines are: whole inactivated 
virus (WIV) vaccines, split virus vaccines, and subunit vaccines. WIV vaccines were 
first developed in the 1940s, consisting of beta-propiolactone inactivated whole 
virus particles. However, the use of these vaccines caused some adverse effects 
(particularly among children), such as local reactions at the site of injection and 
febrile illness [13]. In the 1970s, WIV vaccines were replaced by split vaccines. The 
production of split vaccines is similar to that of WIV vaccines, but is followed by the 
addition of detergent (such as Triton X-100) to extract proteins from the lipid 
membrane. Compared to WIV vaccines, split vaccines are claimed to be less 
reactogenic. Finally, subunit vaccines are prepared similarly to split vaccines, but 
include an extensive purification step, resulted in products containing relatively 
pure HA with small amounts of NA, but lacking most of the viral RNA. Therefore, 
subunit vaccines are considered safer and are therefore preferred over WIV and 
split vaccines.  
The effectiveness of current inactivated influenza virus vaccines can be 
determined by means of protection, which corresponds to the percentage reduction 
in influenza infection frequency among people vaccinated compared with the 
frequency among those who are not vaccinated. The target groups for annual 
vaccination include: people over the age of 50, pregnant women, immunodeficient 
patients, patients with chronic pulmonary or cardio-vascular diseases, residents of 
long-term care facilities, and health care personnel [14]. The results show that 70–
90% of vaccinated healthy young adults attain protection against the virus-specific 
illness. However, the protection rate is lower among the elderly, with 30–60% 
protection [15]. This difference in efficacy has been related to the senescence of the 
immune system and reduced production of protecting antibodies and cytotoxic 
lymphocytes in response to vaccination in elderly people [16]. Vaccines are not fully 
protective, but even being imperfect they still prevent substantial morbidity and 
mortality worldwide. Subunit vaccines are based on purified protein antigens, which 
implies a loss of (1) other viral molecules which would have typically alerted the 
host to the dangerous nature of the pathogen and (2) particulate nature. These 
features appear to be a major drawback of subunit vaccines, as they are too ‘clean’ 
and do not resemble pathogens sufficiently to elicit an adequate immune response 
by themselves [17]. However, the use of adjuvants, i.e., components or delivery 




against the antigen(s), can raise the vaccination efficacy (as described in more detail 
in section 1.3.3.) 
 
1.3.2. Induction of protective immunity with influenza vaccine 
Typical assays used to measure vaccine responses against influenza antigens 
include hemagglutination inhibition (HI) and microneutralization (MN) assays, 
tested in vitro with red blood cells (RBCs) and live viruses, respectively. These 
standardized tests are easy to perform and provide a quantitative measure of 
antibodies based on their ability to neutralize viral particles [18].  
However, protective immunity against influenza has been described to occur in 
influenza vaccine trials in the absence of measurable neutralizing antibodies [19] 
[20]. This indicates an important contribution of cellular responses to protection 
against influenza, which has also become apparent in preclinical studies. For 
instance, BALB/c mice typically respond to inactivated influenza vaccines and 
subunit vaccines with a Th2-type immune response, which is associated with the 
stimulation of IgG1 antibodies [21]. However, the major antibody isotype present in 
the sera of mice that survive viral infections is IgG2a [22], which is stimulated 
during Th1-type immune responses [21].  
One of the explanations could be that the antibodies have the potency to interact 
with Fc receptors, located on NK cells and macrophages. When such antibodies are 
bound to HA expressed on infected cells, they mediate cell lysis. This process is 
known as antibody-dependent cell cytotoxicity (ADCC) [23]. However, the ability to 
contribute to the influenza virus clearance [23] is different between the IgG isotypes 
[24]. IgG2a antibodies demonstrate more efficient protection in mice than IgG1 
antibodies, whereas the IgG1 isotype is preferentially induced in humans during 
natural infection [25]. 
 
1.3.3. Adjuvanted influenza vaccines 
Adjuvants can be used to improve the immune response to subunit influenza 
vaccines in many different ways. They can be used to enhance the speed and 
duration of the immune response; they can enhance immune responses in 
individuals with immature or senescent immune systems; they can decrease the 
dose of antigen and reduce vaccine costs; or they can help overcome antigen 
competition in combination vaccines [26]. The effect of an adjuvant addition to a 
subunit influenza vaccine can lead to stronger hemagglutination inhibition (HI) and 
microneutralization titers, which theoretically should allow a better protection of 
the vaccinee compared to an individual vaccinated with a non-adjuvanted vaccine. 
Adjuvants mechanisms are diverse and not fully understood. They differ from 




induce a “danger signal” [27] [28]. It results in localized tissue damage, and cells will 
be ruptured releasing their intracellular contents (such as uric acid, heat shock 
proteins), which are termed ‘alarmins’ [29]. Other adjuvants such as TLR ligands 
(e.g., lipopolysaccharide [LPS], dsRNA CpG motifs and bacterial lipoproteins [30] 
[31]) can bind to PRRs and be recognized by the innate immune system as PAMPs, 
which can directly activate the DCs. This will result in co-presentation by the 
antigen-presenting cells (APCs) of the antigenic peptide with a co-stimulatory 
molecule such as CD80 and CD86, which is important for successful T cell activation 
[32]. Furthermore, immunostimulatory adjuvants such as saponins and ISCOMS can 
activate T cells independent of TLR activation [33]. 
Other mechanisms are linked to the action of the adjuvant itself. Firstly, colloidal 
adjuvants can be used to ‘carry’ antigen (e.g., through entrapment or adsorption); 
secondly, many of them are based on particulate structures with a size comparable 
to pathogens, which enable endocytosis by immune cells. Intracellular delivery of 
the antigen can also be promoted by the adjuvant composition or its surface charge. 
Moreover, particulate adjuvants enable protection of the antigen against enzymatic 
destruction and physiological clearance, can be maintained at the injection site for 
longer periods, and allow extended antigen presentation to APCs (“depot effect”). 
However, all these effects are dependent on numerous factors such as the route of 
administration, the antigen, the characteristics of the formulation itself (such as 
particle size, zeta potential, antigen loading). Only few adjuvants are licensed for use 
in humans and inclusion in commercial flu vaccines.  
 
1.3.3.1. Aluminum salts 
Aluminum salts were the first licensed adjuvants. They include, amongst others, 
aluminum hydroxide, aluminum phosphate and aluminum potassium sulfate. They 
have an accepted safety profile in humans for almost one century [34]. Their 
adjuvanticity was initially attributed to prolonged retention of antigen at the 
injection site. More recent research resulted in a better understanding of the 
mechanism [35]. The cellular uptake of aluminum salts (or of uric acid produced 
from necrotic cells in response to the salts) leads to lysosomal disruption and 
activation of the NLRP3 inflammasome. The rapid inflammatory mediator release 
recruits innate cells to the site, including eosinophils secreting IL-4 and monocytes 
that differentiate into DCs. The IL-4 environment of CD4+ T cell activation is 
expected to produce a Th2-type response. 
Some studies have shown that one-dose seasonal WIV H1N1 and H3N2 vaccines 
adjuvanted with aluminum phosphate induced relevant HI titers in eldery and adult 
populations (at two dosages: 6 and 15 µg). However, no comparison with non-
adjuvanted vaccine was performed in this trial [36,37]. In fact, the addition of 
aluminum salts to split or subunit influenza vaccines has induced only marginal 
improvements and other, more potent adjuvants are required for these vaccines 




attributed to either partial denaturation of epitopes due to adsorption to aluminum 
salts [40] or conformational changes [41]. 
 
1.3.3.2. Oil-in-water emulsions 
The MF59 adjuvant was originally approved for inclusion in a licensed influenza 
vaccine to be used in the elderly in Europe in 1997. The Novartis MF59 adjuvanted 
seasonal influenza vaccine (Fluad) is now licensed in more than 20 countries 
worldwide and more than 85 million doses have been administered. This oil-in-
water (o/w) emulsion is composed of 5 % squalene (a naturally occurring oil) 
combined with the surfactants sorbitan trioleate (Span 85) and 
polyoxyethylenesorbitan monooleate (Tween 80). The adjuvant mechanism 
attributed to the emulsion is its ability to improve cell recruitment to the site of 
injection and to trigger the production of chemokines by cells at the site of injection 
[42] [43]. Clinical trials showed that MF59-adjuvanted vaccine is well-tolerated and 
has an efficacy of 86% against influenza infection, compared to 43% efficacy for 
unadjuvanted vaccine [44,45]. Several other o/w emulsion-based adjuvants are now 
available, such as AS03 (Glaxo SmithKline Biologicals), which is used in a pandemic 
influenza vaccine, Pandemrix [46].  
However, despite the efficacy of emulsions to raise the immunogenicity of 
influenza vaccines, they still lack the ability to modulate the immune response 
toward a strong T cell response. The availability of several immune modulators and 
the potential association of those with vaccine delivery systems (such as 
nanoparticles) offer many attractive opportunities in terms of new influenza 
adjuvanted vaccines. 
1.4. Nanoparticulate antigen delivery systems 
Antigen delivery systems have proved their ability to enhance the immune 
response against many subunit vaccines. They present the advantage of enabling 
easy change in their composition and physicochemical characteristics. 
Virosomes are a good example of an efficient nanoparticulate adjuvant system for 
influenza vaccines. They consist of reconstituted virus-like particles, including the 
virus envelope and surface antigens (HA and NA) mixed with phospholipids, but lack 
the genetic material of the virus. Virosomes are approved by regulatory authorities 
for human vaccines and several products are licensed such as Isiflu ® (Johnson & 
Johnson). Virosomal influenza vaccines were found to be efficient in the elderly and 
in healthy, chronically ill, and immune compromised adults [47]. However, the 
immune response induced by virosomal vaccines was reported in several studies as 
inferior to that raised by other licensed adjuvanted influenza vaccines [48] [49], 
which illustrates the current need for new adjuvant systems.  
There are numerous lipids and polymer based nanoparticulate delivery systems 




entrapped or surface-associated depending on the physicochemical properties of 
each component. For antigens such as HA, localized in the outer membrane of 
influenza virus, the most straight forward delivery systems consist of a 
nanoparticulate delivery system that can be mixed with the antigen(s). Following 
this approach, the work described in this thesis explored two types of nanoarticulate 
delivery systems: liposomes and polymer-peptide block copolymer nanoparticles. 
 
1.4.1. Liposomes 
Liposomes are artificial vesicles, with particle sizes ranging between 30 nm to 
several microns. They can incorporate hydrophilic drugs in the aqueous 
compartment(s), hydrophobic drugs in the lipid bilayer(s), or amphiphilic 
compounds that partition between both phases. The composition of the lipid bilayer 
consists of (natural or synthetic) phospholipids and cholesterol, and can be 
manipulated to influence the physicochemical characteristics of the liposomes (e.g., 
size, bilayer rigidity, surface charge, pH sensitivity) [50] [51].  
Liposomes are often composed of lipids that occur naturally in cell membranes, 
such as phosphatidyl choline (PC) and cholesterol; these formulations are 
completely biodegradable. A number of parenterally administered liposomal 
products were approved by the FDA for use in humans, such as DoxiI® (Johnson & 
Johnson, USA) and AmBisome® (Gilead Sciences, USA). Besides, there are numerous 
liposomal vaccine formulations which are currently in clinical trials (Table 1). The 
immune response generated by liposomal vaccines can be further enhanced by 
incorporation of immune modulators and/or targeting moieties in the liposomes. 
 
Table 1: Selected liposome and lipid-based vaccines in clinical trials. Adapted from Watson et al. [52] 










Phase 3 [53-55] 
AS01a 
(GSK) Malaria 
Recombinant fusion of P. 
falciparum 
circumsporozoite protein and 
Hepatitis 
B surface antigen 
MPL, QS21PC, 
Chol Phase 3 [56,57] 
Vaxisome 












Tuberculosis protein antigen Ag85B-ESAT DDA, TDB Phase 1 [61] 
 
The adjuvant effect of liposomes is highly dependent on their physicochemical 
properties. In particular, the surface charge has a major influence on the adjuvant 
effect. Cationic liposomes have proved to be superior adjuvants compared to neutral 




liposomes has been attributed to several mechanisms: i) nonspecific cell damage 
(inducing inflammation) at the site of injection, ii) electrostatic interaction between 
the cationic liposomes and negatively charged groups on the surface of APCs, iii) 
formation of an antigen depot at the injection site, and iv) activation of DCs [32] 
[62]. Liposome characteristics influence the antigen’s immunogenicity, which can be 
easily customized, e.g., through the preparation method, the composition, and the 
co-encapsulation of immune modulators. A high density of positive charges at the 
cell surface is likely to be recognized as a signal of danger for cells and/or 
contributes to activation of cascades that are classically activated by endogenous 
cationic compounds [63]. 
 
1.4.2. Polymer-peptide block copolymer nanoparticles 
Polymer-peptide block copolymer nanoparticles are formed from high-
molecular-weight amphiphilic block copolymers composed of distinct hydrophilic 
and hydrophobic blocks. Carefully choosing the polymer architecture and chemistry 
yields a broad and tunable range of carriers, with control over its self-assembly into 
different defined structures like micelles, vesicles (polymersomes), and 
nanoparticles. Peptide copolymer nanoparticles are of particular interest as there is 
a profusion of choice regarding block composition and length, and consequently a 
large variety of particle properties. Furthermore, some studies have found several 
potential applications in drug delivery and vaccine research, as self-assembled 
peptides have been shown to be able to enhance immune responses by acting as an 




Fig. 2: (A) Molecular structure of the poly(γ-benzyl L-glutamate)-E (in black) and peptide “K” (in red); 





In this thesis a new class of polypeptide-b-designed peptides will be tested, 
consisting of a hydrophobic poly(γ-benzyl l-glutamate) (PBLG) block conjugated to a 
hydrophilic peptide block with an exact amino acid sequence. The PBLG block 
adopts a well-defined rod-like α-helical secondary structure, while the hydrophilic 
peptide block has been designed to form a coiled-coil motif  with its complementary 
peptide partner. In this study the well-studied heterodimeric coiled-coil peptide pair 
E/K was used (Fig. 2) [66].  
 
The synthesis and the self-assembly abilities of this class of amphiphilic peptides 
has been described in previous studies [67] [68]. These peptides were applied to 
create versatile systems, based on the hydrophobic polypeptide PBLG blocks and the 
functionality of the designed hydrophilic peptide. Specifically, the different PBLG 
block lengths could be connected non-covalently with various hydrophilic blocks via 
the specific coiled coil interactions of peptide “E” with peptide “K” [69]. The size, 
morphology, and surface functionality of the peptide-based nanoparticles can be 
tailored by combining different building blocks (Fig. 3). Moreover the coiled-coil 
liaison is non-covalent, highly specific and potentially reversible and allows the 
functionalization of the peptide polymer nanovesicle’s surface with poly(ethylene 
glycol) (PEG) molecules [66]. 
 
 
Fig. 3: Cryo-TEM images of PBLG36-E and PBLG36-E/K polymersomes [66]. 
 
 
1.4.3. Nanoparticulate systems and immune modulators 
The encapsulation of TLR ligands in nanoparticle vaccine delivery systems can be 
an efficient strategy to increase the strength and modulate the quality of the 






with TLR ligands co-delivered with nanoparticulate systems (Table 2). Many of such 
studies have been conducted with cationic liposomes, e.g., to investigate the 
influence of their positive charge and the association with immune modulators on 
the immunogenicity of associated antigens. The insights obtained with these studies 
can also partially be applied to amphiphilic peptide nanoparticles. This will enable 
studies of their adjuvant effect and optimization thereof, in order to assess their 
potential use for future adjuvanted subunit vaccines. 
 
 
Table 2: Examples of inactivated influenza vaccines formulated with nanoparticulate delivery systems 
combined with TLR agonist. 
TLR ligand 




(μg / dose) 
Size 
(diameter) Exp. model  Response Ref. 







nm Balb/c mice 
 antibody titers, IFN-γ 
secretion [70,71] 
GLA (20 µg) 4 O/W emulsion (SE) 
Split 
(0.2 μg) 100 nm Balb/c mice 










split  H3N2 200 nm Balb/c mice 
 IFN-γ secretion and 
CTL responses [74] 
MPL (37.5 µg ) 








 antibody and 
T cell responses [75] 




- Balb/c mice  Th1 response 
 serum neutralization [76] 




Subunit 1.3–1.5 μm Balb/c mice   IFN-γ secretion [77] 
 
1.5. Aim and outline of this thesis 
1.5.1. Aim 
As detailed above there is a current lack of effective vaccines against flu, and a 
need for new adjuvanted vaccines, such as nanoparticulate adjuvanted vaccines. 
However, despite all the research on nanoparticulate adjuvant mechanisms, we still 
do not have a clear and complete understanding about how these systems can make 
the host mount a sufficiently strong immune response against an antigen to protect 
this host against seasonal influenza infection.  
The aim of this thesis is to gain a better insight into the role of the formulation of 
nanoparticulate adjuvants on the immunogenicity of subunit influenza vaccines. For 
this purpose, a monovalent subunit influenza vaccine (H3N2), which is one of the 
most common strains responsible for seasonal flu outbreaks, was used as a model. 
Two different approaches of nanoparticulate adjuvanted vaccines were investigated: 
polymer-peptide block copolymer nanoparticles and cationic liposomes.  
In the first track (chapters 2-4) the suitability of a new class of material, peptide-




nanoparticulate delivery systems and their efficacy as adjuvant. Focusing on the 
formulation, the major aim of this work was to investigate how these nanoparticles 
act as an adjuvant for subunit influenza vaccine. In the second track (chapters 5 & 6) 
cationic liposomes were studied in order to gain fundamental insight into the 
relationship between their physicochemical characteristics and immunogenicity. To 
this end, a range of formulations was screened to investigate the immunogenicity of 
these systems in mice. In particular, the effect of nanoparticle composition, surface 
charge, and encapsulation of immune modulators on the immune response against 
associated HA was studied. 
 
1.5.2. Outline of this thesis 
Chapter 2 introduces a new technique to produce polymersomes based on 
PBLG-E. A detergent removal technique that has been used for three decades to form 
liposomes is adapted to prepare PBLG-E polymersomes. This method will be 
particularly useful for incorporating antigens into the vesicles, as it is a benign 
process. 
In chapter 3, subunit influenza vaccine is formulated with PBLG50-K 
polymersomes to evaluate the feasibility of a polymersome adjuvanted subunit 
influenza vaccine. The polymersome formulations are physicochemically 
characterized and administered intramuscularly to mice to evaluate their 
immunogenicity.  
In an attempt to enhance the Th1 response induced with peptide polymer 
nanoparticles (NPs), in chapter 4 the synthesis of a new copolymer peptide is 
presented: PBLG-TAT. TAT peptide is known to be a cell-penetrating peptide. 
Moreover, a TLR ligand, CpG, is encapsulated in the new NP formulation and the NPs 
are associated with subunit influenza vaccine. The ability of the formulations to 
modulate the immune response is tested in vitro (with human dendritic cells [DCs]) 
and in vivo (with mice). 
The use of cationic liposomes is explored in chapter 5 & 6. To better understand 
the mechanisms of the adjuvanticity of cationic liposomes comparisons are made 
between: (1) formulations based on four different cationic compounds, DDA, eDPPC, 
DPTAP and DC-Chol (chapter 5); and (2) formulations based on 100% saturated 
lipids vs. lipids mixed with cholesterol in a 1:1 molar ratio (chapter 6). The 
formulations are physicochemically characterized and tested in vitro for their ability 
to enhance antigen uptake by DCs. Moreover, the immunogenicity of the 
formulations is tested in mice. 
Furthermore, the ability of cationic liposomes to modulate the quality of the 
immune response against HA is explored in chapter 6 by: (1) varying the HA 
antigen loading method and (2) the encapsulation of two different TLR ligands, 
imiquimod and CpG in the liposomes. The DC-stimulating properties of these 




responses after immunization of mice.  
The chapter 7 contains a summary of the work achieved in this thesis and 
discusses some perspectives for further research on nanoparticulate adjuvanted 
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Until now, most preparative methods used to form polymeric vesicles involve 
either organic cosolvents or sonication. In this communication, we demonstrate for 
the first time a detergent-aided method to produce polymersomes. Peptidic 
polymersomes were formed from the rod-rod block copolymer PBLG36-E, where 
PBLG is hydrophobic poly(γ-benzyl L-glutamate) and E is a hydrophilic designed 
peptide. The block copolymer was first solubilized by detergent micelles in aqueous 
buffer, after which the concentration of detergent was reduced by dilution, 
transforming the particle morphology in solution from mixed micelles to 
polymersomes. The polymersome formation was monitored with dynamic light 
scattering and confirmed with transmission electron microscopy. Polymersomes 
with average diameters of approximately 300 nm were obtained as well as discs 
with average diameters of approximately 100 nm. This detergent-based method can 
be used to create polymersomes with a range of properties, as verified by its 
application to another biocompatible block copolymer, the flexible polybutadiene46-
b-poly(ethylene glycol)30. The technique will be particularly useful when delicate 
biomacromolecules such as (membrane) proteins, peptides, or nucleic acids are to 
be encapsulated in the polymersomes because the detergents used are compatible 
with these compounds, and the possible denaturing effect of sonication or organic 
solvents on the biological activity of the molecule of interest is avoided. 
 
  




Polymersomes are structurally similar to viral capsids in many ways and are now 
being designed to perform in a similar way as viruses: to carry, protect, target, and 
release cargo.[1] Biological cargo, such as proteins, peptides, or nucleic acids, is 
becoming increasingly common, intended for biomedical activity in the body.[2] The 
advantage of polymersomes over the traditional nanocapsules, liposomes, is that 
their membranes are more stable, leading to an enhanced ability to carry and 
protect cargo. The targeting and release properties of polymersomes also have more 
potential to be tailored to the intended application than liposomes, owing to the 
wide range of block copolymers available.  
 
There are currently two classes of polymersome preparation: solvent free and 
with organic solvents.[3] In the first class, the block copolymer is hydrated to form 
polymersomes. Some block copolymers require no agitation during hydration, 
whereas others require stirring, vortexing, extrusion, electric current, or sonication. 
Other block copolymers are too hydrophobic to undergo controlled aggregation in 
aqueous solution and first need to be dissolved in an organic solvent, which is then 
mixed with/ exchanged for an aqueous solution. 
In the growing number of cases in which biomacromolecules, whose functions 
depend on intra- and intermolecular structures, are to be incorporated into the 
polymersome membrane or aqueous interior, organic solvents or high energy input 
(that is, sonication) cannot always be used because they would degrade the activity 
of the cargo. Therefore, a dilemma remains: for polymersomes that are intended to 
incorporate sensitive biomacromolecules but are unable to form vesicles directly in 
water or cannot be sonicated, there is currently no suitable method available. 
However, a third method for vesicle formation has been used for nearly 40 years to 
create liposomes: the detergent removal technique.[4] This has been the preferred 
preparation method for liposomes incorporating sensitive membrane proteins with 
preserved structure and function.[5-7] The first step of this method is to solubilize 
the water insoluble phospholipid that is going to constitute the liposomes in a 
detergent (water-soluble surfactant). Low-molecular-weight detergents typically 
have a large hydrophilic section in comparison with the hydrophobic section and 
form micellar structures with highly curved interfaces. Amphiphiles such as 
phospholipids and certain block copolymers have a larger hydrophobic component 
in comparison with the polar section and form lamellar assemblies, such as vesicles. 
When bilayer-forming phospholipids are solubilized by a large excess of high 
curvature detergent molecules above the critical micelle concentration (cmc) of the 
detergent, mixed micelles are formed composed of the detergent and the 
phospholipid. The detergent in the micelles is in equilibrium with the detergent 
monomers in the aqueous phase, with the exchange rate in the microsecond range 




aggregates is dramatically lower than that of the detergent, on the order of seconds 
to hours,[8-10] because of the poor solubility of the larger hydrophobic block in 
water. The second step is to alter conditions such that the morphology of the self-
assembled particles is no longer directed by the molecular properties of the 
detergent but rather by the phospholipid. The mixed micelles are slowly diluted 
below the cmc of the detergent by adding aqueous solution, and as the micellar-
monomer equilibrium is maintained, the amount of detergent in the micelles is 
reduced. As the proportion of bilayer-forming molecules in the mixed micelles 
increases, new, lower curvature structures evolve. With lipids, the departure from 
high curvature micelles passes through sheets, which near the cmc of the detergent 
close to eliminate exposure of the hydrophobic edge to water, culminating in 
vesicles.[11] 
 
Although certain phospolipids and block copolymers share molecular 
characteristics such that they each assemble into vesicles, their interaction 
parameters between the hydrophilic and hydrophobic components and the aqueous 
solvent are very different, which affects the self-assembly process.[8] In this article, 
we adapt the detergent removal method to block copolymers for the first time to 
create polymersomes. The polymer specific adaptations are explained, making this 
technique readily applicable to the creation of biomacromolecule-containing 




Fig. :. Molecular shape, amphiphilic nature, and relative size of (A) cholate, (B) DOPC (1,2-dioleoyl-sn-
glycero-3-phosphocholine), and (C) PBLG36-E [12] are illustrated. The molecules are depicted 
approximately to scale, with the hydrophilic sections of the molecules aligned on the left side of the 
dashed line and the hydrophobic sections on the right.  
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Block Copolymers. PBLG36-E was synthesized as previouslydescribed.[12] The 
amino acid sequence of the E block was G(EIAALEK)3-NH2. The average molecular 
weight of PBLG36-E was 10230 g.mol-1, and the polydispersity index (PDI) was 1.1. 
Polybutadiene46-b-poly(ethylene glycol)30 (PB46-b-PEG30, Polymer Source Inc.) had 
an average molecular weight of 3800 g.mol-1 and a PDI of 1.05. The polybutadiene 
was polymerized by 1,2-addition. 
 
Preparation of Mixed Micelles. A uniform polymer film was created in a 100 mL 
round-bottomed flask using 0.01 μmol of block copolymer (100 μL of a 0.1 mM block 
copolymer stock solution in tetrahydrofuran was added to the round-bottomed 
flask, and the solvent was removed by rotary evaporation under reduced pressure). 
Detergent (40 μmol) was added to the round-bottomed flask (200 μL of 200 mM 
sodium cholate or octyl glucoside in phosphate buffered saline (PBS, 10 mM 
phosphate, 137 mM NaCl, 3.35 mM KCl, pH 7.4 buffer)). The flask was then gently 




Detergent Dilution. The mixed micelle suspension was diluted by the addition of 
PBS over 1/2 h using a syringe pump (NE-300, just infusion, Prosense B.V.) with 
stirring at 700 rpm.  
 
Detergent Removal. The majority of the detergent was removed by means of 
dialysis. Slide-A-Lyser dialysis cassettes (Therm Scientific) with a molecular weight 
cutoff of 3000 g.mol-1 were used. The cassettes were thoroughly rinsed with water 
and then PBS. Samples were dialyzed against PBS for at least 48 h with two changes 
of buffer.  
 
PBLG36-E and Cholate Quantification. After dialysis (against water), the 
amount of PBLG36-E and cholate in the samples was quantified by nuclear magnetic 
resonance spectroscopy. 1H NMR spectra were recorded on a Bruker AV-400 
spectrometer, in 7:3 (v/v) dimethylformamide-d7/trifluoroacetic acid to prevent 
block copolymer aggregation. A residual dimethylformamide proton resonance was 
used to calibrate the chemical shifts, and dioxane was used as an internal calibrant 
to quantify the amount of PBLG36-E and cholate. It was found that 80% of the 
original polymer material was present after dialysis, and no cholate could be 
detected (sensitivity ∼0.1 μmol).  
 
Characterization. Experimental diffusion coefficients, D, were measured at 25 °C 




a Peltier-controlled thermostatic cell holder. The laser wavelength was 633 nm and 
the scattering angle was 173°. The Stokes-Einstein relationship D = kbT/3πηdh was 
used to estimate the hydrodynamic diameter, dh. Here kb is the Boltzmann constant 
and η is the solvent viscosity. 
Transmission electron microscopy (TEM) was conducted on a JEOL 1010 
instrument with an accelerating voltage of 60 kV. Samples for TEM were prepared 
by placing 5 μL of solution on carbon-coated copper grids. After ∼5 min, the droplet 
was removed from the edge of the grid. A drop of 2% phosphotungstic acid (PTA) or 
2% osmium tetroxide (OsO4) stain was applied and removed after 2 min. 
 
 
Results and Discussion 
 
Whereas phospholipids are typically ∼2 nm long and somewhat flexible, the 
amphiphilic block copolymer PBLG36-E used in this study has an average length of 
∼8 nm and is relatively rigid.[12] Both the poly(γ-benzyl L-glutamate) block, 
denoted PBLG36, and the peptide E (amino acid sequence G(EIAALEK)3) can adopt 
an R-helical conformation. In this conformation, the hydrophobic PBLG36 block has 
an average length of 4.5 nm, whereas the water-soluble peptide E block is ∼3.5 nm 
long. Recently, we have shown that PBLG36-E forms bilayered vesicles in aqueous 
solution.[12] Because of the large hydrophobic block size, none of the common 
solvent-free polymersome preparation methods, that is, bulk/film hydration, 
sonication, and so on, which all require hydration of a macroscopic phase of the 
block copolymer, have been successful. In this communication, we use sodium 
cholate as the detergent to solubilize PBLG36-E. Sodium cholate is often used to 
incorporate proteins in liposomes.[7] It is a low-molecular weight, rigid, disk-like 
anionic detergent with a cmc of ∼10 mM in 100 mM NaCl aqueous solution at 25 
°C.[13] The relative sizes of cholate, a phospholipid typically used to prepare 
liposomes by the detergent removal method, and PBLG36-E are illustrated in Figure 
1. From the size disparity between the block copolymer and both the phospholipid 
and detergent, it can readily be appreciated that the balance of self-assembling 
forces between the micelle- and vesicle-forming molecules is very different when 
using this method to prepare liposomes or polymersomes. The process of making 
polymersomes starts with forming mixed micelles of the detergent molecule and the 
block copolymer from a PBLG36-E film and an aqueous solution of cholate micelles. 
The aggregation number of cholate micelles is quite variable, with micelles 
containing between 2 and 30 molecules.[13-15] Cholate micelles (200 mM in PBS, 
25 °C) were determined by DLS to have an average hydrodynamic diameter (dh) of 2 
nm, in agreement with reported values,[16] and a size range of about 1-5 nm 
(Figure2A). Using the detergent dilution method to produce liposomes, lipid/cholate 
molar ratios on the order of 1:2 are typically employed.[17,18] In comparison with 
lipids, the block copolymer has a much larger surface area to be encapsulated; 
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therefore, a PBLG36-E/cholate molar ratio of 1:4000 (0.05 mM PBLG36:200 mM 
cholate) was chosen. Thin films of PBLG36-E were hydrated in aqueous cholate 
solutions for 24 h with occasional gentle agitation to solubilize the block copolymer. 
Because many cholate molecules are required to shield the large hydrophobic PBLG 
block from the aqueous solution, a departure from the morphology of pure cholate 
micelles is expected.[19,18] This was observed by TEM, with images of the mixed 
micelle stage containing a majority of pure cholate micelles and some larger 
particles between 5 and 20 nm in diameter (Figure 2B). With the low block 
copolymer/cholate ratio employed under the current preparation conditions, the 
size distribution of the mixed micelle population as determined by DLS does not 
vary significantly from that of pure cholate micelles (Figure 2A). The size 
distributions of mixed micelle solutions were stable for at least 4 days, as 




Fig. 2: (A) DLS intensity distributions of sodium cholate (Δ) and sodium cholate/PBLG36-E 4000:1 (▲). 
(B) PTA-stained TEM image of a sodium cholate/PBLG36-E 4000:1 mixture showing micelles and mixed 
micelles. Conditions: 200 mM cholate, 0.05 mM PBLG36-E in PBS, 25 °C. 
The second step in the formation of vesicles is the dilution of the mixed micelles 
such that detergent molecules are gradually removed from the micelles and the 
morphology of the structures shifts from being dominated by the selfassembling 
properties of the detergent to those of the block copolymer. This was achieved by 
diluting the mixed micelle solution from 200 mM cholate, well above the cmc, to 2 
mM, which is well below the cmc. The solution was stirred rapidly during detergent 
dilution to prevent uncontrolled aggregation, similar to the preparation of 
liposomes using the detergent dilution method.[20] Moreover, well-defined size 
distributions were only observed when the aqueous solution was gradually added 
(over 30 min or longer). 
 
After this dilution step, the particle sizes as observed with DLS had increased 
from 2 nm to larger structures with a bimodal distribution. The average dh of the 

























predominant structure was ∼350 nm, and the average dh of the second population 
was ∼100 nm (Figure 3A). This size distribution is most likely due to the range of 
molecular lengths and self-assembling characteristics of the block copolymer 
(PBLG≥22,≤46, PDI = 1.1). 
For detergent/phospholipid systems, the initial mixed micelles increase in 
dimension upon dilution and finally form liposomes around the cmc of the 
detergent.[11] This means that the intrinsic self-assembly of the lipids only fully 
emerges and liposomes assemble when the detergent concentration becomes too 
low to form micelles. The energetic determinants of vesicle formation are different 
for block copolymers and lipids; therefore, it may be expected that aspects of the 
micelle to vesicle transition also differ. 
 
 
        
 
Fig. 3: (A) DLS intensity distributions of cholate/ PBLG36-E mixed micelles (▲) and of polymersomes 
formed after diluting the mixed micelles to 2 mM detergent (●), (B) Evolution of micelle/polymersome 
diameters as a function of cholate concentration during dilution from 200 to 2 mM. Initial conditions: 
200 mM cholate, 0.05 mM PBLG36-E in PBS, 25 °C. 
DLS was conducted during the detergent dilution step to gain insight into the 
route of vesicle formation. PBS was added incrementally to mixed micelles (200 mM 
cholate, 0.05 mM PBLG36-E), and the size distribution was monitored after each 
dilution step. Upon the first PBS addition (170 mM cholate), a transition from 
micelles to large structures was observed (Figure 3B), which is in marked contrast 
with the temporal pathway of liposome formation. As more PBS was added, the 
amount of large structures gradually increased, and there was a simultaneous 
decrease in the amount of micelles. As the detergent concentration passed below the 
cmc of cholate (10 mM), micelles were no longer detected. It should be noted, 
however, that because DLS is intrinsically biased toward the detection of large 
particles, it is expected that micelles are present beyond the detection limit of DLS. 
The cholate concentration at which the large structures are first detected is 
approximately 15 times its cmc, implying that the determining factor in the micelle-
to-vesicle transition for this polymer is not the dispersion of the micelles at the cmc 
of the detergent.  
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In fact, it was not necessary to dilute the samples below the cmc of the detergent 
because the 350 nm population was stable before all micelles (many of which would 
be pure cholate micelles) had dispersed, as seen in Figure 3B. To avoid unnecessary 
dilution of the suspensions, it was preferred to dilute the cholate from 200 to 20 
mM, with the vesicle size distribution not significantly different from samples that 
had been diluted below the cmc of the detergent (Figure 4A). After dilution to 20 
mM cholate, TEM revealed polymersomes with diameters matching the DLS 
distribution and with membrane thicknesses of ∼15-20 nm, which is in close 
agreement with the calculated average thickness of 18 nm[12] (Figure 4B). In 
addition to polymersomes, another bilayered structure, discs, was observed. The 
diameter of the discs was ∼100 nm, which is also consistent with the DLS results. If 
polymersomes are required as the exclusive morphology, parameters such as the 
dilution rate or the concentrations of the detergent and block copolymer should be 




Fig. 4: (A) DLS intensity distributions during vesicle preparation: cholate/ PBLG36-E mixed micelles 
(▲), polymersomes formed after diluting the mixed micelles to 2 mM detergent (●), and polymersomes 
formed after diluting the mixed micelles to 20 mM detergent (○). (B) OsO4-stained TEM image of 
polymersomes and polymer discs after diluting the mixed micelles to 20 mM. Initial conditions: 200 
mM cholate, 0.05 mM PBLG36-E in PBS, 25 °C. 
These results show that the relative influence and function of the detergent on 
the vesicle self-assembly process is clearly different for phospholipids and this block 
copolymer. To verify that it is dilution, that is, removal of detergent from the mixed 
micelles, not only stirring that induces self-assembly of the block copolymer, a 
sample with 200 mM cholate and 0.05 mM PBLG36-E was stirred without dilution. A 
population of particles did emerge, although the detected size distribution varied 
haphazardly during stirring, with the average dh ranging between 300 and 1000 nm. 
Additionally, the rate of formation was reduced at least four-fold, with large 
particles still forming after 2 h. In contrast, when samples are diluted and stirred, 
the entire polymer population assembles into stable polymersomes within 0.5 h. 




isolated from one another, and removal of cholate molecules from the mixed 
micelles facilitates complete conversion to well-defined vesicles.  
A possible explanation of the observed results is as follows. In the mixed micelle 
stage, the large hydrophobic PBLG block is shielded from the aqueous environment 
by a layer of disk-like cholate molecules. [15] Because of the high exchange rate of 
cholate between micelles and solution,[21,22] detergent depleted “sticky patches” 
temporarily appear, allowing the block copolymer to exert its native self-assembling 
propensities and leading to coalescence between detergent-coated block 
copolymers. Because of its large hydrophobic block, PBLG36-E exhibits very strong 
phase separation in comparison with phospholipids in aqueous solution, with 
similar block copolymers having exchange rates ranging from hours to being 
nondetectable.[23-25] Once a number of PBLG36-E molecules self-assembles, it is 
unlikely that the reverse process would occur. As a control experiment, PBLG36-E 
polymersomes were prepared, and cholate was added to a final concentration of 200 
mM. The polymersome/ micelle suspension was stirred for 30 min (the standard 
duration of dilution), and no significant changes in the polymersome population 
were observed with DLS. In essence, for this polymersome assembly process, the 
important aspect of the detergent is that it provides a means of solubilizing the 
block copolymer and dampening its strong aggregation tendency en route to 
polymersomes. The micelle,to monomer transition of the detergent does not induce 
polymersome formation. In more general terms, the initial detergent concentration 
should be high enough to solubilize completely the block copolymer, and to trigger 
the structural conversion the mixed micelles should be diluted until all of the block 
copolymer has assembled into vesicles, with the precise detergent concentration 
dependent on the block copolymer and detergent used.  
The polymersome preparation method was also applied to the flexible, 
unstructured, neutral block copolymer polybutadiene46-b-poly(ethyelene glycol)30. 
Although PB46-b-PEG30 and PBLG36-E have very different physical properties, in 
comparison with lipids they both contain very large hydrophobic blocks that 
aggregate strongly in aqueous solution. Mixed micelles of PB46-b-PEG30 and the 
detergent octyl glucoside were diluted, generating polymersomes above the cmc of 
the detergent (Figure S1 of the Supporting Information). These results reveal the 
generality of this detergent based method and indicate that it is applicable to a 
diverse range of block copolymers and detergents.  
Because detergents may interact with other molecules in the environment to 
which the polymersomes are applied, in some instances, detergent removal may be 
desired. Therefore, dialysis was used to reduce the detergent concentration outside 
the PB46-b-PEG30 and PBLG36-E polymersomes from 20 mM to ∼0.1 μM. The 
distributions of polymersome diameters did not change significantly during dialysis 
(e.g., Figure 5A), and the polymersomes were stable for at least 1 week at 4 °C. 
Because detergents may interact with other molecules in the environment to 
which the polymersomes are applied, in some instances, detergent removal may be 
desired. Therefore, dialysis was used to reduce the detergent concentration outside 
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the PB46-b-PEG30 and PBLG36-E polymersomes from 20 mM to ∼0.1 μM. The 
distributions of polymersome diameters did not change significantly during dialysis 
(e.g., Figure 5A), and the polymersomes were stable for at least 1 week at 4 °C. After 
vesicles have formed in solution, the enclosed detergent will not diffuse out of the 
assembly as readily as from micellar or lamellar sheet morphologies. Therefore, the 
rate of detergent removal depends on how readily the detergent diffuses through 
the vesicle membrane and the rate of flip-flop of the amphiphile between the 
bilayers.[7] Polymersomes have relatively thick and rigid bilayers, and the rate of 
flip-flop is expected to be insignificant; therefore, the rate of detergent removal 
depends almost entirely on the diffusion of entrapped detergent through the block 
copolymer membrane, and it is expected to be more difficult to remove residual 
detergent from polymersomes than from liposomes.26 Following dialysis for 48 h, 
PBLG36-Epolymersomes were solubilized, and it was observed with NMR 
spectroscopy that <0.5% of the cholate remained after dialysis. From the NMR 





Fig. 5: (A) DLS intensity distributions of cholate/PBLG36-E mixed micelles (▲), polymersomes formed 
after diluting the mixed micelles to 20 mM detergent (○), and polymersomes after detergent removal 
by dialysis (●). (B) TEM image of OsO4-stained sample after diluting the mixed micelles to 20 mM. 
Insert: after dialysis. Initial conditions:200 mM cholate, 0.05 mM PBLG36-E in PBS, 25 °C. 
Conclusions 
We have demonstrated that the detergent removal technique, which has been 
used to produce liposomes for four decades,[4,27] can also be used to produce 
polymersomes. The dilution of cholate/ PBLG36-E or octyl glucoside/PB46-b-PEG30 
mixed micelles leads to a controlled transition from micelles to polymersomes. 
Whereas in the case of liposome formation, the micelle-to-vesicle transition is 
controlled by the breakup of detergent micelles, these block copolymers dictate the 
self-assembled structures of the two-component systems more forcibly, and the 
























micelle-to-vesicle transition is determined by the self-assembly of predominantly 
detergent-covered hydrophobic polymer blocks well above the cmc of the detergent. 
The detergent is an agent to modulate the force of the phase separation such that 
well-ordered nanophase separation can occur in aqueous solution rather than the 
uncontrolled aggregation that occurs without a shielding layer. In this respect, the 
role of the detergent is reminiscent of the role of organic solvent in the commonly 
used solvent-replacement technique.[28-30]Because the utility of the detergent is 
restricted to its ability to solubilize the polymer, the method is termed “detergent-
aided polymersome preparation”. This new pathway to produce polymersomes 
increases their possible applications because it does not require high energy input 
(e.g., sonication) or possibly damaging organic solvents, and thus it is compatible 
with labile biomacromolecules. Other than the benign nature of the detergent 
removal method, another advantage of this route has traditionally been that is it 
possible to control the liposome size and homogeneity. This can be achieved by 
varying the rate of detergent dilution[20,11] using different classes of 
detergent[31,32,18] or vesicle-forming lipid,[20,27] varying the initial 
detergent/lipid ratios[18] and concentrations,[11] and by changing the pH[27] and 
ionic strength[33] of the aqueous solution. The effect of these parameters on the 
properties of the polymersomes and the structural evolution during the formation of 
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In this study, peptide polymersome based on the peptide polymer –K are tested 
as an immune adjuvant for an antigen, influenza hemagglutinin (HA). The 
polymersomes are loaded with HA antigens and the in vivo immunogenicity of the 
resulting hybrid assemblies was tested in vivo, resulting in an improvement of the 
immune response for the influenza antigen co-administered with the polymersomes. 
 
  




Vaccination against influenza remains the most effective method to prevent 
infection by the virus and to reduce the associated morbidity and mortality.1 
Seasonal influenza vaccines currently in use are mostly subunit formulations, 
consisting of hemagglutinin antigens (HAs) from a mixture of strains. The downside 
of these vaccines is their relatively low immunogenicity, which can necessitate their 
administration with an adjuvant, i.e. a component, added to the antigen to enhance 
its immunogenicity, although the currently marketed seasonal influenza vaccines do 
not contain any adjuvant. Well known examples of adjuvants that are licensed for 
use in humans are colloidal aluminum salts and emulsions, such as MF59. Adjuvants 
can act in several different ways, e.g. by creating an antigen depot at the injection 
site, by protecting the antigen from enzymatic degradation, by improving the 
delivery of the antigen to dendritic cells (DCs) or by activating DCs.[2] Various types 
of nanoparticles have been shown to be able to act as antigen delivery systems 
which can combine several of these mechanisms.[3,4] Polymer as well as lipid based 
nanoparticles with HA have been successfully tested, enhancing antigen uptake by 
the DCs and resulting in enhanced antigen-specific acquired immune responses.[5,6] 
Nanoparticles can range in size from 10 to 1000 nm, and some studies have shown 
that the uptake of particles by DCs and their immune-stimulating effect is dependent 
on their size.[7] Nanoparticles can vary in several other properties, such as 
composition, surface charge and hydrophobicity. The nanoparticles can be loaded 
with antigens by adsorption, covalent attachment, or encapsulation. However, the 
elicited immune responses of the current formulations do not offer adequate 
protection and there is still a need for new alternatives. Polymersomes are self-
assembled polymer shells composed of block copolymers.[8–10] These block 
copolymers have amphiphilic properties similar to lipids, but they have much larger 
molecular weights, and for this reason they have been compared with viral capsids, 
composed of large polypeptide chains. Depending on the choice of the block 
copolymer, its molecular weight and biocompatibility, polymersomes can be used as 
delivery systems with a broad range of tunable properties.[11–13] Polymersomes 
have shown to be stable, in terms of size and structure,[14] they enable the 
encapsulation of both hydrophilic and hydrophobic species and can carry functional 
moieties, such as structures with cell penetrating capabilities.[15] Moreover, 
polymersomes based on the degradable di-block polymer polyethylene glycol–
polybutadiene functionalized with an HIV-derived Tat peptide successfully 
enhanced, in vitro, the cellular delivery of nanoparticles to DCs.[16] These results 
highlight the potential use of polymersomes as robust, virus like antigen delivery 
systems, but they have not been tested for vaccination yet. Recently, we developed a 
new class of polypeptideblock- peptides which self-assemble into 
polymersomes.[17–19] These particles were shown to be stable for several months. 




able to form a coiled–coil complex [20,21] allowing for the non-covalent 
functionalization of the polymersome surface with functional moieties. The ability of 
this recognition motif was indicated by the development of non-covalent triblock 
copolymers and model systems for membrane fusion.[22,23] The hydrophobic block 
is composed of poly(g-benzyl-L-glutamate) and both blocks adopt an a-helical 
conformation when the amphiphiles are assembled into polymersomes. 
 
The aim of this study was to investigate whether polymersomes can enhance the 
immunogenicity of a HA subunit vaccine. The polypeptide- block-peptide used in 
this study was the rod–rod block copolymer PBLG50-K,[17] where PBLG50 is the 
hydrophobic poly-(γ-benzyl-L-glutamate) block with an average degree of 
polymerization of 50, and K is a hydrophilic designed peptide with amino acid 
sequence G(KIAALKE)3–NH2. This amphiphilic block copolymer has been shown to 
self-assemble into polymersomes with a size of 250 nm. The HA antigen was from a 
H3N2 A/Wisconsin strain, which is currently used for seasonal vaccination in 
combination with HA from two other strains. The association of the antigen with the 
polymersomes was investigated, and the DC-stimulating capacity in vitro and the 
immunogenicity in mice of the HA–polymersomes were compared with that of plain 
HA.  
 
PBLG50-K has been shown previously to assemble into well-defined 
polymersomes in aqueous buffered solutions.[17–19] The polymersome size can be 
tuned from 200 to 2000 nm with low polydispersity by varying the conditions 
during the self-assembly process, such as ionic strength and temperature, or the 
preparation method used.[18,19] As previously stated the interaction of 
nanoparticles with DCs and the resulting immune-stimulating effect is dependent on 
their size,[24] with optimum DC uptake for particles with a diameter of 0.5 micron 
and below. Therefore for this study, polymersomes at the lower end of this size 
range were selected. In HEPES sucrose at 20 °C PBLG50-K self-assembled into 
polymersomes with a hydrodynamic diameter of about 250 nm, a polydispersity 
index of 0.1 (Fig. 1) and a zeta potential (ZP) of -40 mV. The polymersomes were 
stable, with no sign of turbidity/sedimentation and no detectable aggregation, as 
observed with dynamic light scattering (DLS) and electron microscopy, for at least 4 
weeks. The HA proteins are elongated molecules that extend 13 nm from the 
exterior of influenza viruses, being anchored in the viral membrane by means of a 
hydrophobic domain. This hydrophobic domain causes free HA to aggregate in 
aqueous solutions. The HA used in this study formed clusters with an average 
hydrodynamic diameter of about 50 nm in PBS, as measured by DLS. The binding of 
HA in these clusters is proposed to be relatively weak, as no clear aggregates were 
observed with transmission electron microscopy (TEM) when sampleswere stained 
with either OsO4 (pH7), or PTA (pH 2 or 7.4) (Fig. 2B inset). Upon the addition of the 
HA solution to the preformed PBLG50-K polymersomes an immediate particle size 
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increase was observed by DLS. Higher final concentrations (from 0.5 to 50 mg.mL-1) 










































































Fig. 1: Average hydrodynamic diameter (Zave) and polydispersity index (PDI) of a fixed amount of 
PBLG50-K polymersomes (100 µg.mL-1), mixed with a raising amount of HA (final concentration 
ranging from 0.5 to 50 µg.mL-1). 
 
A comparative study with another kind of polymersomes, based on a PBLG-E 
polymer,[18] with a different hydrophilic peptide sequence G(EIAALEK)3–NH2, was 
conducted and showed no sign of aggregation (data not shown), indicating that the 
nature of the peptide has a direct impact on the HA/polymersome interaction. TEM 
revealed that the plain PBLG50-K polymersomes did not aggregate which is in 
accordance with the DLS data (Fig. 2A). For the polymersome/HA mixtures, 
clustering was observed, with the HA presumably acting as a non-covalent 
crosslinker (Fig. 2B and D). The TEM images also revealed that the HA proteins 
interact with the polymersomes in a relatively weak manner as the shape and size of 
individual polymersomes did not change. The association of HA with the 
polymersomes was further investigated by filtering the suspension through 0.1 mm 
filters. Under these conditions the PBLG50-K polymersomes were retained on the 
filter. The filtration of free HA showed a recovery of 88%, whereas for the 
polymersome/HA complexes it dropped to 28%, showing that most of the HA was 






Fig. 2: TEM images (PTA staining) of the polymersomes (A, C) and the mixture of polymersome with 10 
µg.mL-1 HA (B, D).  
 
The adjuvant effect of PBLG50-K polymersomes (mixed with HA antigen) was 
investigated in an immunization study with mice. In order to study the effect of the 
polymersomes without any masking from the antigen alone, we  
used HA doses of 0.5 and 2.0 mg per immunization (corresponding to HA 
concentrations of 2.5 and 10 mg.mL-1 in the formulations). The polymersome 
concentration was kept constant for all the formulations (100 mg.ml-1), resulting in a 
final HA/polymersome weight ratio of 1/40 and 1/10, respectively. The two doses 
of HA were tested in the presence and absence of polymersomes. The HA-specific 
serum IgG, IgG1 and IgG2a were assessed after the first (prime) and the second 
(boost) immunization, and hemagglutination inhibition (HI) titers, as ameasure for 
the level of functional antibodies, were measured after the boost. After both the 
prime and the boost (Fig. 3A and B), PBLG50-K polymersomes significantly enhanced 
the IgG titers compared to non-adjuvanted HA for the high-dose (2 mg HA) group. In 
the low-dose group (0.5 mg) there was also a trend toward higher IgG responses for 
the polymersome formulation as compared to free HA, although the differences 
were not statistically significant. The IgG1 titers closely followed the total IgG titers, 
while the IgG2a titers (after prime and boost) were below the detection limit for all 
groups (results not shown). The HI titer was assessed by measuring the inhibition 
Polymersomes enhance the immunogenicity of influenza subunit vaccine 
 
49 
by the mouse sera of HA-induced red blood cell agglutination. The sera from mice 
immunized with non-adjuvanted HA showed a dose dependent HI titer, which was 
close to the detection limit of the assay for the low-dose group (Fig. 3C). For both HA 
doses polymersomes acted as adjuvant, as higher HI titers were found, ca. 20 fold for 
the low HA dose and 8 fold for the high dose, although the latter increase was not 
statistically significant.  
 
Fig. 3: Immune response in mice after subcutaneous injection of HA formulations: HA-specific serum 
IgG titers after prime (A) and boost (B), and HI titers after boost (C). Each bar represents the titer of an 
individual mouse. The formulations tested are:    2.5 µg.mL-1 HA, 
 
 2.5 µg.mL-1 HA + PBLG50-K, 
 
 
10 µg.mL-1 HA,   10 µg.mL-1 HA + PBLG50-K. (**: significant difference between the average titers of 
each group, for p < 0.01). 
 
The cytotoxicity of the polymersomes has been tested in vitro. The cell viability 
was evaluated in Caco-2 cells using the MTT assay. The cells were exposed for 48 
































































dilution in the cell culture media did not allow the testing of higher polymersome 
concentrations). The resulting percentages of cell viability showed no sign of toxicity 
for any of the polymersome concentrations tested (results not shown). 
 
In summary, the immunization study shows an increase of the serum IgG and HI 
titers, when the antigen is co-administered with the polymersomes. The 
improvement of the immune response against HA, when associated with the 
polymersomes demonstrates that the polymersomes can act as an adjuvant. The 
HA/polymersome hybrid has been characterized with DLS and electron microscopy 
showing that HA forms complexes with the polypeptide-block-peptide based 
polymersomes. The HA/polymersome association is presumably a combination of 
both electrostatic and hydrophobic interactions, arising from the hydrophobic 
membrane-anchoring domain of the HA, the localized charge on the HA, and the 
charged corona of the polymersomes. This is confirmed by the difference observed 
in the DLS study between PBLG-K and PBLG-E. The presence of three protonated 
lysine residues (at pH 7.4) in K, instead of three glutamic acids in E, had changed the 
electrostatic interactions between HA and the polymersome surface, resulting in 
different aggregation behaviors. The mechanism by which polymersomes act as an 
adjuvant is unknown, but could include a depot effect,[5] the ability to target the 
antigen presenting cells (APCs) with the antigen/adjuvant complexes and 
enhancement of the antigen uptake by APCs. 
 
As detailed in the introduction, the antigen used in this study is one of the main 
components of the current subunit seasonal influenza vaccines (which consist of a 
mixture of HA from different strains). Since neutralizing antibody levels expressed 
as HI titers are considered to be the main protective immune component for 
parentally administrated subunit vaccines,[25,26] and as this assay is also the test of 
reference according to the industry standards, the increase of the systemic immune 
response against HA formulated with PBLG50-K polymersomes, as observed in our 
study, is a clear improvement compared to the current formulation (HA alone). 
However, in order to provide a superior level of protection against the influenza 
infection than HA alone, it has been shown previously that an IgG2a response 
(indicative of a Th1 immune response) is the strongest isotype in response to viral 
infection.[27] Our formulations induced low IgG2a titers, therefore our future 
research will be directed at enhancing the IgG2a response of the polypeptide-block-
peptide polymersomes by coencapsulation of immuno-modulators. 
 
In conclusion, the work detailed in this paper demonstrates, for the first time, 
that polymersomes are able to enhance the immunogenicity of an antigen. 
Moreover, it shows the proof of concept that they can be used as a delivery tool for 
influenza subunit vaccine with enhanced immune response and no sign of cellular 
toxicity. 
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Experimental section  
 
The polypeptide-block-peptide block copolymer PBLG50-K was prepared and 
characterized as described previously.17-19 Influenza hemagglutinin (HA) antigen 
(H3N2 Wisconsin strain) was obtained from Solvay (Weesp, The Netherlands). 
Bovine serum albumin (BSA) was purchased from Merck (Darmstadt, Germany). 
ELISA plates were obtained from Greiner (Alphen a/d Rijn, The Netherlands). 
Horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (γ chain specific), 
IgG1 (γ1 chain specific) and IgG2a (γ2a chain specific) were ordered from Southern 
Biotech (Birmingham, USA). Chromogen 3,3′,5,5′-tetramethylbenzidine (TMB), 
substrate buffer for ELISA, GM-CSF and interleukin-4 (IL4), were provided by 
Biosource-Invitrogen (Breda, the Netherlands). Hank's Balanced Salt Solution 
(HBSS), fetal bovine serum (FCS) and all culture media, including penicillin/ 
streptomycin (PEST) and trypsin were supplied from Gibco (Invitrogen, Carlsbad, 
CA). Nimatek® (100 mg/ml Ketamine, Eurovet Animal Health B.V., Bladel, The 
Netherlands) and Rompun® (20 mg/ml Xylazine, Bayer B.V., Mijdrecht, The 
Netherlands) were obtained from the pharmacy of Leiden University Medical center. 
4-(2- hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), dichloromethane, 
dimethyl sulfoxide (DMSO), 3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and other chemicals were acquired from Sigma- Aldrich 
(Zwijndrecht, NL), unless stated otherwise.  
 
PBLG50-K polymersomes were prepared by a solvent evaporation method as was 
previously described.19 Briefly, PBLG50-K (0.02 μmol) was dissolved in 2 ml 
tetrahydrofuran (THF) in a 50 ml round flask, then 3 ml of HEPES sucrose buffer 
(Hepes 20 mM, sucrose 10% (w/w), pH 7.4) were added all at once to the polymer 
solution, and the mixture was homogenized by vortexing for 1 minute (200 rpm). 
Finally, the THF was removed by rotary evaporation at 30 kPa, 25°C for 10 minutes. 
HA loaded polymersomes were prepared by adding the HA stock solution (453 
µg.mL-1) to the preformed PBLG50-K polymersome suspension (100 µg.mL-1), 
resulting in a final HA concentration varying between 2.5 to 50 µg.mL-1.  
 
Particle size distributions were determined by means of dynamic light scattering 
(DLS) using a NanoSizer ZS (Malvern Instruments). The zeta potential of the 
particles was measured by laser Doppler velocimetry on the same instrument. The 
PBLG50-K concentration was determined with a BCA protein assay (Pierce) 
according to the manufacturer's instructions, using albumin standard.  
 
Transmission electron microscopy (TEM) was conducted on a JEOL 1010 
instrument with an accelerating voltage of 60 kV. Samples for TEM were prepared 
by placing 5 μL of solution on carbon-coated copper grids. After 5 min, the droplet 
was removed from the edge of the grid. A drop of 2% phosphotungstic acid (PTA) or 




degree of HA association to the polymersomes was determined by filtration as 
described previously [28].  
 
For this study we used labeled HA (IRDye® 800CW, Licor). Briefly, the 
polymersomes/HA complexes and free HA were filtered through polycarbonate 
membranes (Whatman, Nucleopore) of 0.1 μm pore size, using an extruder (T001 10 
ml, Thermobarrel Extruder Lipex Biomembrane). Under these conditions the 
polymersomes are retained on the filter and free HA passes through. The amount of 
HA in the filtrate was quantified with an Infinite M100 microplate reader (Tecan).  
 
Toxicity of the formulations on Caco-2 cells was assessed using the MTT 
method.[29] Caco-2 cells (10,000/well) were seeded in a 96-well plate (Nunc) and 
maintained for 2 days at 37 °C and 5% CO2. After 48 h exposure to a range of 
concentrations of the PBLG50-K polymersomes, the cells were washed twice with 
Hank's Balanced Salt Solution (HBSS) and incubated for 3 h with 0.5 µg.mL-1 MTT in 
DMEM. Medium was removed and the purple formazan crystal was dissolved in 100 
μL DMSO. Absorbance at 570 nm was measured using a μQuant ELISA plate reader 
(Biotek).  
 
The immunogenicity study was achieved with female C57BL/6 mice, 8-weeks old 
at the start of the vaccination study, were purchased from Charles River, and 
maintained under standardized conditions in the animal facility of the 
Leiden/Amsterdam Center for Drug Research, Leiden University. The study was 
carried out under the guidelines compiled by the Animal Ethic Committee of The 
Netherlands. The mice received two subcutaneous injections of 200 μl vacine: a 
prime (day 1) and a boost (day 21). We used two different HA dosages: 0.5 μg and 2 
μg HA/injection. The antigen was either injected alone or mixed with polymersomes 
(100 µg.mL-1). Blood samples were taken one day before prime and boost, and 3 
weeks after the boost. IgG titers were determined by ELISA. The IgG subtype profile 
of influenza-specific antibodies was checked on day 20 and 42 by sandwich ELISA as 
previously described.[30] Briefly, ELISA plates (Greiner) were coated overnight at 
4°C with 100 ng/well of influenza subunit antigen (H3N2) in coating buffer (0.05 M 
sodium carbonate/bicarbonate, pH 9.6). Plates were subsequently washed twice 
with PBS containing 0.05% Tween 20, pH 7.6 (PBST) and then blocked by incubation 
with 1% (w/v) BSA in PBST for 1 h at 37°C. Thereafter the plates were washed three 
times with PBST. Two-fold serial dilutions of sera from individual mice were applied 
to the plates and incubated for 2 h at 37°C. Plates were incubated with HRP-
conjμgated goat antibodies against either mouse IgG, IgG1 or IgG2a (Invitrogen) for 
1.5 h at 37°C. After washing, plates were incubated with TMB and the reaction was 
stopped with sulfuric acid (2M). The detection was done by measuring optical 
density at 450 nm. Antibody titers were expressed as the reciprocal of the sample 
dilution that corresponds to half of the maximum absorbance at 450 nm of a 
complete s-shaped absorbance–log dilution curve. Hemagglutination inhibition (HI) 
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titers in serum were determined as described by Amorij et al. [31] Briefly, serum 
was inactivated at 56°C for 30 min. In order to reduce nonspecific hemagglutination, 
25% kaolin suspension was added to inactivate sera. After centrifμgation at 1,200×g, 
50 μL of the supernatant was transferred in duplicate to 96-well round bottom 
plates (Greiner) and serially diluted twofold in PBS. Then, four hemagglutination 
units of A/Wisconsin influenza inactivated virus were added to each well, and the 
plates were incubated for 40 min at room temperature. Finally, 50 μL of 1% guinea 
pig red blood cells were added to each well and incubated for 2 h at room 
temperature. The highest dilution capable of preventing hemagglutination was 
scored as the HI titer. Antibody and HI titers were logarithmically transformed 
before statistical analysis.  
 
Unpaired Student’s t-test analysis was performed for each antigen dosage, in 
order to demonstrate significant differences between the two experimental groups 
(HA alone and the polymersome/HA mix). The statistical analysis was carried out 
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We developed a new class of polypeptide-b-peptide amphiphiles (PbP-A), based 
on a hydrophilic peptide conjugated to a hydrophobic poly-γ-benzyl-L-glutamate 
(PBLG) block. These peptide amphiphiles are able to self-assemble into 
nanostructures. In this study we have shown that properties such as size, 
morphology and surface charge of the resulting nanoparticles can be tuned. These 
polypeptide nanoparticles were tested for their adjuvant capacity. Immunogenicity 
of the hybrid assemblies was tested in vivo and showed an improvement of the 
immune response for the influenza antigen co-administered with polypeptide 
nanoparticles or CpG containing polypeptide nanoaprticles. This advanced 
formulation demonstrated enhanced efficacy when compare to HA alone, or with 
commonly used commercial adjuvant “Alum”. 
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Peptide and protein-derived materials have come into the spotlight for 
supramolecular chemists in recent years. Sequence-depending, peptides can fold 
into secondary structures such as β-sheets, α-helices or random coils that can 
further direct the hierarchical self-assembly of these macromolecules.[1] Over the 
last decade, self-assembly of peptide amphiphiles has been studied extensively and 
more recently as potential biomaterials.[2] These self-assembling peptide 
amphiphiles can be divided into three classes: [3] (a) amphiphilic peptides 
composed solely of a specific amino acid sequence [4] (b) hydrophilic peptides 
conjugated to a hydrophobic anchor like alkyl chains[5] and lipids,[6] and (c) hybrid 
peptide-polymers.[7] Conjugation of a peptide to a hydrophobic anchor strongly 
affects the supramolecular assembly and various morphologies have been reported, 
such as spherical and worm-like micelles, bicelles and vesicles.[8] These peptide 
amphiphile-based materials have found several potential applications in drug 
delivery,[9] in vivo imaging,[10] and regenerative medicine.[11] Only recently these 
materials have entered the field of vaccine research[12] where self-assembled 
peptides have been shown to enhance immune responses by acting as an adjuvant. 
Pioneering work by Collier and team demonstrated the capacity of self-assembling 
peptide motifs to provoke an immune response in mouse models against conjugated 
ovalbumin (OVA) peptide or protein antigens.[13] Tirrell and coworkers used 
peptide amphiphiles based micelles as a “self-adjuvanting” vaccine.[12] A dialkyl tail 
was conjugated to a peptide containing a cytotoxic T-cell epitope derived from the 
model tumor antigen OVA. These initial studies aimed at understanding the in vivo 
immune modulation using these micellar peptide-based materials. In both studies an 
enhanced Th2 response was observed, while the Th1 response was rather low. In 
our laboratory we have a long-term interest in developing effective adjuvants for 
influenza hemagglutinin (HA). Ideally, a viral vaccine should induce, besides 
antibodies, a substantial Th1 immune response, as this helps to protect against 
intracellular pathogens. Optimization of peptide amphiphile-based vaccines can be 
achieved by varying the amino acid sequence or the hydrophobic element, or by the 
addition of low molecular weight immune modulators.[14]  
In order to improve cellular delivery, antigen-containing particles have been 
decorated with cell-penetrating peptides such as the TAT peptide.[15] Its arginine 
rich amino acid sequence results in a positive surface charge. Cationic nanoparticles 
(NP) generally show better efficacy for enhancing the immunogenicity of the carried 
antigen than neutral or negatively charged particles, presumably due to an 
enhanced interaction between the negatively charged cell membranes and the 
cationic particles.[16] [17] For example, poly(ethylene glycol)-polybutadiene 
polymersomes functionalized with TAT peptides successfully enhanced the cellular 
delivery of these NP to antigen-presenting cells (APC).[18] Furthermore, in order to 
enhance and modulate the immune response towards a higher Th1 response, co-
delivery of an immune potentiator such as the TLR9 ligand CpG (bacterial cytosine 




initiate a rapid innate immune response characterized by the secretion of a variety 




Fig. 1: Synthesis of PBLG-TAT and PBLG-K using solid phase peptide synthesis followed by N-




We have previously reported a new class of polypeptide-b-peptide amphiphiles 
(PbP-A), based on a hydrophilic peptide block (denoted peptide “K”) with a specific 
amino acid sequence conjugated to a hydrophobic poly-γ-benzyl-L-glutamate 
(PBLG) block.[14b] [21] [22] In this design peptide “K” is able to form a coiled-coil 
motif with the complementary peptide “E”. These peptide amphiphiles self-assemble 
into micellar or vesicular structures depending on their composition. Control over 
both shape and size of the assemblies was achieved utilizing this coiled-coil 
motif[14b, c] The efficacy of peptide amphiphile PBLG50-K [amino acid sequence 
peptide “K”; (KIAALKE)3] was tested as a vaccine delivery system for an HA 
influenza subunit vaccine.[23] Injection of HA mixed with PBLG50-K NP in adult mice 
resulted in an enhanced IgG1 antibody response against HA and an increased 
hemagglutination inhibition (HI) titer as compared to HA alone.[23] Unfortunately, 
the Th1 response remained low, as measured by the IgG2a titer. These initial results 
showed that the PbP-A NP might be used as an adjuvant, however a redesign is 
required to evoke a strong Th1 response in order to create an effective viral vaccine.  
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In this contribution, we aimed to design an effective vaccine containing two key 
features: 1) efficient delivery and uptake of the antigen (HA) by APC and 2) the 
incorporation of an immune potentiator that modulates the immune response 
towards an enhanced Th1 response. We designed PbP-A using the peptide “TAT” 
and peptide “K” sequence as hydrophilic head group for cellular delivery as well as 
to capture CpG by ionic interactions. PBLG-K was also part of this formulation 
enabling functionalization of the resulting NP through specific coiled coil peptide 
binding in future studies.[14c] PBLG-TAT and PBLG-K mixed with CpG were used to 
form NPs and these NPs were used to adsorb HA on the surface. This approach 
enables the co-delivery of the antigen together with an immune modulator aiming to 
induce a strong immune response.[24] The NP were examined in vitro for their 
capability of stimulating dendritic cells (DC) and their immunogenicity was studied 
in vivo by subcutaneous administration in mice and compared with that of HA 
formulated with aluminum salt [Al(OH)3], a frequently used adjuvant in commercial 
vaccines. 
 
Synthesis of the polypeptide-b-peptides was performed as shown in Fig. 1. 
Peptides “TAT” [Amino acid sequence: GLRKKRRQRRR] and “K” [G (KIAALKE)3] 
were synthesized on a sieber amide resin using standard Fmoc solid phase peptide 
synthesis protocols. The N-terminal amine was used to initiate solid phase ring 
opening polymerization (ROP) of γ-benzyl-L-glutamate N-carboxyanhydride (BLG-
NCA). The reaction was carried out in dichloromethane (DCM) under an inert 
atmosphere for two days to obtain resin-bound polypeptide-b-peptides. The resin 
was washed thoroughly with DCM to remove any residual homopolymers formed 
during the polymerization and the protected polypeptide-b-peptides were released 
from the solid support using 1:99 (v/v) TFA/DCM (TFA; trifluoroacetic acid) for two 
minutes in several fractions with subsequent precipitation in cold methanol. 
Polypeptide-b-peptides with high molecular weight are cleaved first and therefore 
macromolecules with different molecular weight can be separated. The purity of 
each fraction was ascertained with gel permeation chromatography (GPC) and 
fractions with a similar polydispersity index (PDI 1.3-1.4) and molecular weight 
were combined. The protecting groups were removed from the hydrophilic peptide 
sequence using a mixture of TFA/DCM/water/TIS (TIS; triisopropylsilane). Under 
the used conditions, the benzyl protecting groups of the PBLG block are unreactive. 
The resulting product was precipitated in cold methanol and washed several times 
resulting in the desired amphiphilic polypeptide-b-peptides. The removal of the 
protecting groups from the hydrophilic peptide and the degree of polymerization 
(DP) of the hydrophobic PBLG block were determined by 1H-NMR analysis in DMF-d 
7 at 60°C. The peak integral of the benzylic protons in the PBLG block was compared 
with the integral arising from the leucine and isoleucine methyl protons of the K or 
TAT block and revealed that the average degree of polymerization for the PBLG 
block was 30 for both peptide amphiphiles (PBLG30-K and PBLG30-TAT, Fig. S2 




determined using 1H-NMR spectroscopy are in good agreement with the data 
obtained by GPC. 
 
 
Table 1: Molecular characteristics of the peptide compounds used in this study  
Molecules Structurea) Mn [g.mol-1] PDId) 
K G(KIAALKE)-NH2 2335.8b)  
TAT G(LRKKRRQRRR)-NH2 1508.8b)  





a) The sequence for the peptide “K” and “TAT” are written using the one letter amino acid code. PBLG; 
poly(γ-benzyl L-glutamate). b) Determined by MALDI-TOF mass spectrometry. c) Determined by 
comparing 1H NMR spectroscopy. d) Determined for protected polypeptides using GPC calibrated with 
polystyrene standards.   
 
 
Peptide amphiphile NP were prepared by the rapid water addition-solvent 
evaporation (WASE) method,[22] as this procedure is fast and has been proven to be 
compatible with in vivo applications.[23] Four NP formulations were designed with 
different physicochemical properties (Table 2). Two formulations, NP1 and NP2, 
were composed of PBLG30-K and PBLG30-TAT, respectively. The third formulation, 
NP3, consisted of a PBLG30-TAT:PBLG30-K (9:1) mixture, combining peptide “TAT” 
to enhance cellular uptake and peptide “K”. Moreover, this will enable future 
modification of the NP through coiled-coil formation with the complementary 
peptide “E”, allowing further surface functionalization if desired.[7c] The 9:1 molar 
ratio of peptide amphiphiles PBLG30-TAT:PBLG30-K was selected after an initial 
screen by zeta potential and dynamic light scattering (DLS) measurements, which 
revealed that it is the most cationic mixture of all formulations that assembled into 
NP with reproducible size (data not shown). We expected that triggering the 
immune response by an immune modulator was desired and thus formulation NP4 
contained the TLR9 ligand CpG oligonucleotide (10 μg.mL−1). For this formulation, 
CpG in HEPES sucrose buffer was added to the THF solution containing peptide 
amphiphile PBLG30-TAT:PBLG30-K (9:1), ensuring the efficient incorporation of CpG 
into the PBLG30-TAT/K (9:1) polypeptide NP based on attractive electrostatic 
interactions. All NP formulations were subsequently mixed with HA and used in all 
in vivo and in vitro experiments (Table 2). The final HA concentration and NP 
concentration in all formulations were always 10 μg.mL−1 and 6.77×10−6 M, 
respectively. 
  




The self-assembled NPs were first characterized by DLS and zeta potential 
measurements. DLS revealed that the NP1 and NP2 formulations had comparable 
hydrodynamic diameters (Z av 200-240 nm), with a zeta potential of -30 mV and 
+20 mV, respectively (Fig. 2A). Immune modulator CpG was added during the self-
assembly of NP3 to obtain NP formulation NP4. This resulted in a drop of the zeta 
potential from +20 mV (NP3) to -41 mV in presence of CpG (NP4), and also resulted 
in smaller NP (Z av of 216 nm and 160 nm, respectively). This decrease in both size 
and zeta potential is indicative of the tight binding of the negatively charged CpG 
oligonucleotides with the positively charged NP. The CpG loading was determined 
by measuring the adsorption of fluorescently-labeled CpG (ODN 1826-FITC, 
Invitrogen), showing a CpG loading efficiency between 55% and 60%. [19c] 
 
 
Table 2: Formulations used in in vitro and in vivo studies, hereafter referred to as annotated.  
Zave; Z-average hydrodynamic diameter and pdi; polydispersity index obtained from dynamic light 
scattering measurements (n=3) 
 
 
Addition of HA to the preformed NP1-4 resulted in a size increase and a 
significant drop in zeta potential for the two cationic nanoparticles NP2 and NP3 
(Fig. 2 A). HA is a negatively charged protein that interacts with the cationic surface 
of the NP, resulting in the drop of the zeta potential. The adsorption efficiency of HA 
correlated well with the surface charge of the NP. A fluorescent labeled HA (IR Dye 
800CW, Licor) was used to quantify the amount of HA associated with each NP 
formulation. [23] The highest amount of HA was adsorbed on cationic NP2 and NP3 
(adsorption efficiency 79% and 76%, respectively), while HA association with 
negatively charged NP1 and NP4 was significantly lower (39% and 36%, 














PBLG30-TAT: PBLG30-K (9:1) 
PBLG30-TAT: PBLG30-K (9:1) + CpG 
210 ± 42 
233 ± 69 
216 ± 45 
160 ± 68 
0.07 ± 0.03 
0.13 ± 0.09 
0.14 ± 0.07 










HA/PBLG30-TAT: PBLG30-K (9:1) 
HA/PBLG30-TAT: PBLG30-K (9:1) + 
CpG 
753 ± 393 
799 ± 314 
1210 ± 
430 
688 ± 457 
0.24 ± 0.04 
0.31 ± 0.17 
0.33 ± 0.13 
0.31 ± 0.07 
Control 
formulations 




















Fig. 2:  (A) Zeta potential (ZP) of polypeptide-b-peptide NP1-4; before (   ) and after HA adsorption, 
HA/NP1-4 (  ). Each bar represents the average of 3 different batches. (B) Percentage of the 
fluorescently labeled HA associated with HA/NP1-4. Error bars represent the standard deviation (n=3). 
 
 
The morphology of the resulting assemblies was visualized using cryo electron 
microscopy (Cryo-EM). Cryo-EM imaging showed that NP1 self-assembled into 
micellar structures of approximately 200 nm in diameter (Fig. 3 A). Self-assemblies 
of NP2 resulted in 20-30 nm micelles and aggregation of these micelles with a 
typical size of 200 nm (Fig. 3 B). Next, we studied the self-assembling behavior of 
NP3 and we found structures resembling to those observed for NP1 as well as NP2 
(Fig. 3C). Interestingly, the addition of the negatively charged CpG resulted in a 
better defined and more homogeneous population of NP with a diameter around 
200 nm (Fig. 3 D). Moreover, a clear contrast between (CpG-containing) NP4 (Fig. 3 
D) and NP3 (without CpG) (Fig. 3 C) was found, most likely because of electrostatic 
interactions between the surface bound CpG and the positively charged polypeptide 
NP. As expected, the addition of HA to the four NP formulations induced aggregation 
as observed by DLS. Within these aggregates, the individual NP morphology and size 
were maintained (Fig. 3 F-I). We also observed 10-15 nm structures on the surface 
of NP which are similar to those observed for free HA in solution (Fig. 3 E), 
presumably due to association of HA with the NP surface. 
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Fig. 3: Cryo-EM imaging of polypeptide-b-peptide NP. Plain NP: A) NP1, B) NP2, C) NP3, D) NP4; HA 
alone (E); NP mixed with 10 µg.ml-1 HA: F) HA/NP1, G) HA/NP2 H) HA/NP3, I) HA/NP4. Scale bar is 
100 nm. 
 
To assess the immunogenicity of the HA/NP formulations in vivo, these were 
injected subcutaneously in C57BL/6 mice. All mice received a first (prime) injection 
at day 0, and a second (boost) injection after 21 days with the same mixture. Serum 
was collected on day 20 and 42. HA-specific serum IgG1 (Fig. S3, Supporting 
Information) and IgG2a/c titers (Fig. 4 A, B) were assessed after the first (prime) 
and the second (boost) immunization, and HI titers, as a measure for the level of 
functional antibodies, were measured after the boost (Fig. 4 C). Interestingly, after 
boost, all HA/NP formulations induced superior  levels of IgG1 compare to the 
antigen alone, which is consistent with the observations made in our first paper (Fig. 
S3-A, Supporting Information). Although, important differences were noticed, after 
both, prime and boost injections of the HA/NP4 formulation, as they elicited high 
levels of IgG2a/c compared with all the other groups, including HA mixed with the 
commercially available adjuvant Al(OH)3 (Fig. 4 A, B), resulting in a shift of the 
IgG2a/c/IgG1 ratio (Fig. S3-B, Supporting Information). Increased levels of IgG2a/c 
indicate an enhanced Th1 response, which is in line with the superior level of 
interferon-γ secretion from the spleen cells collected from the mice injected with the 
HA/NP4 formulation (Fig. S4, Supporting Information). Moreover, the sera from 
mice immunized with HA/NP4 had an enhanced HI titer compared with all other 
groups with a significant difference compared with the non-adjuvanted HA control 











Fig. 4: Immune response in mice after subcutaneous injection of 2.0 µg HA, free or mixed with CpG or 
Al(OH)3 or NP formulations: HA-specific serum IgG2a/c titers after prime (A) and boost (B), and HI 
titers after boost (C). For panels A & B each dot represents the log serum titer of an individual mouse 
(non-responding mice were given an arbitrary titer of 10) bars represent the geometric mean. For 
panel C, each dot represents the log HI titer in serum of an individual mouse and bars represent the 
geometric mean. Significant difference between the groups were indicated with *, ** and *** 
(Respectively: p < 0.05, p < 0.01, p < 0.001). 
 
Stimulation of antigen uptake by APC is important to generate a robust antiviral 
immune response; however, it is not the only prerequisite. Adjuvant systems should 
also enable a potent stimulation of the innate immune response. Therefore DC 
activation by the HA/NP was studied. DC derived from monocytes isolated from 
human donor blood were used to measure the upregulation in vitro of two 
maturation surface markers (MHCII and CD86) upon stimulation by the HA/NP. 
Cells exposed to the different HA/NP formulations showed upregulated MHCII 
marker levels as compared with HA. However, the increase was only significant 
when the DC were stimulated by NP3 containing the TAT peptide sequence.  For the 
CD86 markers a similar trend was observed: the CpG-containing NP (HA/NP4) 
induced a significant upregulation as compared with HA alone. In contrast, injection 
of a HA/CpG solution did not yield an increase in CD86 marker expression (Fig. 5), 
showing the cooperative effect of CpG and PbP-A NP.  





















Fig. 5:  Upregulation of the MHC II (  ) and CD86 (  ) DC maturation markers induced by the various 
polypeptide-b-peptide NP formulations versus free HA; relative to the 100 ng.mL-1 LPS control group. 
Error bar represents SEM (n=3). Significant difference between the polypeptide-b-peptide NP 
formulation and free HA are indicated with * (p < 0.05). 
 
In summary, we have synthesized two new peptide amphiphiles, PBLG30-TAT 
and PBLG30-K, and demonstrated their ability to self-assemble into cationic NP in 
various formulations. Co-delivery of CpG with HA/NP (HA/NP4) resulted in an 
enhanced immune response in mice against the HA antigen, towards a Th1 response 
(as reflected by elevated levels of IgG2a/c). A Th1 response is important to target 
intracellular pathogens, thus opening an avenue for vaccine development against 
viral pathogens. This formulation also demonstrated a higher immunogenicity when 
compared with the commonly used adjuvant Al(OH)3. Further studies are required 
to obtain a better understanding of the self-assembly of the polypeptide amphiphiles 
and the effect of the resulting NP on the immunogenicity of associated antigens.   
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ANOVA, analysis of variance; APC, antigen-presenting cells; BLG-NCA, γ-benzyl L-
glutamate N-carboxyanhydride; BSA, bovine serum albumin; CpG, bacterial cytosine 
phosphodiester guanine oligomer; DIPEA, N,N-diisopropylethylamine; DC, dendritic 
cells; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMF, N,N-
dimethylformamide; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked 
immunosorbent assay; NMP, N-methyl-2-pyrrolidone; FCS, fetal calf serum; FITC, 
fluorescein isothiocyanate; FMOC, 9-fluorenylmethoxycarbonyl; GPC, gel permeation 
chromatography; HA, hemagglutinin; HBSS, Hank's balanced salt solution; HCTU, O-
(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; 
HEPES, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid; 1H-NMR, 1H nuclear 
magnetic resonance; HPLC, high-pressure liquid chromatography; HRP, horseradish 
peroxidase; Ig, immunoglobulin; LC-MS, liquid chromatography–mass spectrometry; 
MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NMP, 1-
methyl-2-pyrrolidinone; NP, nanoparticles; PbP-A, polypeptide-b-peptide 
amphiphiles; PDI, polydispersity index; THF, tetrahydrofuran; Cryo-EM, cryogenic 
electron microscopy; TFA, trifluoroacetic acid; TIS, triisopropyl silane. 
  
2. Materials and Methods 
Fmoc protected amino acids and peptide synthesis grade DMF, DCM and NMP 
solvents were obtained from BioSolve Ltd. Sieber amide resin was purchased from 
Iris Biotech GmbH, Germany. Influenza hemagglutinin antigen (H3N2 Wisconsin 
strain) was obtained from Solvay (Weesp, The Netherlands). BSA was purchased 
from Merck (Darmstadt, Germany). ELISA plates were obtained from Greiner 
(Alphen a/d Rijn, The Netherlands). HRP conjugated goat anti-mouse IgG (γ chain 
specific), IgG1 (γ1 chain specific) and IgG2a (γ2a chain specific) were ordered from 
Southern Biotech (Birmingham, USA). Chromogen 3,3′,5,5′-tetramethylbenzidine 
(TMB), GM-CSF and interleukin-4 (IL4), were provided by Biosource-Invitrogen 
(Breda, The Netherlands). HBSS, FCS and all culture media, including penicillin/ 
streptomycin (PEST) and trypsin were supplied from Gibco (Invitrogen, Carlsbad, 
CA). Nimatek® (100 mg.mL-1 ketamine, Eurovet Animal Health B.V., Bladel, The 
Netherlands) and Rompun® (20 mg.mL-1 xylazine, Bayer B.V.,Mijdrecht, The 
Netherlands) were obtained from the pharmacy of Leiden University Medical 
Center. HEPES, DCM, DMSO, MTT and other chemicals were acquired from Sigma-
Aldrich (Zwijndrecht, The Netherlands), unless stated otherwise. 
 
3. Solid-Phase Peptide Synthesis of Peptide “K” and “TAT” 
Peptide “K” and “TAT” were prepared following standard Fmoc chemistry on sieber 
amide resin using Liberty-1 (CEM corporation, Matthews, NC, United States) 
microwave assisted automated peptide synthesizer. Scale of synthesis was 0.25 
Peptide amphiphile nanoparticles enhance the immune response 
 
69 
mmol and activation of amino acid derivatives was achieved using HCTU/DIPEA. 
After the peptide “K” and “TAT” were prepared, the resin was removed from the 
reaction vessel, The amount of successfully synthesized “K” and “TAT” was 
estimated using the mass added to the resin during the synthesis, and by integration 
of HPLC peaks from an LC-MS run of a test cleavage of 10 mg of resin-bound peptide 
using TFA/TIS/water; 95/2.5/2.5 (v/v). 
 
 
Fig. S1: HPLC traces of peptide K (with 67% purity) and peptide TAT (with 60% purity) along with 
mass observed for main peak and corresponding TFA adducts.  
 
4.  Solid-Phase Synthesis of Poly(γ-benzyl L-glutamate)-block-K (PBLG-K) and 
Poly(γ-benzyl L-glutamate)-block-TAT (PBLG-TAT) 
γ-benzyl L-glutamate N-carboxyanhydride was synthesized and characterized as 
described previously.[1] The poly(γ-benzyl L-glutamate) block was synthesized on 
the solid phase using one-pot NCA polymerization of BLG-NCA initiated from the N-
terminus amine of resin-bound peptide “K” or “TAT”. The resin-bound peptide was 
dried overnight in vacuum oven at 37 °C, and then placed in argon atmosphere for 5 
h. Next, under an argon atmosphere, the peptide bound 0.25 mmol resin was 
swollen in dry DCM. Subsequently the appropriate weight of NCA (determined from 
the mass loading and HPLC peak integration) was added. [1] The flask was shaken 
for 48 h. The resin was drained and washed extensively with DCM to wash away the 
homopolymer formed during the reaction. The yields of the resin-bound block co-
polypeptides were 50-60%.  While keeping the side chains of the peptides intact, 
PBLG-Peptide “K” or “TAT” hybrid block copolymer was cleaved from the resin using 



















































TFA:DCM (1:99) (v/v) for 2 min, 10 times. Each cleavage mixture was precipitated in 
cold methanol and centrifuged to obtain pellets. Pellets were washed 3 times using 
cold methanol and vacuum-dried. The protecting groups of peptide “K” and “TAT” 
were removed using TFA:DCM:water:TIS; 47.5:47.5:2.5:2.5 (v/v) for 3 h. The 
product was precipitated drop wise in cold methanol and centrifuged. Further 3 
washes of cold methanol were performed. The product was vacuum dried to obtain 
both block copolymers in 20-25% in yield. 
 
5. Characterization of the PBLG-K and PBLG-TAT Polypeptide-b-Peptides 
Molecular weights and polydispersity index (PDI) of the protected PBLG-K and 
PBLG-TAT PbP-A were determined using gel phase chromatography (GPC). GPC 
analyses were performed using a Shimadzu system and a Polymer Laboratories 
column (3M-RESI-001-74, 7.5 mm diameter, 300 mm length). To prevent 
aggregation, DMF was used as the eluent at 60 °C with a flow rate of 1 mL.min-1. 
Molecular weights were calibrated using polystyrene standards.  
 
 
Fig. S2:. 1H NMR spectrum of PBLG30-TAT (A) and PBLG30-K (B) in N,N-dimethylformamide-d7 (DMF-
d7) at 60 °C. By comparing benzylic -CH with respective leucine or leucine/isoleucine -CH3 peak, an 
average degree of polymerization of 30 was estimated for both block copolymers. The high intensity 
signal at 3.3 ppm for PBLG30-TAT is due to residual water.  
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6. Preparation of PBLG30-K and PBLGPBLG-TAT Nanoparticles 
The nanoparticles (NP) were prepared by a solvent evaporation method as 
described previously.[2] Briefly, the polymer (0.02 µmol) was dissolved in 2 ml THF 
in a 50 ml round flask, then 3 ml of HEPES sucrose buffer (HEPES 20 mM, sucrose 
10% (w/w), pH 7.4) was added all at once to the polymer solution, and the mixture 
was homogenized by vortexing for 1 minute (200 rpm). Immediately, the THF was 
removed by rotary evaporation at 30 kPa, 25°C for 10 minutes. The CpG loaded NP 
were prepared by using the same method, but with HEPES sucrose buffer containing 
10 μg.mL−1 CpG. Finally, the HA/NP were prepared extemporaneously, by mixing 
(prior to the injection) the proper volumes of HA stock solution (453 μg.mL−1) to the 
preformed polypeptide NP suspension (Unbound HA was not removed and the final 
HA concentration was 10 μg.mL−1). 
 
7. Size, Charge and Morphology Characterization of the Polypeptide 
Nanoparticles 
Particle size distributions were determined by means of dynamic light scattering 
(DLS) using a NanoSizer ZS (Malvern Instruments). The zeta potential of the 
particles was measured by laser Doppler electrophoresis on the same instrument.  
Samples for cryo-EM were concentrated by centrifuging using Amicon Ultra, 
Ultracel®-100K (regenerated cellulose 100,000 MWCO, Millipore, Ireland) at room 
temperature. HA was added to the samples just before the vitrification process. 
Typically 10 μg.mL−1 concentration of HA is used during the experiments therefore 
for imaging concentration of HA was adjusted to the resulting centrifuged sample.  
Sample stability was verified by DLS and TEM. Cryo-EM measurements were 
performed on a FEI Technai 20 (type Sphera) transmission electronmicroscope or 
on a Titan Krios (FEI). A Gatan cryo-holder operating at ∼ -170 °C was used for the 
cryo-EM measurements. The Technai 20 was equipped with a LaB6 filament 
operating at 200 kV, and the images were recorded using a 1k × 1k Gatan CCD 
camera. The Titan Krios was equipped with a field emission gun (FEG) operating at 
300 kV. Images were recorded using a 2k × 2k Gatan CCD camera equipped with a 
post column Gatan energy filter (GIF). The sample vitrification procedure was 
carried out using an automated vitrification robot: a FEI Vitrobot Mark III. TEM 
grids, both 200 mesh carbon coated copper grids and R2/2 Quantifoil Jena grids, 
were purchased from Aurion. Copper grids bearing lacey carbon films were 
homemade using 200 mesh copper grids from Aurion. Grids were treated with a 
surface plasma treatment using a Cressington 208 carbon coater operating at 25 A 
for 40 s prior to the vitrification procedure. 
 
8. Quantification of HA and CpG Associated with the Nanoparticles  
Estimation of the HA adsorption onto the nanoparticles was done as described 
previously [3]. For this study we used labeled HA (IRDye® 800CW, Licor). Briefly, 
the HA/NP complexes and the free HA were filtered through polycarbonate 




ml, Thermobarrel Extruder Lipex Biomembrane). Under these conditions the NP are 
retained on the filter and HA passes through. The amount of HA, remaining in the 
filtrate, was quantified with an Infinite M1000 microplate reader (Tecan). 
The amount of CpG present in the NP was determined using fluorescently labeled 
analogs (10% of used CpG were labeled), as described previously [4]. Free TLR 
ligand was separated from the NP by filtration using an Amicon Ultra, Ultracel®-
100K (Regenerated cellulose 100000 MWCO, Millipore, Ireland) and quantified 
using a FS920 fluorimeter (Edinburgh Instruments, Campus Livingston, UK). 
 
9. DC Maturation Assay  
Monocytes isolated from buffy coats (Sanquin, Amsterdam, The Netherlands) were 
cultivated to differentiate into immature DC, as described previously. DC were 
incubated for 48 h at 37°C in RPMI 1640, containing 500 U/ml GM-CSF and 100 
U/ml IL4, with 100 μl volume of HA/NP suspension in 1 ml cell culture medium, and 
LPS (100 ng.mL−1 cell culture medium) was used as a positive control. Cells were 
washed 3 times with PBS containing 1% (w/v) BSA and 2% (v/v) FBS and incubated 
for 30 min with a mixture of 50× diluted anti-HLADR-FITC or anti-CD86-APC 
(Becton Dickinson) on ice, to measure the expression of MHCII or CD86, 
respectively, on the surface of the DC. Cells were washed and expression of the 
surface markers was quantified by using flow cytometry (FACSCanto, BD 
Biosciences, San Jose, CA, USA). Live cells were gated based on forward and side 
scatter. The upregulation of the two surface markers by 100 ng.mL−1 LPS was set as 
100%. A minimum of 10,000 gated cells were analyzed in each experiment.  
 
10. In vivo Experiments  
Female C57-BL/6 mice, 8-weeks old at the start of the vaccination study, were 
purchased from Charles River Laboratories International, Wilmington, MA, USA, and 
maintained under standardized conditions in the animal facility of the Leiden 
Academic Centre for Drug Research, Leiden University. The study was carried out 
under the guidelines compiled by the Animal Ethic Committee of The Netherlands. 
The mice received two subcutaneous injections of 200 μl vaccine (2 μg 
HA/injection): a prime (day 1) and a boost (day 21). The antigen was either injected 
alone or mixed with NP to the final concentration of 10 μg HA/ml of NP solution. 
Unbound HA was not removed and each mouse received the same amount of HA and 
NP. Blood samples were taken one day before prime and boost, and 3 weeks after 
the boost. IgG titers were determined by ELISA.  
The IgG subtype profile of influenza-specific antibodies was checked on day 20 and 
42 by sandwich ELISA as previously described. Briefly, ELISA plates (Greiner Bio-
One B.V., The Netherlands) were coated overnight at 4°C with 100 ng HA/well in 
coating buffer (0.05 M sodium carbonate/bicarbonate, pH 9.6). Plates were 
subsequently washed twice with PBS containing 0.05% Tween 20, pH 7.2 (PBST) 
and then blocked by incubation with 1% (w/v) BSA in PBST for 1 h at 37°C. 
Thereafter the plates were washed three times with PBST. Two-fold serial dilutions 
Peptide amphiphile nanoparticles enhance the immune response 
 
73 
of sera from individual mice were applied to the plates and incubated for 1.5 h at 
37°C. Plates were incubated with HRP-conjugated goat antibodies against either 
mouse IgG1 or IgG2a (Invitrogen, The Netherlands) for 1 h at 37°C. After washing, 
plates were incubated with TMB and the reaction was stopped with sulfuric acid (2 
M). The detection was achieved by measuring optical density at 450 nm. C57BL/6 
mice express the Igh1-b gene, which encodes the IgG2c isotype rather than IgG2a. 
However, here we used an anti-IgG2a isotype (which cross-reacts with IgG2c[5] and 
titers are reported as IgG2a/c titers. Finally, antibody titers were expressed as the 
reciprocal of the sample dilution that corresponds to half of the maximum 
absorbance at 450 nm of a complete s-shaped absorbance–log dilution curve. 
 
 
Fig.S3: Immune response in mice after subcutaneous injection of HA/NP; (A): HA-specific serum IgG1 
titers after boost, each dot represents the log serum titer of an individual mouse (non-responding mice 
were given an arbitrary titer of 10) bars represent the geometric mean and significant difference 
between the groups were indicated with * and ** (Respectively: p < 0.05, p < 0.01). (B): Corresponding 
average Log IgG 2 a/c/Log IgG1 ratio, indicative of the quality of the immune response. 
 
11. Hemagglutination Inhibition Assay 
Hemagglutination inhibition (HI) titers in serum were determined as described 
previously. [3] Briefly, serum was inactivated at 56°C for 30 min. In order to reduce 
nonspecific hemagglutination, 25% kaolin suspension was added to inactivate sera. 
After centrifugation at 1,200×g, 50 µL of the supernatant was transferred in 
duplicate to 96-well round-bottom plates (Greiner) and serially diluted twofold in 
PBS. Then, four hemagglutination units of A/Wisconsin influenza inactivated virus 
were added to each well, and the plates were incubated for 40 min at room 
temperature. Finally, 50 µL of 1% guinea pig red blood cells (Harlan Scientific, The 
Netherlands) diluted in PBS, were added to each well and incubated for 2 h at room 
temperature. The highest dilution capable of preventing hemagglutination was 
scored as the HI titer.  
All the data of the in vitro studies were analyzed with a one-way analysis of variance 
(ANOVA) with Bonferroni’s post-test. Regarding the in vivo data, Antibody titers 




a Kruskal Wallis post-test analysis was performed in order to demonstrate 
significant differences between the experimental groups, the statistical analysis was 
carried out using Graphpad Prism software and a p value less than 0.05 was 
considered to be significant. 
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Cationic liposomes are known as potent adjuvants for subunit vaccines. The 
purpose of this work was to study whether the content and the physicochemical 
properties of the positively charged compound affect the adjuvanticity of cationic 
liposomes. Cationic liposomes containing a cationic compound (DDA, DPTAP, DC-
Chol, or eDPPC) and a neutral phospholipid (DPPC) were prepared by the film 
hydration-extrusion method and loaded with influenza hemagglutinin (HA) by 
adsorption. The liposomes were characterized (hydrodynamic diameter, zeta 
potential, membrane fluidity, HA loading) and their adjuvanticity was tested in mice. 
The formulations were administered twice subcutaneously and mouse sera were 
analyzed for HA-specific antibodies by ELISA and for HA-neutralizing antibodies by 
hemagglutination inhibition (HI) assay.First, the influence of cationic lipid 
concentration in the DC-Chol/DPPC liposomes (10 vs. 50 mol%) was investigated. 
The DC-Chol/DPPC (50:50) liposomes showed a higher zeta potential and HA 
loading, resulting in stronger immunogenicity of the HA/DC-Chol/DPPC (50:50) 
liposomes compared to the corresponding (10:90) liposomes.Next, we used 
liposomes composed of 50mol% cationic lipids to investigate the influence of the 
nature of the cationic compound on the adjuvant effect. Liposomes made of the four 
cationic compounds showed similar hydrodynamic diameters (between 100 and 
170nm), zeta potentials (between +40 and +50mV), HA loading (between 55% and 
76%) and melting temperatures (between 40 and 55°C), except for the DC-Chol 
liposomes, which did not show any phase transition. HA adjuvanted with the DC-
Chol/DPPC (50:50) liposomes elicited significantly higher total IgG1 and IgG2a titers 
compared to the other liposomal HA formulations and non-adjuvanted HA. A similar 
trend was observed for the HI titers. These results show that the adjuvanticity of 
cationic liposomes depends on both the content and the physicochemical properties 
of the charged compound. 
 
  




During the past few decades, new approaches for vaccination have been 
developed for the delivery of subunit vaccines based on (recombinant) purified 
proteins [1–3]. In general, subunit vaccines offer a better safety profile than live or 
inactivated vaccines, but are less immunogenic. The poor immunogenicity of subunit 
vaccines can be enhanced by the use of adjuvants such as colloidal aluminum salts 
(e.g., phosphate, hydroxide) or emulsions such as MF59 [4]. Depending on the 
nature of the adjuvant, it can enhance the immunogenicity of a vaccine via several 
mechanisms, for example, by creation of an antigen depot at the injection site, 
improvement of the antigen delivery to dendritic cells (DCs), or the induction of DC 
activation and the differentiation of T and B cells [5].  
Liposomes have been studied as adjuvants for many decades [6–9]. From these 
previous studies, it emerges that the adjuvant effect of the liposomes depends on 
their physicochemical properties and may be related to prolonged release and 
protection of encapsulated antigen against the environment and enhanced uptake 
by DCs. It is generally accepted that cationic liposomes are more potent adjuvants 
compared to anionic and neutral liposomes [9]. Their adjuvant effect has been 
attributed to several mechanisms, such as non-specific cell damage (inducing 
inflammation) at the site of injection, formation of an antigen depot, and improved 
antigen uptake by antigen-presenting cells (APCs) through electrostatic interaction 
between the cationic liposomes and negatively charged groups on the surface of 
APCs. Cationic liposomes can both enhance and modulate the immune response. 
After antigen uptake by DCs, these cells mature, migrate and present the antigen on 
MHC II molecules to T helper (Th) cells, inducing two major subtypes: Th1 cells 
primarily involved in cellular immune responses and Th2 cells involved in humoral 
immune responses [10]. Interestingly, cationic liposomes have been shown to 
induce Th1-mediated responses, meaning potentially increased efficacy against 
intracellular pathogens [11] [12]. Many different amphiphilic cationic compounds 
have been tested for inclusion into liposomes and hold promise for vaccine delivery, 
such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) [13], 1,2-dioleoyl-sn-
glycero-3-ethylphosphocholine (eDOPC) [14], dimethyl dioctadecyl-ammonium 
(DDA) [15], and 3ß-[N-(N’,N’-dimethylaminoethane)- carbamoyl] cholesterol (DC-
Chol) [16]. It is very difficult to compare these vaccination studies as awide range of 
conditions was used (e.g., different formulations, antigens routes of administration, 
immunization schemes, and read-out systems). The immunogenicity of different 
cationic liposomes has been compared systematically in only very few studies. For 
instance, Rosenkrands et al. [17] showed in a subcutaneous immunization study in 
mice that DDA liposomes mixed with an extract of lipids from the cell wall of bacillus 
Calmette-Guérin (average hydrodynamic diameter = 738 nm) induced a strong Th1 
response, whereas DC-Chol/BCG induced a Th2-biased response, and DOTAP/BCG 




characteristics of the latter two formulations were not provided. Different results 
were obtained by Joseph et al. [18], who produced liposomes made of DC-Chol, DDA, 
DSTAP or DOTAP, mixed with DOPE (molar ratio of 1/1), and loaded with an 
influenza antigen. The relatively large hydrodynamic diameters ranged from 1 to 4 
µm the zeta potentials from+ 25 to + 83 mV. The results of an intranasal 
immunization study in mice showed that DC-Chol, DDA, and DSTAP liposomes 
induced a very low immune response, whereas DOTAP-based vaccines induced 
strong Th1 and Th2 responses [18]. Both the differences in liposome characteristics 
and the different routes of administration (subcutaneous vs. intranasal) could 
explain the different outcomes of these two studies. A recent study by Slütter et al. 
showed that the same cationic liposomes widely differ in immunogenicity 
depending of the route of administration [19]. The aim of this work was to study 
how the content and the physicochemical properties of the positively charged 
compound influence the adjuvant effect of cationic liposomes. To this end, we 
prepared cationic liposomes made of different cationic compounds but with similar 
physicochemical characteristics (particle size, zeta potential, bilayer rigidity), in 
association with an influenza HA antigen from a H3N2 A/Wisconsin strain. We 
selected three cationic compounds with a melting temperature (Tm) similar to that 
of DPPC [20]: DDA [21], DPTAP [18], and eDPPC [22] (see Table 1).  
Furthermore, DC-Chol was studied as it also has shown immunogenic potential. 
Since no DC head group with a saturated lipid tail was available, it was included in 
our comparison, while recognizing that its characteristics will differ from the other 
cationic compounds with respect to both the head group and the hydrophobic tail. 
We aimed to prepare liposomes with a similar hydrodynamic diameter of about 200 
nm, as it has been previously reported that nanoparticles below the size of 0.5 µm 
enhance the uptake by APCs [23] [24] or the INFɣ secretion [25] better than larger 
particles (>500 nm). 
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2. Materials and methods 
2.1. Materials 
1,2-Dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2- diacyl-sn-glycero-
3-ethylphosphocholine (eDPPC), dimethyl dioctadecyl-ammonium bromide (DDA), 
and 3ß-[N-(N0,N0-dimethylaminoethane)- carbamoyl] cholesterol (DC-Chol) were 
obtained from Avanti Lipids (Alabaster, USA). 1,2-Dipalmitoyl-sn-glycero-3- 
phosphocholine (DPPC) was kindly provided by Lipoid GmbH (Ludwigshafen, 
Germany). Influenza hemagglutinin (HA) antigen (H3N2 Wisconsin strain) was 
obtained from Solvay (Weesp, The Netherlands). Bovine serum albumin (BSA) was 
purchased from Merck (Darmstadt, Germany). ELISA plates were obtained from 
Greiner (Alphen a/d Rijn, The Netherlands). Horseradish peroxidase (HRP) 
conjugated goat anti-mouse Gig (c chain specific), IgG1 (c1 chain specific), and IgG2a 
(c2a chain specific) were ordered from Southern Biotech (Birmingham, USA). 
Chromogen 3,30,5,50-tetramethylbenzidine (TMB) substrate buffer for ELISA, 
granulocyte macrophage colony stimulating factor (GM-CSF), and interleukin-4 (IL4) 
were provided by Biosource-Invitrogen (Breda, The Netherlands). Fetal bovine 
serum (FBS) and all culture media, including penicillin/streptomycin (PEST) and 
trypsin, were supplied from Gibco (Invitrogen, Carlsbad, CA). Nimatek® _ (100 
mg/ml ketamine, Eurovet Animal Health B.V., Bladel, The Netherlands) and 
Rompun®_ (20 mg/ml xylazine, Bayer B.V., Mijdrecht, The Netherlands) were 
obtained from the pharmacy of Leiden University Medical Center. All other 
chemicals were acquired from Sigma–Aldrich (Zwijndrecht, The Netherlands), 
unless stated otherwise. 
2.2. Preparation of cationic liposomes  
Liposomes were prepared by the film hydration method, followed by extrusion. 
Briefly, desired amounts of a cationic compound (DDA, DPTAP, eDPPC, or DC-Chol) 
and a neutral phospholipid (DPPC) were dissolved in chloroform, and mixed in a 
round-bottom flask of 50 ml. A thin lipid film was formed at the bottom of this flask 
using a rotary evaporator, under reduced pressure. The film was rehydrated in a 
HEPES sucrose buffer (20 mM HEPES, 10% (w/w) sucrose, pH 7.4) to obtain a final 
lipid (cationic compound + DPPC) concentration of 5 mg/ml. During the rehydration 
step, the temperature was maintained at 60 °C for 20 min, with continuous stirring 
at 300 rpm. The dispersion was extruded (LIPEX™ extruder, Northern Lipids Inc., 
Canada) 5 times through a polycarbonate filter (Nuclepore Track-Etched 
Membranes, Whatman, The Netherlands) with a pore size of 800 nm and 5 times 
through a filter with a pore size of 200 nm (Nucleopore Millipore, Amsterdam, The 
Netherlands). HA loaded liposomes (HA/liposomes) were prepared by adding the 




mg/ml) to obtain a final HA concentration varying between of 2.5 and 10 µg/ml 
(corresponding to 0.5 and 2 µg/dose injected to the mice, respectively). 
2.3. Characterization of the cationic liposomes  
2.3.1. Hydrodynamic diameter and zeta potential 
Particle’s hydrodynamic diameter and polydispersity index (pdi) were 
determined by means of dynamic light scattering (DLS) using a NanoSizer ZS 
(Malvern Instruments). The zeta potential of the particles was measured by laser 
Doppler velocimetry on the same instrument, using a zeta dip cell (Malvern 
Instruments). Prior to analysis, samples were diluted 10-fold in 20 mM HEPES, pH 
7.4. 
 
2.3.2. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) measurements were performed with a 
differential scanning calorimeter (TA Instruments Q2000) for determining the 
melting temperatures (Tm) of the liposomes. DSC analysis was done using sealed 
aluminum pans containing 10 µl of the undiluted samples or 10 µl buffer (20 mM 
HEPES, 10% (w/w) sucrose, pH 7.4) as reference. The measurements were done in 
an inert atmosphere within the temperature range of 20 °C to 80 °C, at 2 °C/min. Tm 
were determined from the onset of the endothermic peak. 
 
2.3.3. HA loading 
HA was labeled with IRDye 800CW (Licor Bioscience, The Netherlands) 
according to the manufacturer’s instructions and the labeled HA (IR-HA) was used 
to estimate the extent of antigen adsorption to the surface of the cationic liposomes. 
The IR-HA was mixed with the cationic liposomes (2 µg IR-HA/400 µg total lipids). 
HA adsorption to the cationic liposome was measured via ion-exchange 
chromatography. More specifically, it was based on the recovery of labeled antigen 
after manual application to a cation-exchange column (Hi Trap CM FF, GE 
Healthcare, USA). The column was equilibrated at room temperature with 5 ml of 
starting buffer (50 mM HEPES, pH 10.5) after which 5 ml of elution buffer (starting 
buffer + 1 M NaCl), and finally, 5 ml of starting buffer were added. Then, 200 µl of 
the sample were applied and the column was washed with 10 ml of starting buffer at 
1.2 ml/min, to elute the free IR-HA from the column. It was detected and quantified 
using a fluorescence plate reader (Infinite 1000, Tecan, Switzerland). 
2.4. Immunogenicity study 
2.4.1. Immunization of mice 
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Female C57-BL/6 mice, 8-week old at the start of the vaccination study, were 
purchased from Charles River and maintained under standardized conditions in the 
animal facility of the Leiden/ Amsterdam Center for Drug Research, Leiden 
University. The study was carried out under the guidelines compiled by the Animal 
Ethic Committee of The Netherlands. The mice received two subcutaneous injections 
of 200 µl vaccine: a prime (day 1) and a boost (day 22). We used two different HA 
dosages: 0.5 µg and 2 µg HA/injection. The antigen was either injected alone or 
mixed with liposomes (400 µg total lipid/ml). Blood samples were taken one day 
before prime and boost, and 3 weeks after the boost. IgG titers were determined by 
ELISA. 
 
2.4.2. ELISA assay 
The IgG subtype profile of influenza-specific antibodies was checked on day 20 
and 42 by sandwich ELISA as previously described [26]. Briefly, ELISA plates 
(Greiner Bio-One B.V., The Netherlands) were coated overnight at 4 °C with 100 ng 
HA/well in coating buffer (0.05 M sodium carbonate/bicarbonate, pH 9.6). Plates 
were subsequently washed twice with PBS containing 0.05% Tween 20, pH 7.2 
(PBST) and then blocked by incubation with 1% (w/v) BSA in PBST for 1 h at 37 °C. 
Thereafter, the plates were washed three times with PBST. Twofold serial dilutions 
of sera from individual mice were applied to the plates and incubated for 1.5 h at 37 
°C. Plates were incubated with HRP-conjugated goat antibodies against either mouse 
IgG, IgG1, or IgG2a (Invitrogen, The Netherlands) for 1 h at 37 °C. After washing, 
plates were incubated with TMB and the reaction was stopped with sulfuric acid (2 
M). The detection was done by measuring optical density at 450 nm. Antibody titers 
were expressed as the reciprocal of the sample dilution that corresponds to half of 
the maximum absorbance at 450 nm of a complete s-shaped absorbance–log 
dilution curve. 
 
2.4.3. HI assay  
Hemagglutination inhibition (HI) titers in serum were determined as described 
by Amorij et al. [27]. Briefly, serum was inactivated at 56 °C for 30 min. In order to 
reduce nonspecific hemagglutination, 25% kaolin suspension was added to 
inactivate sera. After centrifugation at 1200g, 50 µl of the supernatant were 
transferred in duplicate to 96-well round-bottom plates (Greiner Bio-One B.V., The 
Netherlands) and serially diluted twofold in PBS. Then, four hemagglutination units 
of A/Wisconsin influenza inactivated virus were added to each well, and the plates 
were incubated for 40 min at room temperature. Finally, 50 µl of 1% guinea pig red 
blood cells (obtained from Harlan Scientific, The Netherlands) diluted in PBS was 
added to each well, and the plates were then incubated for 2 h at room temperature. 





2.5. In vitro dendritic cell maturation 
Monocytes isolated from buffy coats (purchased from Sanquin, The Netherlands) 
were cultivated to differentiate into immature DCs, as described previously [28]. 
DCs were incubated for 48 h at 37 °C in RPMI 1640, containing 500 U/ml GM-CSF 
and 100 U/ml IL4, with a fixed volume of liposomes mixed with HA: 20, 50 or 100 µl 
of liposome suspension (containing 2 mg total lipid/ml and 10 µg HA/ml) in 1 ml 
cell culture medium, and LPS (100 ng/ml cell culture medium) was used as a 
positive control. Cells were washed 3 times with PBS containing 1% (w/v) BSA and 
2% (v/v) FBS and incubated for 30 min with a mixture of 50_ diluted anti-HLADR-
FITC, CD40-PE or anti-CD86-APC (Becton Dickinson) on ice, to measure the 
expression of MHCII, CD40 or CD86, respectively, on the surface of the DCs. Cells 
were washed and expression of the surface markers was quantified by using flow 
cytometry (FACS canto, Becton Dickinson). Live cells were gated based on forward 
and side scatter. The upregulation of the three surface markers by 100 ng/ml LPS 
was set as 100%. A minimum of 10,000 gated cells were analyzed in each 
experiment. The study was repeated using DCs from at least three different donors. 
2.6. Statistical analysis 
All the data of the in vitro studies were analyzed with a one way analysis of 
variance (ANOVA) with Bonferroni’s post-test. Regarding the in vivo data, Antibody 
titers were logarithmically transformed before statistical analysis. A one-way 
ANOVA with a Kruskal–Wallis post-test analysis was performed in order to 
demonstrate significant differences between the experimental groups, with the 
exception of the comparison between HA/DC-Chol10 and HA/DC-Chol50 liposomes 
(HA loaded liposomes containing 10 mol% and 50 mol% DC-Chol, respectively), 
which were analyzed using a Student’s t-test. The statistical analysis was carried out 
using Prism (Graphpad, San Diego, USA), and a p value less than 0.05 was considered 
to be significant. 
 
3. Results and discussion 
3.1. Preformulation and immunogenicity testing of DC-Chol/DPPC liposomes  
The stability of vaccine components is important for further development of 
experimental vaccines. Since it was not possible to produce stable 100% DC-Chol 
liposomes, we mixed the cationic compounds with a neutral phospholipid, DPPC, 
which has a similar Tm compared to the other cationic compounds selected (see 
Table 1). In order to study how the content of a cationic compound affects the 
liposome characteristics and the immune response, we first produced DPPC/DC-
Chol liposomes with 10 and 50 mol% of the cationic compound, further referred to 
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as DC-Chol10 and DCCho50 liposomes, respectively. The two liposome formulations 
resulted in liposomes showed a similar average hydrodynamic diameter (ca. 160 
nm) and polydispersity (Table 2). However, the surface charge of the two liposome 
formulations differed significantly: the zeta potential of the DC-Chol10 and DC-Chol50 
liposomes was +24.6 ± 0.5 mV and +51.1 ± 4.5 mV (mean ± SD of n = 3), respectively. 
Based on a stability study (data not shown), we selected two relatively low HA/lipid 
ratios for the rest of our experiments: 1/ 800 and 1/200 (w/w), with an equivalent 
of 0.5 and 2 µg HA/dose injected. The addition of both HA dosages to the empty DC-
Chol liposomes resulted in four formulations: HA0.5/DC-Chol10, HA0.5/ DC-Chol50, 
HA2/DC-Chol10, and HA2/DC-Chol50 liposomes. After mixing the antigen with the 
liposomes, no detectable change in hydrodynamic diameter and zeta potential was 
observed for the HA0.5/DC-Chol liposomes, whereas the HA2/DC-Chol liposomes 
showed a slight increase in their hydrodynamic diameter and a decrease in their 
zeta potential (Table 2), suggesting adsorption of the negatively charged antigen to 
the surface of the cationic liposomes to occur. To estimate the amount of adsorbed 
HA to the liposomes, we used fluorescently labeled HA (IR-HA) and cation-exchange 
chromatography to separate the free IR-HA from the IR-HA/liposomes based on 
charge differences (IR-HA is negatively charged, whereas the IR-HA/liposomes are 
positively charged). There was a clear influence of the pH on the retention of free IR-
HA to the cation-exchange column, and a pH of 10.5 was required in order to limit 
the retention of free IR-HA to 9%, whereas the liposomes were fully retained. When 
the HA/liposomes were applied to the column, any retention above 9% was 
assumed to be due to HA adsorption to the liposomes. While we recognize that the 
separation conditions necessary for optimum separation between free and liposome 
associated HA significantly deviate from physiological conditions, by using this 
method, we do obtain insight in the relative interaction of the different liposomes 
with the antigen. Separation of liposomes and HA by gel permeation 
chromatography was not successful because of the particulate nature of the free 
antigen (results not shown).  
 
 
Fig. 1: Estimated amount of liposome-associated HA: The columns represent the percentage of 
fluorescently labeled HA retained on cation exchange column (compared to the total amount applied) 




The method was applied to the IR-HA/DC-Chol liposomes. The results showed 
less retention of IR-HA with the IR-HA/DC-Chol10 liposomes (11% retention) 
compared to IR-HA/DC-Chol50 liposomes (55% retention) (Fig. 1). This 
proportional (fivefold) increase of both the amount of cationic compound and HA 
retained would imply that the higher positive charge density, resulting in a higher 
zeta potential (see results above and Table 2), led to a stronger interaction of the 
negatively charged antigen with the surface of the liposomes. 
Next, we investigated the influence of the amount of the cationic compound in the 
liposomes on the immune response. In order to compare the immunogenicity of 
HA2/DC-Chol10 and HA2/ DC-Chol50 liposomes, the liposome formulations were 
injected subcutaneously in mice, and HA-specific serum IgG1 and IgG2a were 
assessed after the first (prime) and the second (boost) immunization. The results 
show that HA2/DC-Chol50 liposomes induced significantly higher IgG1, IgG2a (Fig. 
2), and HI titers (Fig. 5) than the HA2/DC-Chol10 liposomes (after both prime and 
boost). A high zeta potential (i.e., high density of cationic charge) and strong binding 
of HA to the liposomal surface seem to be a key to the induction of a strong immune 
response. These results correlate with recent studies which showed that increasing 
the density of cationic charge at the liposome surface induced stronger DCs 
maturation [29] and that cationic liposomes induced a stronger Th1 response than 
neutral ones [30]. Based on these results, we selected the 50% liposomes for the rest 
of our study (i.e., the comparison of the four cationic compounds). 
 
 
Fig. 2: Immune response in mice after subcutaneous injection with HA2/DC-Chol10 and HA2/DC-Chol50 
liposomes: HA-specific serum IgG1 and IgG2a after prime (  ) and boost (  ). Each bar represents the 
average log titer of a group of mice + SEM (n=7). Significant differences between groups are indicated with * 
(p < 0.05). 




3.2. Comparison of liposomes containing different cationic compounds 
As previously detailed, the comparison of the four cationic compounds required 
the incorporation of a neutral phospholipid in the liposome formulation. Based on 
the pilot study, each formulation was based on HA mixed with empty liposomes 
composed of an equimolar amount of DPPC and one of the four cationic compounds: 
DDA, DPTAP, eDPPC, and DC-Chol. They are further referred to as: HA/DDA50, 
HA/DPTAP50, HA/ eDPPC50, and HA/DC-Chol50 liposomes. The liposomes were 
prepared, physic chemically characterized, and tested in vivo. As shown in Table 2, 
the DDA50, eDPPC50, and DC-Chol50 liposomes showed similar average 
hydrodynamic diameters (Z ave between 148 and 174 nm) and zeta potentials (ca. 
50 mV). However, the DPTAP50 liposomes were smaller (Z ave 104 nm) and 
exhibited a slightly lower zeta potential (+41 mV). The size and the charge of the 
empty liposomes were found to be stable during storage at 4 °C for at least 56 days 
(data not shown). The melting temperature (Tm) of the liposomes as determined by 
DSC ranged from 40 °C (eDPPC50 liposomes) to 55 °C (DPTAP50 and DDA50 
liposomes) (Table 2). The higher Tm of the latter might be the result of concentrated 
and highly organized DDA or DPTAP regions with elevated phase transition 
temperatures, as observed previously [31]. Despite these differences in melting 
temperature, the liposomes will show similar rigidity at body temperature. The DC-
Chol50 liposomes did not show any observable melting temperature. The very 
similar structure of DC-Chol and cholesterol can relate these results to previous 
studies investigating the effect of cholesterol concentration into the liposome 
membrane on the bilayer organization. These studies showed that an amount of 
10% cholesterol results in a slight decrease in the Tm (Tm DC-Chol10 = 38 °C, as 
compared to 41 °C for pure DPPC liposomes), whereas above 30% cholesterol, a 
liquid-ordered phase is induced, where no Tm can be detected [32,33]. Each of the 
four types of liposomes was mixed with two different concentrations of HA (0.5 and 
2 µg /dose), resulting in eight formulations, the characteristics of which are 
summarized in Table 2. The addition of 0.5 µg HA induced small changes in 
hydrodynamic diameters (from -2 to +29 nm), and a slight decrease (with 0.5–4 mV) 
in zeta potential. These changes were more pronounced with 2 µg HA: a rise in size 
(with 2–33 nm) and pdi (with 0.03– 0.1) was observed, along with a drop in zeta 
potential (with -2.3 to -9.3 mV). These results suggest the adsorption of the 
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The HA/liposome’s hydrodynamic diameter and zeta potential were monitored 
for 56 days. No changes were observed for the zeta potential (data not shown). 
Regarding the size (Fig. 3) and the polydispersity (Supplementary Fig. S1), the 
HA/DC-Chol50 and HA/eDPPC50 liposomes were stable for at least 56 days, with 
both HA dosages. Similar results were obtained with HA0.5/DDA50 and 
HA0.5/DPTAP50 liposomes. However, with a higher amount of HA (HA2/DDA50 and 
HA2/DPTAP50), the liposomes showed a major increase in hydrodynamic diameter 
and pdi after 56 days. Besides, the retention rate of HA with the liposomes ranged 
from 55% to 76% (Fig. 1).  
Fig. 3: 
Colloidal stability of HA/DDA50 liposomes (A), HA/DPTAP50 liposomes (B), HA/eDPPC50 liposomes (C) 
and HA/DC-Chol50 liposomes (D) stored at 4 °C. Two different types of HA/liposomes have been tested: 
HA0.5/liposomes (open symbols; dashed lines) and HA2/liposomes (solid symbols and lines). Error 
bars represent the standard deviation (n=3). 
 
These results confirm that there was a strong interaction between the liposomes 
and the antigen. The HA2/DC-chol50 liposomes showed somewhat lower adsorption 
rates compared to the three other formulations, which is likely due to the high pH 
used (10.5) during the cation-exchange chromatography, which was required to 
achieve separation of free and liposome-associated HA. At this pH, the tertiary 
amine group of DC-Chol becomes partially deprotonated, as reflected by a drop in 
zeta potential (not shown), whereas the other cationic compounds carry a 
quaternary ammonium group that remains charged independent of the pH. 
Therefore, at a physiological pH, the HA2/DC-chol50 liposomes may show a similar 




hydrodynamic diameters in the same order of magnitude and comparable positive 
zeta potentials. Despite the relatively unstable HA2/DDA50 and HA2/DPTAP50 
formulations, the eight formulations were similar in size and zeta potential at the 
day of preparation and injection. This allowed us to study the influence of the 
liposome composition on the adjuvant effect. In order to compare the adjuvant effect 
of the liposomes containing any of the four cationic compounds, the liposome 
formulations (400 µg total lipid/dose) with two different doses of HA (0.5 and 2 µg 
HA/dose) were injected subcutaneously in mice. The HA-specific serum IgG, IgG1, 
and IgG2a titers were assessed after the first (prime) and the second (boost) 
immunization, and hemagglutination inhibition (HI) titers, as a measure for the level 
of functional antibodies, were measured after the boost. Since for all groups the HA-
specific serum IgG titers were very comparable to the IgG1 titers, we present here 
only the IgG1 data. After immunization with 2 µg HA, the antigen alone (plain HA) 
showed fairly high levels of IgG1, with a small increase when it was associated to the 
cationic liposomes (Fig. 4A). However, this enhancement of the IgG1 response was 
only significant for the HA2/DC-Chol50 liposomes, after both prime and boost. With 
the lower dose of HA (0.5 µg), the plain HA induced lower IgG1 titers and we 
observed more differences between the groups (Fig. 4B). After the prime, the 
HA0.5/DC-Chol50 liposomes were significantly more immunogenic than plain HA and 
the HA0.5/DPTAP50 liposomes. After the boost, the HA0.5/DC-Chol50 liposomes 
enhanced the IgG1 titers compared to plain HA, the HA0.5/DDA50 liposomes, and the 
HA0.5/eDPPC50 liposomes. The other liposome formulations did not induce 
significantly higher IgG1 titers than plain HA. The IgG2a titers, although 
substantially lower than the IgG1 titers, showed a similar trend. With 2 µg HA, the 
HA2/DC-Chol50 liposomes enhanced significantly the IgG2a titers compared to the 
HA2/DPTAP50 and the HA2/eDPPC50 groups (Fig. 4A). Although HA2/DC-Chol50 
showed superior titers compared to the non-adjuvanted group after the prime and 
the boost and for both HA  dosages (0.5 and 2 µg), no statistical significance could be 
established as plain HA induced a response in only one or two mice (Fig. 4B). 
Similarly, the other formulations showed a trend toward increased IgG2a titers. 
Overall, the lower (0.5 µg) dose of HA resulted in lower IgG1 titers and enabled a 
better discrimination of the immunogenicity of the formulations as compared to the 
higher (2 µg) HA dose. Interestingly, the dose reduction had very little effect on the 
intensity of the IgG2a titers, but did reduce the number of responders, especially 
after the prime, both for IgG1 and IgG2a. Besides the intensity of the immune 
response, the type of immune response induced is an important criterion, and in 
order to induce a good antiviral protection, the Th1 pathway should preferably be 
induced [10]. A Th1 mediated immune response is notably characterized by high 
IgG2a antibody titers, and a Th2 type response by IgG1 titers. Thus, the high levels of 
IgG2a and IgG1 induced by the HA/DC-Chol50 liposomes are in favor of a balanced 
Th1/Th2 response compared to the Th2-biased response induced by plain HA and 
the other cationic liposomes (Fig. 4).  




Fig. 4: Immune response in mice after subcutaneous injection with 2.0 µg (A) or 0.5 µg (B) of plain HA 
and liposomal HA: HA-specific serum IgG1 and IgG2a after prime (
 
) and boost (  ). Each bar 
represents the average log titer + SEM of a group of 7 mice. For groups containing non-responders, the 
ratio of number of responding mice/total number of mice is indicated. Significant differences between 
groups are indicated with ** (p < 0.01), or * (p < 0.05). 
 
These results correlate with the HI titers measured after boost immunization 
(Fig. 5). For both HA doses, the HA/DC-Chol50 liposomes tended to induce the 
highest HI titers, with statistical significant differences observed with the HA0.5/DC-
Chol50 liposomes. Unfortunately, we were unable detect any significant increase in 
INFɣ secretion by spleen cells (collected from spleens isolated at the end of the in 
vivo study) induced by our formulations, after restimulation with HA (data not 
shown). This is however in accordance with a study by McNeil et al., who showed 
that, unlike DSPC/Chol/DDA/TDB liposomes, DSPC/Chol/DDA liposomes 
(associated with the Ag85B-ESAT-6 antigen) failed to promote INFɣ production 
from mice’s isolated blood lymphocytes 3 weeks after immunization [34].  
In summary, not only the intensity of the immune response was improved by the 
HA/DC-Chol50 liposomes, but also the quality of the immune response, as reflected 
by a strong elevation of the IgG2a titers compared to plain HA. The other cationic 
liposome formulations (HA/DDA50, HA/DPTAP50, and HA/eDPPC50) induced lower 




IgG2a levels induced after immunization with 2 µg HA (Fig. 4A) and the HI titers, 
even though the latter did not show significant differences between each other, the 
potency of the formulations can be ranged in the following order: HA/DC-
Chol50>>HA/DDA50 > [HA/eDPPC50 ~ HA/DPTAP50] > HA.  
 
Fig. 5: HI titers after boost subcutaneous injection of mice with plain HA and HA/liposomes: 0.5 µg 
HA/dose (
 
) and 2 µg HA/dose (  ).. Each bar represents the average + SEM of a group of 7 mice. 
Significant differences between groups are indicated with * (p < 0.05). 
 
In a recent study, Henriksen-Lacey et al. [30] compared the INFɣ secretion by 
mice’s peripheral blood mononuclear cells (PBMCs) induced by DDA, DC-Chol, and 
DOTAP liposomes mixed with trehalose dibehenate (TDB). The results showed that 
400-nm DDA/TDB liposomes were more potent to induce a Th1 response compared 
to the 200-nm DC-Chol/TDB liposomes (no pdi value available) and 760-nm 
DOTAP/TDB liposomes (pdi = 0.32). Although the goal of that study was to 
investigate the adjuvant effect of several cationic lipids, the use of TDB, the 
heterogeneity of size, and zeta potential (DC-Chol/TDB liposome’s zeta potential 
dropped from +45 to +20 mV after 56 days of storage) are other factors that could 
have influenced the immune response. The authors ascribed the superior 
adjuvanticity of DDA liposomes to a mechanism of longer- term retention and 
slower release of liposomes and antigen from the injection site, but it is still not clear 
which of the cationic lipids or what physicochemical characteristics are responsible 
for this effect. Indeed according to the literature, larger liposomes (0.5–2 µm) 
remain at the site of injection and are taken up by DCs, whereas small liposomes 
(<200 nm) are drained to the lymph nodes [35,36], implying different mechanisms 
depending on the size of the liposomes. For comparison, the formulations tested in 
our study were very similar in size (hydrodynamic diameter between 100 and 200 
nm), allowing us to compare the effect of different cationic compounds on the 
immunogenicity of the liposomes. Although a potential influence of small differences 
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in size on the antibody response cannot be totally excluded, we conclude that the 
DC-Chol-containing cationic liposomes have a stronger adjuvant effect than any of 
the other cationic compounds in liposomes with otherwise similar physicochemical 
characteristics. 
 
3.3. Effect of HA/cationic liposomes on DC maturation in vitro 
In order to obtain a better understanding of the superiority of DC-Chol liposomes 
over the other formulations tested, we studied the ability of DC-Chol liposomes 
compared to DDA liposomes (as a representative of the other liposome types) to 
enhance DC maturation. The up-regulation of the surface markers MHCII, CD40, and 
CD86 was determined after culturing immature DCs in the presence of the 
HA2/liposomes. The HA2/DDA50 liposomes had no significant effect on the 
expression level of any of the surface markers tested (Fig. 6). However, after 
incubation with the HA2/ DC-Chol50 liposomes, the DCs showed elevated MHCII 
expression compared to untreated cells. The levels of expression of MHCII proved to 
be concentration dependent, with statistical significant differences for the higher 
dosages, up to levels even higher than those induced with the positive control (LPS) 
(Fig. 6; see Supplementary Fig. S2 for representative histograms). A similar (but 
statistically not significant) trend was observed for the effect of HA2/DC-Chol50 
liposomes on the expression of CD40, whereas only a marginal effect on the CD86 
expression was observed. To rule out LPS contamination in our experiments, TLR-4 
transfected HEK cells were exposed to the formulations and we found the LPS 
content to be below the detection limit (<0.1 ng/ml, data not shown). The 
concomitant increase in MHCII and CD40 expression is usually known as a sign of 
DC activation [37]. However, the low level of CD86 observed in this study is not in 
favor of such activation. The different levels of upregulation of the DC surface 
markers might be explained by the influence of the cholesterol backbone of the DC-
Chol, as cholesterol has been shown to upregulate MHC-II expression [38]. The lack 
of DC activation by DDA liposomes is consistent with another study [39]. However, 
the upregulation of the DC surface markers induced by our DC-Chol liposomes 
differs from a previous investigation using a DC-Chol dispersion that did not result 






Fig. 6: Upregulation of DC maturation markers induced by raising amounts of HA2/DDA50 and 
HA2/DC-Chol50 liposome suspensions: 20, 50 or 100 μl (expressed as volume of liposome suspension, 
containing 2mg total lipid/ml and 10 µg HA/ml) added per 1 ml culture medium. M = culture medium, 
LPS = lipopolysaccharide. The values are expressed as mean fluorescence intensity (compared to that 
of the control group: 100 ng LPS /ml culture medium) after application of the liposomal HA 
formulations. Error bars represent the SEM (n=3). Significant differences between groups are indicated 
with ** (p < 0.01), or * (p < 0.05). 
 
4. Conclusions and perspectives 
In this study, we studied the influence of charge density, liposome composition, 
and chemistry of the cationic compound on the adjuvant effect of cationic liposomes, 
loaded with two different dosages of HA. Taken together the results of the 
immunogenicity studies, we noticed that (1) liposomes with a similar size, surface 
charge, and HA loading but different composition induced different immune 
responses, (2) DC-Chol liposomes containing a higher amount of cationic compound 
and showing a higher HA association were the most potent adjuvant for HA, (3) they 
induced a stronger immune response, and (4) they enhanced the expression of some 
DC maturation markers. This implies that, although the cationic charge is a critical 
factor for the adjuvanticity of cationic liposomes, the adjuvant effect is also 
influenced by the composition of the liposomes. The superiority of the HA/DC-Chol50 
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liposomes raises a new question regarding the physicochemical properties 
responsible for the enhanced adjuvant effect induced by these cationic liposomes. 
The DC-Chol compound was the only one with a tertiary amine and also the only 
sterol-containing lipid included in our study. As detailed previously, the 
hydrodynamic diameters, the zeta potential and the HA loading of the HA/DCChol50 
liposomes were similar to those of the other liposomes tested; only the composition 
and the Tm differed. The absence of a detectable Tm in the HA/DC-Chol50 liposomes 
can be related to the liquid organized state observed in lipid bilayers made of DPPC 
containing more than 30% DC-Chol. Whether this difference in bilayer organization 
or the chemistry of the head group of DC-Chol, or both, is responsible for the 
increased adjuvanticity of the HA/ DC-Chol50 liposomes is subject of ongoing 
studies. However, as observed in the in vitro study, the interaction with the DCs 
seems to be one of the key point of the adjuvant mechanism of these formulations. In 
conclusion, the role of cationic liposomes as adjuvant for HA depends on their 
composition. The characteristics of both the hydrophilic head group and the 
hydrophobic tail may affect the immune response. Moreover, the differences 
observed between our results and other studies should make anyone cautious with 
generalizations about the adjuvant effect of cationic liposomes. In order to gain 
more insight into the influence of the physichochemical characteristics of the 
cationic liposomes on their adjuvant effect, studies comparing the effect of 
liposomes with different Tm, size, administered via different routes of 
administration [41] should be performed. Finally, the encapsulation of TLR ligands 
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Fig. S1: Polydispersity of HA/DDA50 liposomes (A), HA/DPTAP50 liposomes (B), HA/eDPPC50 
liposomes (C) and HA/DC-Chol50 liposomes (D) stored at 4 °C. Two different types of HA/liposomes 
have been tested: HA0.5/liposomes (open symbols; dashed lines) and HA2/liposomes (solid symbols 







Fig. S2: Representative flow cytometry histograms of different DC maturation markers (FITC-MHCII, 
plots on the left; PE-CD40, plots in the middle; and APC-CB86, plots on the right) induced by: DC-Chol50 
liposomes (green histograms, upper plots), DDA50 liposomes (pink histograms, lower plots), culture 
medium (red histograms) and 100 ng/ml LPS (blue histograms). 
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Cationic liposomes are potential adjuvants for influenza vaccines. In a previous 
study we reported that among a panel of cationic liposomes loaded with influenza 
hemagglutinin (HA), DC-Chol:DPPC (1:1 molar ratio) liposomes induced the 
strongest immune response. However, it is not clear whether the cholesterol (Chol) 
backbone or the tertiary amine head group of DC-Chol was responsible for this. 
Therefore, in the present work we studied the influence of Chol in the lipid bilayer of 
cationic liposomes. Moreover, we investigated the effect of the HA loading method 
(adsorption versus encapsulation) and the encapsulation of immune modulators in 
DC-Chol liposomes, on the immunogenicity of HA. Liposomes consisting of a neutral 
lipid (DPPC or Chol) and a cationic compound (DC-Chol, DDA, or eDPPC) were 
produced by film hydration-extrusion with/without an encapsulated immune 
modulator (CpG or imiquimod). The liposomes generally showed comparable size 
distribution, zeta potential and HA loading. In vitro studies with monocyte-derived 
human dendritic cells and immunization studies in C57Bl/6 mice showed that (1) 
liposome-adsorbed HA is more immunogenic than encapsulated HA, (2) the 
incorporation of Chol in the bilayer of cationic liposomes enhances their adjuvant 
effect, and (3) CpG loaded liposomes are more efficient at enhancing HA-specific 
humoral responses than plain liposomes or Alhydrogel. 
  




The main strategy against seasonal influenza outbreaks is vaccination. Subunit 
vaccines are known to be the safest influenza vaccines produced, but they are less 
immunogenic than whole virus and split vaccines. Some populations are less 
protected after vaccination, such as the elderly due to senescence of their immune 
system [1]. One way to enhance the immunogenicity of subunit vaccines is the use of 
adjuvants.  
Cationic liposomes are known for their ability to enhance the potency of subunit 
vaccines and may serve to lower the dose and thereby, enable the increase of 
vaccine supply. There is a large number of publications investigating cationic 
liposomes as an adjuvant for diverse antigens (reviewed in [2–5]). It has been 
demonstrated that the surface charge of the liposomes influences the immune 
response: positively charged lipid vesicles are taken up more efficiently than 
negatively charged or neutral vesicles by macrophages and dendritic cells (DCs) 
[6,7]. However, the different formulations, immunization schedules and read-out 
models used in these studies hamper straight comparisons and make it very difficult 
to judge which cationic liposomes have the most favorable adjuvant effect. 
The work presented here is a follow up of our previous study in which we 
investigated the adjuvant effect of cationic liposomes mixed with a subunit H3N2 
influenza vaccine based on purified hemagglutinin (HA) [8]. In that study, we 
showed that the adjuvant effect of cationic liposomes not only depends on their 
charge, but also on the cationic compound selected and its amount in the liposomal 
bilayer. The best adjuvant effect was obtained with liposomes containing DC-Chol 
(compared to DDA, eDPPC and DPTAP). However, it is not clear whether the tertiary 
amine head group and/or the sterol backbone of the DC-Chol molecule was 
responsible for this.  
The major aim of the present study was to get a better understanding of the 
superior adjuvant effect of DC-Chol liposomes. Ideally, we should compare 
liposomes made of DC-Chol with liposomes based on a cationic compound based on 
the same DC head group (a tertiary amine) but linked to a saturated carbon chain. 
Unfortunately, such a compound is not commercially available. Therefore, in the 
work presented here we focused on the influence of the Chol backbone in the 
cationic liposomal bilayer on HA immunogenicity by comparing the adjuvant effect 
of liposome formulations based on the same saturated cationic compounds mixed 
with either Chol or DPPC. Furthermore, we studied the effect of antigen loading 
method (encapsulation versus adsorption) and the encapsulation of immune 
modulators on the immune response against HA [9,10]. In general, co-delivery of an 
antigen with an immune modulator in one particulate system is an effective way to 
generate a strong immune response [11,12]. Moreover, the ability of cationic 
liposomes to enhance DC uptake could potentially help to target endosomal toll-like 




bacterial cytosine phosphodiester guanine oligomer (CpG), an agonist of TLR-9 [13], 
imiquimod, a TLR-7 agonist [14,15]. The immunogenicity of the liposomal HA 
formulations was evaluated for APC maturation in vitro as well as in a mouse model 
and compared to that of HA formulated with aluminum hydroxide (Al(OH)3), an 
adjuvant known to promote a Th2 type response. 
 
2. Experimental Section 
2.1. Materials 
Cholesterol, 1,2-diacyl-sn-glycero-3-ethylphosphocholine (eDPPC), dimethyl 
dioctadecyl-ammonium bromide (DDA), 3β-[N-(N',N'-dimethylaminoethane)-
carbamoyl] cholesterol (DC-Chol) were obtained from Avanti Lipids (Alabaster, AL, 
USA). 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was kindly provided by 
Lipoid GmbH (Ludwigshafen, Germany). Influenza hemagglutinin (HA) antigen 
(H3N2 Wisconsin strain) was obtained from Solvay (Weesp, The Netherlands). 
Bovine serum albumin (BSA) was purchased from Merck (Darmstadt, Germany). 
ELISA plates were obtained from Greiner (Alphen a/d Rijn, The Netherlands). 
Horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (γ chain specific), 
IgG1 (γ1 chain specific) and IgG2a/c (γ2a chain specific) were ordered from 
Southern Biotech (Birmingham, AL, USA). Chromogen 3,3',5,5'-tetramethylbenzidine 
(TMB) substrate buffer for ELISA, granulocyte macrophage colony stimulating factor 
(GM-CSF) and interleukin-4 (IL4), were provided by Biosource-Invitrogen (Breda, 
The Netherlands). CpG (1826 and 2006) and imiquimod were purchased from 
InvivoGen (Toulouse, France). Alhydrogel was kindly provided by Brenntag 
(Frederikssund, Denmark). Fetal bovine serum (FBS) and all culture media, 
including penicillin/streptomycin and trypsin were supplied from Gibco (Invitrogen, 
Carlsbad, CA, USA). Nimatek® (100 mg/mL ketamine, Eurovet Animal Health B.V., 
Bladel, The Netherlands) and Rompun® (20 mg/mL xylazine, Bayer B.V., Mijdrecht, 
The Netherlands) were obtained from the pharmacy of Leiden University Medical 
Center. 
2.2. Preparation of Cationic Liposomes 
Liposomes were prepared by the film hydration method, followed by extrusion, 
as described previously [8]. Briefly, desired amounts of a cationic compound (DDA, 
eDPPC, or DC-Chol) were dissolved in a chloroform/methanol 9:1 (v/v) solution 
with a neutral phospholipid (DPPC) or with Chol, and mixed in a round bottom flask 
of 50 mL. A thin lipid film was formed at the bottom of this flask under reduced 
pressure by using a rotary evaporator. The film was hydrated in a HEPES sucrose 
buffer (20 mM HEPES, 10% (w/v) sucrose, pH 7.4) to obtain a final lipid 
concentration of 5 mg/mL. During the hydration step the temperature was 
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maintained at 60 °C for 20 min, with continuous stirring at 300 rpm. The dispersion 
was extruded (LIPEX™ extruder, Northern Lipids Inc., Burnaby, Canada) 5 times 
through a polycarbonate filter (Nuclepore Track-Etched Membranes, Whatman, 's-
Hertogenbosch, The Netherlands) with a pore size of 800 nm and 5 times through a 
filter with a pore size of 200 nm (Nucleopore Millipore, Amsterdam, The 
Netherlands).  
Loading of TLR ligands into the DC-Chol:DPPC liposomes was done in two 
different ways, depending on the TLR ligand:CpG was dissolved in the buffer used to 
hydrate the lipid film, while imiquimod was dissolved in a chloroform/methanol 9:1 
(v/v) solution and mixed with the lipid solution before preparation of the lipid film. 
For both TLR ligands, a dose of 2 µg adjuvant/400 µg total lipids was used to obtain 
an adjuvant/antigen ratio of ca. 1:1 (w/w).  
2.3. Preparation of HA Formulations 
HA was adsorbed to liposomes (HA/liposomes) as described before [8]. Briefly, 
the antigen stock solution (453 µg/mL HA) was mixed with the preformed 
liposomes to obtain a final concentration of 10 µg/mL HA (corresponding to 2 µg HA 
per injected dose) and 2000 µg/mL lipid compounds. Al(OH)3 formulations were 
prepared by diluting Alhydrogel with HEPES sucrose buffer. Subsequently, the 
antigen solution was added to an equal volume of adjuvant, to obtain a final 
concentration of 10 µg/mL HA and 600 µg/mL Al(OH)3. For the encapsulation of HA 
in DC-Chol:DPPC liposomes, we adapted a method described by Babai et al. [16]. 
Briefly the HA/DC-Chol:DPPC liposomes, produced with the adsorption method 
described above, were freeze-dried overnight, followed by a stepwise rehydration 
with warm (40 °C) Milli-Q water. 
2.4. Characterization of the Formulations  
2.4.1. Hydrodynamic Diameter and Zeta Potential 
Particles’ hydrodynamic diameter and polydispersity index (pdi) were 
determined by means of dynamic light scattering (DLS) using a NanoSizer ZS 
(Malvern Instruments, Worcestershire, UK). The zeta potential (ZP) of the liposomes 
was measured by laser Doppler velocimetry on the same instrument by using a zeta 
dip cell (Malvern Instruments, Worcestershire, UK). Prior to analysis, samples were 
diluted 10 fold in 20 mM HEPES, pH 7.4. The measurements were performed at 25 
°C and Malvern DTS software (version 6.10, Worcestershire, UK) was used for data 
acquisition and analysis. 




HA was labeled with IRDye 800 CW (Licor Bioscience, The Netherlands) 
according to the manufacturer’s instructions and the labeled HA (IR-HA) was used 
to estimate the extent of antigen adsorption to the cationic liposomes. The IR-HA 
was mixed with the cationic liposomes (2 µg IR-HA/400 µg total lipids). HA 
adsorption to the cationic liposome was measured via cation-exchange 
chromatography on a Hi Trap CM FF column (GE Healthcare, Pittsburgh,PA, USA) 
and measuring the fluorescence intensity of the unbound fraction, as described 
before [8]. 
2.4.3. Adjuvant Loading 
The amount of CpG incorporated in the liposomes was indirectly determined by 
using FITC-labeled CpG (10% of total CpG). The free TLR ligand was separated from 
the liposomes by filtration using a Vivaspin 2 centrifugal concentrator (PES 
membrane, MWCO 300 kDa, Sartorius Stedim, Nieuwegein, The Netherlands) and 
quantified using a fluorescence plate reader (TECAN infinite M1000, Tecan Group 
Ltd., Männedorf, Switzerland). The same separation method was used for the 
imiquimod-containing liposomes and (unlabeled) imiquimod was quantified by its 
absorbance at 247 nm. 
2.5. Immunogenicity Study  
Female C57-BL/6 mice, 8 weeks old at the start of the vaccination study, were 
purchased from Charles River (Maastricht, The Netherlands) and maintained under 
standardized conditions in the animal facility of the Leiden Academic Centre for 
Drug Research at Leiden University. The study was done under the guidelines 
compiled by the Animal Ethic Committee of The Netherlands. The mice received two 
subcutaneous injections of 200 µL vaccine containing 2 µg HA: a prime (day 1) and a 
boost (day 22). Blood samples were taken one day before prime and boost, and 3 
weeks after the boost. Hemagglutination inhibition (HI) titers in serum after boost 
were determined as described previously [8]. IgG isotype-specific analysis was 
performed by ELISA using the horseradish peroxidase-conjugated anti-mouse total 
IgG, IgG1 and IgG2a. C57BL/6 mice express the Igh1-b gene, which encodes the 
IgG2c isotype rather than IgG2a. However, here we used an anti-IgG2a isotype 
(which cross-reacts with IgG2c [17]) and titers are reported as IgG2a/c titers. 
Antibody titers were determined at the midpoint of the optical density-log dilution 
curves after subtraction of the naïve background, and none-responding mice were 
given an arbitrary titer of 10. Furthermore, mouse spleens were collected three 
weeks after the last immunization, and after homogenization the cells were re-
stimulated in vitro with 5 µg/mL of HA, while the release of interferon gamma (IFN-
γ) was determined by ELISA. 
 
Adjuvant Effect of Cationic Liposomes for Subunit Influenza Vaccine 
 
107 
2.6. In Vitro Uptake of HA by Dendritic Cells 
HA was conjugated with FITC by using the FluoReporter® FITC Protein Labeling 
Kit (Invitrogen, Paisley, UK) according to the manufacturer’s instructions. Immature 
DCs were incubated for 4 h (at 4 °C and 37 °C) with to 2.5 µg/mL HA-FITC, free or 
adsorbed to 50 µL of a 2 mg/mL liposome suspension. The cells were washed three 
times with PBS containing 1% (w/v) bovine serum albumin and 2% (v/v) fetal 
bovine serum). Next, HA-FITC association with the DCs was quantified by flow 
cytometry (FACSCanto II, Becton Dickinson, San Jose, CA, USA). Living cells were 
gated based on forward and side scatter and HA-FITC association was expressed as 
the mean fluorescence intensity (MFI). 
2.7. In Vitro Dendritic Cell Maturation 
Monocytes isolated from buffy coats (purchased from Sanquin, Leiden, The 
Netherlands) were cultivated to differentiate into immature dendritic cells (DCs), as 
described previously [8]. Briefly, immature DCs were incubated for 48 h at 37 °C in 1 
mL cell culture medium in presence of 10 µL of a 2 mg/mL liposome suspension. 
After being washed three times the cells were incubated for 30 min with a mixture 
of 50× diluted anti-MHCII-FITC or anti-CD86-APC, anti-CD40-PE (Becton Dickinson, 
Breda, The Netherlands) on ice. The expression of the surface markers was 
quantified by using flow cytometry (FACS canto, Becton Dickinson). Live cells were 
gated based on forward and side scatter. The up-regulation of the three surface 
markers by 100 ng/mL LPS (positive control) was set at 100%. At least 10,000 gated 
cells were analyzed in each experiment. 
2.8. Statistical Analysis 
Antibody and HI titers were logarithmically transformed before statistical 
analysis. All data were analyzed by a two-tailed Mann-Whitney test to demonstrate 
significant differences between the experimental groups, except for Figures 4 and 5 
where the increase of the immune responses induced by DPPC:DC-Chol liposomes + 
immunomodulators was compared to the negative control (DPPC:DC-Chol liposomes 
alone), and thus we used a one-tailed Mann-Whitney test. 
3. Results 
3.1. DC-Chol:DPPC Liposomes with Adsorbed versus Encapsulated HA 
We prepared DC-Chol:DPPC liposomes loaded with the antigen HA using two 
different methods: adsorption (HA ad./DC-Chol:DPPC) and encapsulation (HA 
enc./DC-Chol:DPPC). After preparation, the particle size, the zeta-potential and the 




Table 1. Physicochemical characteristics of DC-Chol:DPPC liposomes before and after hemagglutinin 
(HA) loading. 
Formulation Lipid  molar ratio 
HA/liposomes 
Zave (nm) pdi ZP (mV) LE HA (%) 
DC-Chol:DPPC 1:1 160 (±4) 0.07 (±0.01) +51.1 (±4.5) not applicable 
HA ad./DC-Chol:DPPC 1:1 165 (±5) 0.08 (±0.02) +41.8 (±9.5) 60 (±4) 
HA enc./DC-Chol:DPPC 1:1 155 (±18) 0.08 (±0.04) +46.5 (±2.3) 63 (±5) 
Results are expressed as average ± standard deviation (n = 3 independent batches). 
The results (Table 1) showed that the size and pdi of the HA/liposomes were 
similar (also compared to the empty DC-Chol:DPPC liposomes). Additionally, the HA 
loading efficiency measured was very similar for the two HA loading methods (60% 
versus 63%). Finally, the positive ZP of the liposomes tended to become smaller with 
the encapsulation or adsorption of HA.  
 
Fig. 1: Immune response in mice vaccinated with 2.0 µg of free HA versus HA adsorbed to DC-
Chol:DPPC liposomes (HA ad./DC-Chol:DPPC) and HA encapsulated in DC-Chol:DPPC liposomes (HA 
enc./DC-Chol:DPPC): HA-specific serum IgG1 titer after prime (A) and boost (B); IgG2a/c titer after 
boost (C); and HI titer after boost (D). For panels A–C, each dot represents the log serum titer of an 
individual mouse (non-responding mice were given an arbitrary titer of 10) and bars represent 
average log titer + SEM. For panel D, each dot represents the log HI titer in serum of an individual 
mouse and bars represent the geometric mean. Significant differences between the groups treated with 
liposomal formulations are indicated with * (p < 0.05). 
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To assess the immunogenicity of the two liposomal HA formulations (HA ad./DC-
Chol:DPPC and HA enc./DC-Chol:DPPC), these were injected subcutaneously in mice. 
HA-specific serum IgG1, and IgG2a/c titers were assessed after the first (prime) and 
the second (boost) immunization, and hemagglutination inhibition (HI) titers, as a 
measure for the level of functional antibodies, were measured after the boost. The 
results (Figure 1) show a superior HI titer induced by the HA adsorbed liposomes 
after the boost immunization compared to the HA encapsulated liposomes (p < 0.05) 
(Figure 1D). The IgG1 titers measured after the boost showed the same trend 
(Figure 1B), although the difference was not statistically significant. No difference 
was observed between the IgG2a/c titers induced by the two formulations (Figure 
1C). In conclusion, HA ad./DC-Chol:DPPC liposomes were slightly more 
immunogenic and are easier to prepare than HA enc./DC-Chol:DPPC liposomes. 
Therefore, we followed the adsorption procedure in the follow-up studies described 
below. 
 
3.2. Cationic Liposomes with Different Bilayer Compositions 
A series of liposome formulations was prepared to investigate the influence of 
the Chol backbone on the adjuvant effect of cationic liposomes. As detailed earlier, 
we were not able to use the DC-Chol for this study as there are no commercially 
available compounds with the same head group linked to saturated carbon chains. 
Instead, we prepared cationic liposomes either composed of (50 mol% Chol + 50 
mol% cationic compound) or (50 mol% neutral saturated phospholipid + 50 mol% 
cationic compound). For this study, two cationic compounds were selected: DDA and 
eDPPC (the two best cationic compounds after DC-Chol identified in our previous 
study [8]); and the neutral saturated phospholipid DPPC. The four resulting 
formulations enabled the comparison of cationic liposomes containing either 100% 
saturated chain liposomes or 50% Chol. 
Using the HA adsorption method, the antigen was mixed with each type of 
liposomes and the physicochemical characteristics of the resulting formulations 
were determined, as summarized in Table 2. In line with our previous paper [8], the 
addition of HA to the four liposome formulations induced an increase in the 
liposome’s hydrodynamic diameter (from 2–31 nm) and a slight decrease of their ZP 
(data not shown). These results indicate that the negatively charged antigen was 
successfully adsorbed to the surface of the cationic liposomes. The adsorption of HA 
to the liposomal surface was confirmed by measuring the retention of HA during 
cation exchange chromatography, showing HA loading between 68% and 79% 
(Table 2). Apart from the difference in pdi noticed for the DDA:DPPC formulation, 
likely due to some aggregation, the formulations were similar in size and ZP, and 
showed a similarly strong interaction with the antigen, irrespective of the presence of 




corresponding to the gel-to-liquid-crystalline phase transition temperature of the 
saturated lipid, for liposomes containing DC-Chol or Chol. In contrast, sharp 
transitions were detected at 40 °C and 55 °C for liposomes prepared from DDA:DPPC 
and eDPPC:DPPC, respectively (data not shown). These observations are consistent 
with our previous results [8]. 
Table 2. Physicochemical characteristics of cholesterol- and DPPC-based cationic liposomes after 
mixing with HA. 
Formulation Molar ratio HA/liposomes Zave (nm) pdi ZP (mV) LE HA (%) 
DDA:DPPC 1:1 207 (±11) 0.44 (±0.02) +44 (±3.3) 76 (±2) 
DDA:Chol 1:1 179 (±2) 0.09 (±0.01) +46.5 (±1.2) 78 (±3) 
eDPPC:DPPC 1:1 150 (±5) 0.13 (±0.02) +47.8 (±1.4) 68 (±3) 
eDPPC:Chol 1:1 166 (±4) 0.10 (±0.02) +45.5 (±0.9) 79 (±1) 
Results are expressed as average ± standard deviation (n = 3 independent batches). 
We investigated if the cationic liposome composition influences the interaction 
between the antigen and monocyte derived DCs. For this purpose we produced a 
HA-FITC conjugate (referred to as HA*), which was adsorbed to different cationic 
liposomes formulations, and monitored the relative amount of DC associated HA* 
with flow cytometry. Figure 2 shows that after 4 h incubation at 37 °C, the DCs 
mixed with positively charged liposomes (HA*/DC-Chol:DPPC) showed a higher MFI 
compared to the groups incubated with either HA* alone (p < 0.05) or HA* mixed 
with a neutral liposome formulation (HA*/DPPC:Chol). Not only the liposome’s 
charge, however, affected HA’s interaction with the DCs, but also the presence of 
Chol in the cationic liposomes: incubation of DCs with HA*/eDPPC:Chol resulted in a 
higher MFI than DCs incubated with HA*/eDPPC:DPPC. Besides, for DDA liposomes, 
the MFI induced by HA*/DDA:Chol tended to exceed that induced by 
HA*/DDA:DPPC, but no statistical significance was demonstrated.  
With the above incubation study we assessed HA* association with DCs (i.e., the 
sum of adhesion and uptake). In order to study the extent of HA* uptake by DCs, the 
incubation study was also performed at 4 °C, where energy dependent uptake is 
inhibited but adhesion will still occur [18].  
DCs incubated with the cationic HA*-containing liposomes at 4 °C showed a lower 
MFI compared to the 37 °C groups, indicating that the cell-associated fluorescence at 
37 °C was mainly caused by HA* uptake rather than association with the cell 
membrane. In contrast, DCs incubated with HA* alone or mixed with neutral 
liposomes showed hardly any decrease in MFI compared to the 37 °C conditions, 
indicating that most of the (low) MFI intensity at 37 °C was due to adhered HA*. 
 
 




Fig. 2: Effect of formulations on HA-FITC (indicated as HA*) uptake by DCs. Bars represent the 
mean fluorescence intensity (+SEM) of three batches of DCs incubated with HA-FITC alone or 
mixed with liposomes for 4 h at 37 °C versus 4 °C. Significant differences between the 
formulations are indicated with * (p < 0.05). See Supplementary Material, Figure S1, for 
representative side scatter-forward scatter dot plots. 
With the above incubation study we assessed HA* association with DCs (i.e., the 
sum of adhesion and uptake). In order to study the extent of HA* uptake by DCs, the 
incubation study was also performed at 4 °C, where energy dependent uptake is 
inhibited but adhesion will still occur [18].  
DCs incubated with the cationic HA*-containing liposomes at 4 °C showed a lower 
MFI compared to the 37 °C groups, indicating that the cell-associated fluorescence at 
37 °C was mainly caused by HA* uptake rather than association with the cell 
membrane. In contrast, DCs incubated with HA* alone or mixed with neutral 
liposomes showed hardly any decrease in MFI compared to the 37 °C conditions, 
indicating that most of the (low) MFI intensity at 37 °C was due to adhered HA*. 
The immunogenicity of the HA loaded cationic liposomes was assessed in mice. 
Figure 3 shows that the presence of Chol positively influenced the immune response 
against HA. In particular, eDPPC:Chol liposomes induced superior IgG1 titers after 
prime (p < 0.05) and boost (p < 0.001), as well as superior IgG2a/c and HI titers 
after boost (p < 0.05 and p < 0.01, respectively), compared to eDPPC:DPPC 
liposomes. The influence of Chol was not as clear for the DDA liposomes: DDA:Chol 
liposomes induced either a similar (IgG1 and HI titer) or a slightly but not 
significantly higher (IgG2a/c) immune response compared to liposomes without 
Chol (DDA:DPPC). These results are in line with the in vitro DC studies discussed 
above and suggest an overall positive effect of the presence of Chol in the liposomal 





Fig. 3: Immune response in mice vaccinated with 2.0 µg HA, either free or mixed with liposomes with or 
without Chol: HA-specific serum IgG1 after prime (A) and boost (B); IgG2a/c after boost (C); and HI titer 
after boost (D). For panels A–C, each dot represents the log serum titer of an individual mouse (non-
responding mice were given an arbitrary titer of 10) and bars represent average log titer + SEM. For 
panel D, each dot represents the log HI titer in serum of an individual mouse and bars represent the 
geometric mean. Significant differences between the groups treated with the liposomal formulations 
are indicated with * (p < 0.05), ** (p < 0.01), or *** (p < 0.001). 
3.3. Encapsulation of Immune Modulators in DC-Chol:DPPC Liposomes 
We prepared DC-Chol:DPPC liposomes with two different immune modulators: 
CpG and imiquimod (10 µg/mL). This resulted in three formulations with similar 
physicochemical characteristics and the addition of HA had little effect on their size, 
while a small drop of the ZP was observed (data not shown). The characteristics of 
the liposomes after mixing them with HA are summarized in Table 3. The average 
size of the adjuvanted HA/liposomes ranged between 165 and 177 nm and the 
average ZP between +43.4 and +47.2 mV. The incorporation of imiquimod in the DC-
Chol:DPPC bilayer did not affect the HA loading efficiency. However, the 
encapsulation of CpG in the liposomes induced a drop of the HA loading efficiency 
from 60% (Table 1) to 30% (Table 3), probably due to competition between the 
antigen and the TLR ligand, both of which are negatively charged. The loading 
efficiency of CpG and imiquimod was practically 100%. 
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Table 3. Physicochemical characteristics of aluminium hydroxide and adjuvanted cationic liposomes 
after mixing with HA. 
Formulation Molar ratio 
HA/liposomes (HA/alum) 
Zave (nm) pdi ZP (mV)  
Al(OH)3 1:1 5,624 (±543) 0.34 (±0.09) +2.7 (±0.3 )  
DC-Chol:DPPC + CpG 1:1 177 (±4) 0.10 (±0.04) +46.2 (±0.6)  
DC-Chol:DPPC + Imiquimod 1:1 168 (±3) 0.09 (±0.02) +43.6 (±2.6)  
Results are expressed as average ± standard deviation (n = 3 independent batches). 
In our previous study, DC-Chol:DPPC liposomes showed a relatively weak ability 
to activate DCs, in spite of their adjuvant effect demonstrated in vivo [8]. Since 
imiquimod and CpG have been described in the literature as potent immune 
modulators for DCs’ activation [19,20], we investigated the potency of these two 
immune modulators incorporated in HA/DC-Chol:DPPC liposomes to enhance DC 
maturation. After 48 h of incubation, the DCs incubated with HA/liposome 
formulations containing immune modulators showed a significantly higher level (p < 
0.05) of MHCII expression compared to DCs exposed to HA/DC-Chol:DPPC 
liposomes (Figure 4A). A comparable effect (p < 0.05) was observed for CD86 (Figure 
4C), but not for CD40 (Figure 4B). These results indicate that encapsulating immune 
modulators in DC-Chol:DPPC liposomes enhances their adjuvanticity, as shown by 




Figure 4. Upregulation of DC maturation markers induced by free HA versus HA mixed with 
liposomes: MHCII (A); CD40 (B); and CD86 (C). The values are expressed as percentage of mean 
fluorescence intensity (compared to a 100 ng/mL LPS control group, arbitrarily set as 100%). 
Error bars represent SEM (n = 3). Significant differences between the formulations and the DC-
Chol:DPPC group are indicated with * (p < 0.05). See Supplementary Material, Figure S2, for 





The liposomal formulations were tested for their immunogenicity in mice in 
comparison with HA/DC-Chol:DPPC liposomes and HA adjuvanted with the licensed 
adjuvant: aluminum hydroxide (HA/Al(OH)3) [22]. Our results showed CpG 
increased the immunogenicity in mice of the HA/liposomes, whereas imiquimod 
appeared to be ineffective (Figure 5). The incorporation of CpG in the HA/DC-
Chol:DPPC liposomes resulted in a raise of the IgG2a/c titer and the number of 
responders compared to the HA/DC-Chol:DPPC liposomes alone (p < 0.05). Also the 
HI titer seemed to be increased, although not significantly (p = 0.0548). When 
compared to HA alone, Al(OH)3 enhanced the anti-HA IgG1 titers (Figure 5A,B) and 
HI titers (Figure 5D), but not the IgG2a/c titers (Figure 5C). This is in line with 
aluminum salts known ability to enhance a Th2 type response [22]. The liposomal 
CpG formulation, however, not only induced significantly higher IgG1 and HI titers 
but also elicited higher IgG2a/c titers after the boost compared to HA/Al(OH)3 
(Figure 5B–D). In contrast, CpG alone (without liposomes) when mixed with HA did 
not induce a stronger immune response compared to HA/DC-Chol:DPPC liposomes 
or HA/Al(OH)3 (unpublished results). This, together with the above-mentioned 
results, illustrates that encapsulation of CpG in cationic liposomes is advantageous 




Fig. 5: Immune response in mice vaccinated with 2.0 µg HA, free or mixed with Al(OH)3 or with 
liposomes containing different immune modulators: HA-specific serum IgG1 after prime (A); and boost 
(B); IgG2a/c after boost (C); and HI titer after boost (D). For panels A–C, each dot represents the log 
serum titer of an individual mouse (non-responding mice were given an arbitrary titer of 10) and bars 
represent average log titer + SEM. For panel D, each dot represents the log HI titer in serum of an 
individual mouse and bars represent the geometric mean. Significant differences between the 
liposomal formulations and the DC-Chol:DPPC group are indicated with * (p < 0.05); significant 
differences between the liposomal formulations and the Al(OH)3 group are indicated with ++ (p < 0.01).  




In the present study, adsorption of HA to cationic DC-Chol:DPPC liposomes was 
shown to be a simple and effective method to enhance the immunogenicity of the 
antigen, as compared to liposomal encapsulation of the antigen. The higher HI titers 
induced by adsorbed HA compared to encapsulated HA might be explained by the 
presentation of the antigen at the outer surface of the liposomes, as previously 
detailed for a virosomal vaccine composed of influenza membrane fragments 
(including HA) mixed with phospholipids. It was shown that the positioning of the 
antigen in the virosomes influenced its processing and presentation pathway [23]. 
Although encapsulated and surface-associated liposomal antigens may induce T cell 
responses equivalently, several studies have shown increased antibody induction 
mediated by surface-associated antigen [24–26]. This may be because surface-associated 
antigen is available on the particle surface for antibody or B cell receptor 
recognition, whereas encapsulated antigen requires vesicle disruption to become 
accessible [27,28]. For surface-associated antigens, B cells may recognize intact 
liposomal antigen directly or via opsonized liposomes bound to Fc receptors or 
complement receptors on APCs [29]. Another hypothesis is that the way HA is 
associated with the liposomes could induce different processing of the antigen and a 
different kinetics of the anti-HA antibody response.  
In our previous study, DC-Chol:DPPC liposomes were shown to be a stronger 
adjuvant for HA than cationic DPPC liposomes containing other cationic compounds 
(DDA, DPTAP, or eDPPC) [8]. However, it remained unclear whether the cationic 
tertiary amine (DC-) head group or the Chol backbone was responsible for the 
superior adjuvant effect. The results of our present study indicate that the presence 
of Chol contributes to the adjuvant effect of cationic liposomes. In particular, the 
HA/eDPPC:Chol liposomes enhanced both the antigen uptake by DCs in vitro and the 
immunogenicity of HA (HI titer, IgG2a/c and IgG1 antibody secretion) compared to 
the liposomes without Chol (HA/eDDPC:DPPC). A positive correlation between 
uptake by APCs and adjuvanticity in vivo has been described previously [30]. 
However, for the DDA-liposomes we noticed only a small influence of Chol, although 
there was a trend that the presence of Chol in DDA-liposomes increased HA uptake 
in vitro and enhanced the IgG2a/c response in vivo.  The influence of Chol in 
liposomal formulations for vaccination has been investigated in some other studies. 
For instance, in a study about the relationship between the phospholipid 
composition and the immunogenicity of a liposomal tumor antigen, Bakouche et al. 
showed that optimal immunogenicity in rats was obtained with 20 mol% Chol in the 
liposomal bilayer [31]. Batenjany et al. [32] reported that the immunogenicity of a 
Muc1 mucin peptide in DPPC/Chol liposomes for immunotherapy of 
adenocarcinoma was optimal when the Chol content was above 30 mol%. Other 
studies also showed a beneficial effect of Chol on vaccination [33], but it is still not 




membranes contain about 25 mol%–50 mol% of Chol, this lipid could play an 
important role in the interaction between cells and liposomes [28]. Furthermore, 
Chol is known to influence membrane fluidity and to enhance liposomal stability. 
For instance, the interaction of liposomes with plasma proteins has no negative 
effect on liposome stability when they are enriched in Chol [29], which is explained 
by its influence on the lipid packing in the liposomal membrane and its ability to 
prevent phospholipid loss due to uptake by high density lipoproteins [30].  
Regarding the different antibody subtypes, we noticed a raise in the anti-HA 
IgG2a/c response after immunization with HA/eDPPC:Chol liposomes, which are 
known to modulate the immune response to a Th1 direction [34]. This effect might 
be explained not only by the improved ability of these liposomes to be taken up by 
DCs, but also by a more favorable environment for HA to interact with the cell 
membrane when associated with Chol-containing liposomes. Hemagglutinin in its 
natural environment (the influenza virus envelope) interacts with Chol rich 
membranes [35]. For virosomal HA it has been reported that, following endosomal 
uptake, acidification within the endosome induces HA-mediated fusion (resulting 
from a conformational change in HA), leading to release of the virosomes into the 
cytoplasm and a potential MHC class I presentation [36]. Therefore, even though we 
did not investigate those aspects in our study, it may be that HA itself enhances its 
own delivery into the cells, leading a potent immune response.  
We focused our investigations on the influence of Chol in the lipid bilayer of 
different cationic liposomes. Christensen et al. [37] compared the immunogenicity of 
the antigen Ag85B-ESAT-6 combined with cationic liposomes prepared with either 
the saturated DDA (mixed with the immune modulator D-(+)-trehalose 6,6'-
dibehenate [TDB]) or its unsaturated analog dimethyl dioleoyl ammonium bromide 
(DODA:TDB), which was also suggested as a comparison between rigid and fluid 
liposomes. The results showed that (gel-state) DDA liposomes were more retained 
at the injection site than (fluid-state) DODA liposomes, and were better at attracting 
APCs and inducing a Th1 response. Although we did not investigate the influence of 
liposome fluidity, the conclusion of Christensen et al. differs from what we observed 
in our work, as we concluded that liposomes based on a liquid organized state (50% 
Chol) were superior to rigid liposomes. However, it is very difficult to compare these 
two studies due to some major differences between the components used (e.g., the 
antigen, the immune modulator) and likely the physico-chemical characteristics 
(such as size and antigen loading). 
In our last experiments, we used Al(OH)3 as a reference adjuvant. It is known that 
aluminum salts promote a Th2 response, and their adjuvant mechanisms is 
supposedly acting through antigen depot effect, enhancement of antigen uptake by 
antigen presenting cells (APCs) and the induction of inflammation (known to be 
activated through local release of uric acid and the triggering of the NALP3 
inflammasome) [38,39]. In comparison, the encapsulation of immune modulators in 
the DC-Chol:DPPC liposomes not only enhanced the overall immune response, but 
also resulted in a raise of the anti-HA IgG2a/c response. This is in line with a raise of 
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INF-γ secretion by spleen cells (collected from spleens isolated after the in vivo 
study) induced by our formulations (see Supplementary Material, Figure S3). The 
encapsulation of CpG in nanoparticles has been shown in other studies to enhance 
the immune response against the co-encapsulated antigen toward a Th1 response 
[9,40,41,13]. For instance, Joseph et al. [42] succeeded to enhance the 
immunogenicity of a subunit influenza vaccines combined with CpG loaded 
DMPC:DMPG (dimyristoyl-phosphatidylcholine, dimyristoyl-phosphatidylglycerol) 
liposomes. Whereas they used 5 µg CpG per dose, we used only 2 µg. Dose reduction 
might be interesting with regard to the potential side effects of CpG. In contrast with 
liposomal CpG, free CpG administrated with HA was not effective in our study. This 
can be explained by the physicochemical properties of CpG for its delivery in soluble 
form to the intracellularly localized TLR-9 receptor. 
Surprisingly, imiquimod, when encapsulated in HA/DC-Chol:DPPC liposomes, did 
not lead to a better immune response compared to plain HA/DC-Chol:DPPC 
liposomes. The beneficial activity of TLR-7 ligands was reported in by Geeraedts et 
al. [43], who explained the superior protection induced by H5N1 whole inactivated 
virus (WIV) compared with subunit or split virus by TLR-7 stimulation from the 
RNA contained in the WIV vaccine. Therefore, we expected a stronger impact of the 
TLR-7 agonist imiquimod on the immunogenicity of our influenza subunit vaccine. 
Weldon et al. [44] reported that skin delivery of influenza H1N1 subunit vaccine 
combined with imiquimod elicited higher levels of serum IgG2a antibody and HI 
titers as compared to unadjuvanted vaccine in Balb/c mice. They used a similar 
antigen/imiquimod ratio and imiquimod dose compared to our present study. 
Besides the different mouse model, the route of administration [45] could be a 
reason for the discrepancy between their and our results. Moreover, the imiquimod 
dose used in our study might have been too low. For instance, Rizwan et al. [14] 
succeeded to raise the humoral response against OVA after intramuscular injection 
in C57Bl/6 mice using liposomes adjuvanted with monophosphoryl lipid A 
combined with very high doses of imiquimod (150 µg/immunization). Finally, the 
localization of the imiquimod in the DC-Chol:DPPC liposomal membrane might have 
limited its interaction with the TLR-7 receptor. Indeed, imiquimod is a hydrophobic 
molecule [46] and it was mixed with the lipid film before hydration. This might have 
led to entrapment deep in the lipid bilayer. It would be of interest in future studies 
to determine to which extent CpG and imiquimod are liberated from the liposomes. 
As mentioned earlier, IgG1 and IgG2a/c antibody levels can be used as indicators 
of a Th2 and Th1 immune response, respectively. As demonstrate in this study, HA 
needs to be combined with adjuvants to efficiently stimulate both Th1 and Th2 
responses, as has also been shown by others [16]. There is growing evidence that 
both (CD4+) T helper cells and (CD8+) cytotoxic T lymphocytes not only play an 
important role in controlling viral infection, but also may reduce the severity of 
disease and decrease mortality [47,48]. The use of cationic liposomes containing 




modulate the immune response towards the Th1 direction is therefore a highly 
relevant approach.  
5. Conclusions 
Notwithstanding the clear advantage of using DC-Chol cationic liposomes as an 
adjuvant for HA, there is still a lack of knowledge regarding their adjuvant 
mechanism. The data presented here shed some more light on this. First, HA 
adsorption to the liposome surface was shown to be at least as effective, and an 
easier way to enhance the immunogenicity of HA, compared to HA encapsulation. 
Moreover, the presence of Chol in the cationic liposomes appeared to be beneficial 
for the immune response against HA, an effect that depended on the cationic 
compound selected. Furthermore, HA was taken up by DCs to a higher extent and 
was more immunogenic in mice when it was mixed with eDPPC:Chol liposomes 
compared to eDPPC:DPPC liposomes. Finally, co-delivery of CpG with HA/DC-
Chol:DPPC liposomes was found to further promote the immunogenicity of the 
antigen. In conclusion, cationic liposomes have potential for influenza vaccination 
provided that the bilayer components and the immune modulator to be 
encapsulated in these liposomes are carefully selected and their adjuvant 
mechanism is further investigated. 
 
  




1. Parodi, V.; de Florentiis, D.; Martini, M.; Ansaldi, F. Inactivated influenza vaccines: Recent 
progress and implications for the elderly. Drugs Aging 2011, 28, 93–106. 
2. Perrie, Y.; Mohammed, A.R.; Kirby, D.J.; McNeil, S.E.; Bramwell, V.W. Vaccine adjuvant systems: 
Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 2008, 364, 272–280. 
3. Korsholm, K.S.; Andersen, P.L.; Christensen, D. Cationic liposomal vaccine adjuvants in animal 
challenge models: Overview and current clinical status. Expert Rev. Vaccines 2012, 11, 561–577. 
4. Watson, D.S.; Endsley, A.N.; Huang, L. Design considerations for liposomal vaccines: Influence of 
formulation parameters on antibody and cell-mediated immune responses to liposome associated 
antigens. Vaccine 2012, 30, 2256–2272. 
5. Perrie, Y.; Kastner, E.; Kaur, R.; Wilkinson, A.; Ingham, A.J. A case-study investigating the 
physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum. Vaccin. 
Immunother. 2013, 9, doi:10.4161/hv.24694. 
6. Schwendener, R.A.; Lagocki, P.A.; Rahman, Y.E. The effects of charge and size on the interaction of 
unilamellar liposomes with macrophages. Biochim. Biophys. Acta 1984, 772, 93–101. 
7. Miller, C.R.; Bondurant, B.; McLean, S.D.; McGovern, K.A.; O’Brien, D.F. Liposome-cell interactions 
in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and 
sterically stabilized liposomes. Biochemistry 1998, 37, 12875–12883. 
8. Barnier-Quer, C.; Elsharkawy, A.; Romeijn, S.; Kros, A.; Jiskoot, W. Cationic liposomes as adjuvants 
for influenza hemagglutinin: More than charge alone. Eur. J. Pharm. Biopharm. 2012, 81, 294–302. 
9. Bal, S.M.; Hortensius, S.; Ding, Z.; Jiskoot, W.; Bouwstra, J.A. Co-encapsulation of antigen and toll-
like receptor ligand in cationic liposomes affects the quality of the immune response in mice after 
intradermal vaccination. Vaccine 2011, 29, 1045–1052. 
10. Alving, C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140,  
1–13. 
11. Amorij, J.P.; Kersten, G.F.; Saluja, V.; Tonnis, W.F.; Hinrichs, W.L.; Slütter, B.; Bal, S.M.; Bouwstra, 
J.A.; Huckriede, A.; Jiskoot, W. Towards tailored vaccine delivery: Needs, challenges and 
perspectives. J. Control. Release 2012, 161, 363–376. 
12. O’Hagan, D.T.; de Gregorio, E. The path to a successful vaccine adjuvant—‘the long and winding 
road’. Drug Discov. Today 2009, 14, 541–551. 
13. Wilson, K.D.; de Jong, S.D.; Tam, Y.K. Lipid-based delivery of cpg oligonucleotides enhances 
immunotherapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61, 233–242. 
14. Rizwan, S.B.; McBurney, W.T.; Young, K.; Hanley, T.; Boyd, B.J.; Rades, T.; Hook, S. Cubosomes 
containing the adjuvants imiquimod and monophosphoryl lipid a stimulate robust cellular and 
humoral immune responses. J. Control. Release 2013, 165, 16–21. 
15. Suzuki, H.; Wang, B.; Shivji, G.M.; Toto, P.; Amerio, P.; Tomai, M.A.; Miller, R.L.; Sauder, D.N. 
Imiquimod, a topical immune response modifier, induces migration of langerhans cells.  
J. Invest. Dermatol. 2000, 114, 135–141. 
16. Babai, I.; Samira, S.; Barenholz, Y.; Zakay-Rones, Z.; Kedar, E. A novel influenza subunit vaccine 
composed of liposome-encapsulated haemagglutinin/neuraminidase and il-2 or gm-csf. II. 
Induction of th1 and th2 responses in mice. Vaccine 1999, 17, 1239–1250. 
17. Martin, R.M.; Brady, J.L.; Lew, A.M. The need for igg2c specific antiserum when isotyping 
antibodies from c57bl/6 and nod mice. J. Immunol. Methods 1998, 212, 187–192. 
18. Copland, M.J.; Baird, M.A.; Rades, T.; McKenzie, J.L.; Becker, B.; Reck, F.; Tyler, P.C.;  
Davies, N.M. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003, 21, 883–890. 
19. Hartmann, G.; Weiner, G.J.; Krieg, A.M. Cpg DNA: A potent signal for growth, activation, and 
maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 1999, 96, 9305–9310. 
20. Larange, A.; Antonios, D.; Pallardy, M.; Kerdine-Romer, S. Tlr7 and Tlr8 agonists trigger different 




21. Jeras, M.; Bergant, M.; Repnik, U. In vitro preparation and functional assessment of human 
monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. 
Transpl. Immunol. 2005, 14, 231–244. 
22. Lindblad, E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004, 82, 497–505. 
23. Huckriede, A.; Bungener, L.; ter Veer, W.; Holtrop, M.; Daemen, T.; Palache, A.M.; Wilschut, J. 
Influenza virosomes: Combining optimal presentation of hemagglutinin with 
immunopotentiating activity. Vaccine 2003, 21, 925–931. 
24. Vannier, W.E.; Snyder, S.L. Antibody responses to liposome-associated antigen. Immunol. Lett. 
1988, 19, 59–64. 
25. Therien, H.M.; Lair, D.; Shahum, E. Liposomal vaccine: Influence of antigen association on the 
kinetics of the humoral response. Vaccine 1990, 8, 558–562. 
26. Tan, L.; Weissig, V.; Gregoriadis, G. Comparison of the immune response against polio peptides 
covalently-surface-linked to and internally-entrapped in liposomes. Asian Pac. J. Allergy Immunol. 
1991, 9, 25–30. 
27. White, W.I.; Cassatt, D.R.; Madsen, J.; Burke, S.J.; Woods, R.M.; Wassef, N.M.; Alving, C.R.; Koenig, S. 
Antibody and cytotoxic t-lymphocyte responses to a single liposome-associated peptide antigen. 
Vaccine 1995, 13, 1111–1122. 
28. Serre, K.; Machy, P.; Grivel, J.C.; Jolly, G.; Brun, N.; Barbet, J.; Leserman, L. Efficient presentation of 
multivalent antigens targeted to various cell surface molecules of dendritic cells and surface ig of 
antigen-specific b cells. J. Immunol. 1998, 161, 6059–6067. 
29. Batista, F.D.; Harwood, N.E. The who, how and where of antigen presentation to b cells.  
Nat. Rev. Immunol. 2009, 9, 15–27. 
30. Foged, C.; Arigita, C.; Sundblad, A.; Jiskoot, W.; Storm, G.; Frokjaer, S. Interaction of dendritic cells 
with antigen-containing liposomes: Effect of bilayer composition. Vaccine 2004, 22, 1903–1913. 
31. Bakouche, O.; Gerlier, D. Enhancement of immunogenicity of tumour virus antigen by liposomes: 
The effect of lipid composition. Immunology 1986, 58, 507–513. 
32. Batenjany, M.M.; Boni, L.T.; Guo, Y.; Neville, M.E.; Bansal, S.; Robb, R.J.; Popescu, M.C. The effect of 
cholesterol in a liposomal muc1 vaccine. Biochim. Biophys. Acta 2001, 1514, 280–290. 
33. Ishida, T.; Yasukawa, K.; Kojima, H.; Harashima, H.; Kiwada, H. Effect of cholesterol content in 
activation of the classical versus the alternative pathway of rat complement system induced by 
hydrogenated egg phosphatidylcholine-based liposomes. Int. J. Pharm. 2001, 224, 69–79. 
34. Finkelman, F.D.; Holmes, J.; Katona, I.M.; Urban, J.F., Jr.; Beckmann, M.P.; Park, L.S.; Schooley, K.A.; 
Coffman, R.L.; Mosmann, T.R.; Paul, W.E. Lymphokine control of in vivo immunoglobulin isotype 
selection. Annu. Rev. Immunol. 1990, 8, 303–333. 
35. Veit, M.; Thaa, B. Association of influenza virus proteins with membrane rafts. Adv. Virol. 2011, 
2011, doi:10.1155/2011/370606. 
36. Amacker, M.; Engler, O.; Kammer, A.R.; Vadrucci, S.; Oberholzer, D.; Cerny, A.; Zurbriggen, R. 
Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic t cells.  
Int. Immunol. 2005, 17, 695–704. 
37. Christensen, D.; Henriksen-Lacey, M.; Kamath, A.T.; Lindenstrom, T.; Korsholm, K.S.; Christensen, 
J.P.; Rochat, A.F.; Lambert, P.H.; Andersen, P.; Siegrist, C.A.; et al. A cationic vaccine adjuvant based 
on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a 
distinct cd4 t cell-inducing capacity compared to its unsaturated analog.  
J. Control. Release 2012, 160, 468–476. 
38. Lambrecht, B.N.; Kool, M.; Willart, M.A.; Hammad, H. Mechanism of action of clinically approved 
adjuvants. Curr. Opin. Immunol. 2009, 21, 23–29. 
39. Martinon, F.; Mayor, A.; Tschopp, J. The inflammasomes: Guardians of the body. Annu. Rev. 
Immunol. 2009, 27, 229–265. 
40. Bal, S.M.; Slütter, B.; Verheul, R.; Bouwstra, J.A.; Jiskoot, W. Adjuvanted, antigen loaded  
n-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent 
immunogenicity in mice. Eur. J. Pharm. Sci. 2012, 45, 475–481. 
Adjuvant Effect of Cationic Liposomes for Subunit Influenza Vaccine 
 
121 
41. Nembrini, C.; Stano, A.; Dane, K.Y.; Ballester, M.; van der Vlies, A.J.; Marsland, B.J.;  
Swartz, M.A.; Hubbell, J.A. Nanoparticle conjugation of antigen enhances cytotoxic t-cell 
responses in pulmonary vaccination. Proc. Natl. Acad. Sci. USA 2011, 108, E989–E997. 
42. Joseph, A.; Louria-Hayon, I.; Plis-Finarov, A.; Zeira, E.; Zakay-Rones, Z.; Raz, E.; Hayashi, T.; 
Takabayashi, K.; Barenholz, Y.; Kedar, E. Liposomal immunostimulatory DNA sequence  
(iss-odn): An efficient parenteral and mucosal adjuvant for influenza and hepatitis b vaccines. 
Vaccine 2002, 20, 3342–3354. 
43. Geeraedts, F.; Goutagny, N.; Hornung, V.; Severa, M.; de Haan, A.; Pool, J.; Wilschut, J.; Fitzgerald, 
K.A.; Huckriede, A. Superior immunogenicity of inactivated whole virus h5n1 influenza vaccine is 
primarily controlled by toll-like receptor signalling. PLoS Pathog. 2008, 4, e1000138. 
44. Weldon, W.C.; Zarnitsyn, V.G.; Esser, E.S.; Taherbhai, M.T.; Koutsonanos, D.G.; Vassilieva, E.V.; 
Skountzou, I.; Prausnitz, M.R.; Compans, R.W. Effect of adjuvants on responses to skin 
immunization by microneedles coated with influenza subunit vaccine. PLoS One 2012, 7, e41501. 
45. Slütter, B.; Bal, S.M.; Ding, Z.; Jiskoot, W.; Bouwstra, J.A. Adjuvant effect of cationic liposomes and 
cpg depends on administration route. J. Control. Release 2011, 154, 123–130.  
46. Chollet, J.L.; Jozwiakowski, M.J.; Phares, K.R.; Reiter, M.J.; Roddy, P.J.; Schultz, H.J.; Ta, Q.V.; Tomai, 
M.A. Development of a topically active imiquimod formulation. Pharm. Dev. Technol. 1999, 4, 35–
43. 
47. O’Neill, E.; Krauss, S.L.; Riberdy, J.M.; Webster, R.G.; Woodland, D.L. Heterologous protection 
against lethal a/hongkong/156/97 (h5n1) influenza virus infection in c57bl/6 mice. J. Gen. Virol. 
2000, 81, 2689–2696. 
48. Droebner, K.; Haasbach, E.; Fuchs, C.; Weinzierl, A.O.; Stevanovic, S.; Buttner, M.; Planz, O. 
Antibodies and cd4(+) t-cells mediate cross-protection against h5n1 influenza virus infection in 







Fig. S1: Side scatter-forward scatter (SSC/FSC) dot plots of DCs after 4 h incubation at 4 °C and 37 °C 
with plain HA and HA/liposome formulations. The gate represents the DC population and excludes 
cellular debris. The percentages of cells included in the DC gate decreased by ca. 10% when the DCs 
were incubated with cationic liposomes, suggesting a slight toxic effect. No such a decrease was noticed 
with either HA or (neutral) DPPC:chol liposomes. 
 




Fig. S2: Side scatter-forward scatter (SSC/FSC) dot plots of DCs after 48 h incubation at 37 °C with 
plain HA, plain HA/DC-Chol:DPPC liposomes and adjuvanted HA/DC-Chol:DPPC liposome formulations. 
The gate represents the DC population and excludes cellular debris. The percentages of cells included 
in the DC gate when the DCs were incubated with cationic liposomes were similar to those observed 






Fig. S3: IFN-γ levels secreted by spleen cells collected from mice immunized with 2.0 µg HA, free or 
mixed with Al(OH)3 or with liposomes containing different immune modulators. The spleens were 
collected three weeks after the boost immunization, after homogenization the cells were re-stimulated 
with 5 μg/mL HA, and the release of IFN-γ was determined by ELISA. Significant differences between 









7.1 – Summary 
The best form of protection against influenza is vaccination, in terms of efficacy 
to protect individuals and reduction of the social impact of epidemics on our human 
societies. Chapter 1 of this thesis details the current influenza vaccines available and 
their lack of efficacy, and the current need for new adjuvanted influenza 
formulations. Pathogens are often particles and formulating antigens into 
nanoparticles (NP) results in systems that resemble the pathogens in terms of size, 
and notably can promote antigen uptake by dendritic cells (DC). The principal aim of 
the research in this thesis was to investigate how NP systems can act as an adjuvant 
for subunit influenza vaccine.  
To achieve this aim two types of NP are described: peptide polymer NP and 
cationic liposomes, and the following three sub-aims were defined: 
• to explore different nanoparticulate systems in order to modulate the 
immunogenicity of a subunit influenza vaccine; 
• to study the impact of the composition, charge and preparation of these 
systems on their adjuvant effect; 
• to investigate the co-delivery of HA antigen with immune-modulators, 
encapsulated into nanoparticulate systems.  
 
First, the potential of polymer-peptide block copolymer NP as adjuvant for 
seasonal influenza vaccine was studied (chapter 2- 4). For this purpose we 
customized the constituents and the preparation method. The poly(γbenzyl L-
glutamate)-E (PBLG-E) represents the first of a new class of peptides: polypeptide-b-
peptides. These compounds are versatile regarding their chain length and 
functionality. Different methods are available to produce polymer-peptide based NP, 
but each of them has limitations and might not be suitable for vaccine delivery. 
Therefore, in chapter 2 we have developed a new method for producing 
nanovesicles, also known as polymersomes, from polypeptide-b-peptides PBLG36-E, 
using a detergent removal method that has been used for many decades to produce 
liposomes. The method was adapted to be suitable for use with block copolymers, 
which have different assembly characteristics than lipids. The detergent aided 
polymersome preparation utilizes detergent molecules (sodium cholate) to 
molecularly disperse the block copolymer in aqueous solution, a role that is usually 
taken by organic solvents. The shielding effect of the detergent on the block 
copolymer is then reduced such that the intrinsic morphology of the block 
copolymer particles, i.e. polymersomes, emerges. This method has the advantage of 
not requiring organic solvent or a high energy input (e.g., sonication), known has 
factors which can denature biomolecules.  
Chapter 3 presents a study of the adjuvant effect of polymersomes loaded with a 
seasonal influenza subunit vaccine (H3N2 A/Wisconsin strain). The polymersome’s 




evaporation method was used to produce the nanovesicles. The block copolymer 
was dissolved in tetrahydrofluran (THF) and the solution was quickly added to an 
aqueous phase, allowing the THF to evaporate in a couple of minutes. The PBLG50- K 
was shown to be assembled into polymersomes with an average size of 250 nm and 
a negative zeta potential. Then different amounts of vaccine (the purified viral 
membrane protein hemagglutinin (HA) were mixed with the NP, resulting in a raise 
of the average size and polydispersity. The physical association of HA and 
polymersomes in these aggregates was confirmed by transmission electron 
microscopy (TEM). The immune response induce by the polymersomes was 
investigated in vivo in a mouse model. The polymersomes succeeded to enhance 
significantly both total serum IgG and hemagglutination inhibition (HI) titers, 
compared to non-adjuvanted antigen. However, the polymersome formulation 
induced a high IgG1 response and a low IgG2a/c response, which is indicative of 
strong Th2 response, while the Th1 response was rather low.  
To optimize the efficacy of the peptide polymer NP toward a Th1 response, two 
major changes were introduced, as described in chapter 4: firstly, a new peptide 
polymer copolymer (PBLG30-TAT), based on the amino acid sequence derived from 
the cell-penetrating TAT peptide; second, an immune modulator (CpG) was 
encapsulated into the NP. After a comprehensive physicochemical characterization 
of these new systems, the immunogenicity was tested in vitro with human DC, and 
the formulations showed the ability to induce an upregulation of maturation 
markers (MHC-II and CD86) when codelivered with CpG (NP/HA+CpG). 
Furthermore, after intramuscular vaccination in mice, the NP/HA+CpG formulation 
elicited stronger HI titers compared to non-adjuvanted NP/HA and the Al(OH)3/HA 
control. Besides, NP/HA+CpG provoked significantly higher levels of IgG2 a/c 
antibodies compared to all other formulations. 
 
In chapter 5 & 6, cationic liposomes’ adjuvant mechanism was investigated, 
using HA as a model antigen. The different immunological effects induced by 
cationic liposomes, when they are used for vaccine formulation, suggest that not 
only their cationic charges initiate their adjuvant abilities by increasing antigen 
protection and delivery, but also that possible specific effect of the lipids or 
liposomes exist. However, previous studies used liposomes that are not directly 
comparable (e.g., due to the use of variable antigens, different administration routes, 
etc.). Therefore, in chapter 5 we studied how the content and the physicochemical 
properties of the positively charged compound influence the adjuvant effect of 
cationic liposomes. In order to enable the focus on the liposome content, we 
prepared cationic liposomes made of different cationic compounds (DDA, DPTAP, 
eDPPC ) but with similar physicochemical characteristics (size, zeta potential, 
bilayer rigidity, etc.), loaded via adsorption with HA. We also included DC-Chol 
based liposomes in our comparison, while recognizing that their characteristics will 
differ from the other cationic compounds with respect to both the head group and 




liposomes elicited significantly higher total anti-HA antibodies (IgG1 and IgG2a/c) 
and HI titers compared to the other liposomal HA formulations and non-adjuvanted 
HA. However, it was not clear whether the cholesterol backbone or the tertiary 
amine head group of DC-Chol was responsible for this. 
Therefore, in chapter 6 the influence of cholesterol in the lipid bilayer of cationic 
liposomes on the immunogenicity of adsorbed HA was studied. For this purpose, 
liposomes consisting of a neutral lipid (DPPC or cholesterol) and a cationic 
compound (DDA, or eDPPC) were produced and characterized. They generally 
showed comparable size distribution, zeta potential and HA loading. Furthermore, in 
vitro studies of the formulations with monocyte-derived human DC and 
immunization studies in C57BL/6 mice showed that the incorporation of cholesterol 
in the bilayer of cationic eDPPC liposomes enhances the cellular uptake and also 
their adjuvant effect in vivo. Moreover, to further improve the immunogenicity of 
HA-loaded DC-Chol liposomes, they were loaded with CpG or imiquimod. Whereas 
encaspulaton of imiquimod did not seem to have any impact on the immune 
response, encapsulation of CpG in DC-Chol liposomes enhanced significantly the 
IgG2 a/c titers against adsorbed HA compared to HA adsorbed to non-adjuvanted 
DC-Chol liposomes or Alhydrogel, and showed increased IFN-γ production by 
restimulated splenocytes. 
 
7.2 - Perspectives 
This thesis has set out to study the impact of nanoparticulate adjuvants on the 
immune response against the antigen, HA. In the next sections several important 
aspects of adjuvanted influenza vaccine design are discussed and recommendations 
for future development are provided. 
 
7.2.1 - Further investigation of the immune response induced by nanoparticulate 
adjuvanted influenza vaccines 
Several aspects concerning nanoparticulate influenza vaccine formulations have 
been studied in this thesis, in particular the characterization of the formulations and 
their immunological effects (in vitro and in vivo). The results obtained showed that 
both cationic liposomes and peptide polymer NP have good adjuvant properties, 
enabling the raise of the immune response against HA. Importantly, IgG2a/c 
antibodies were significantly raised when HA was formulated in NP (chapter 4 & 6), 
which reflects the induction of a Th1 response (confirmed by the increase in INFγ 
secretion), and likely a CTL response which is more efficient at eliminating influenza 
infected cells. In order to evaluate the protective effect our best formulations, a 




immunogenicity results in a better protection against influenza infection. Moreover, 
the dose-sparing ability of our adjuvant systems should be studied. 
Subunit influenza vaccines might be less efficient at inducing cell-mediated 
immunity normally induced by natural infections. Subunit influenza vaccines are 
“clean vaccines”, purified and with a low content of influenza nucleoproteins, and 
rich in HA protein which is the most variable region of the virus. However, if the 
vaccines induce a humoral and a cell-mediated immune responses directed to 
conserved regions of influenza virus, they are more likely to induce protective 
immunity to a large variety of influenza viruses, including drift variants and viruses 
of novel subtypes. For instance, MF59 can both improve the antibody 
responsiveness to influenza and redirect the quality of the antibody response 
against influenza antigens. This oil-in-water emulsion induced more cross reactive 
responses when administered with split or subunit H5N1 vaccines than non-
adjuvanted or aluminum-adjuvanted vaccines [1] [2]. Similarly, investigation of 
cross-reactive responses after immunization with our nanoparticulate influenza 
vaccines would be of high interest.  
 
Also, the preliminary DC maturation studies conducted on human monocyte-
derived DC suggest an immunostimulatory adjuvant effect of our formulations. 
Future experiments should be done to investigate whether the influence of these 
formulations on the immune response is the same in murine DC and in other animal 
models, along with toxicity studies (local and systemic). Additionally, more effort 
should be put to investigate the persistence of the immune response and to study 
the immunogenicity induced by other routes of immunization, especially the 
intradermal route. Intradermal vaccination, e.g. by using microneedle-mediated 
delivery, could also be an attractive alternative to intranasal immunization in the 
context of the potential induction of protective mucosal IgA. Nasal administration 
has been associated with adverse effects, such as the occurrence of Bell's palsy 
syndrome (facial nerve paralysis) induced by an adjuvanted virosomal vaccine after 
intranasal immunization in humans [3]. 
 
7.2.2 – Specific interaction between delivery systems with the influenza antigen 
The core of each vaccine formulation is the antigen. It is therefore not surprising 
that the rational design of a vaccine should be based on the characteristics of the 
antigen. The model antigen in this thesis is (HA) a viral membrane protein, which is 
water soluble and negatively charged at physiological pH. As noticed in the different 
in vivo studies conducted in this thesis, HA is immunogenic when injected alone, but 
it induces mainly IgG1 antibodies and moderate HI titers. As demonstrated in 
chapter 4 & 5, HA interaction with cationic liposomes and peptide polymer NP is 
driven by electrostatic forces. Moreover, the antigen’s lipophilic domains may profit 




the liposomal bilayer, thereby mimicking more closely the natural way these 
antigens are presented to the immune system. Cryo-TEM characterization of the 
liposomes produced could help understand if the positioning of HA could contribute 
to the differences observed between our formulations. Interestingly, in Chapter 3 
the interaction of HA with the peptide polymer NPs showed that HA/polymersome 
association was presumably a combination of both electrostatic and hydrophobic 
interactions, arising from the hydrophobic membrane-anchoring domain of the HA, 
the localized charge on the HA, and the charged corona of the polymersomes. 
Moreover, the action of HA is not limited to its immunogenic properties. 
Following endosomal uptake, acidification within the endosomes induces HA-
mediated fusion (resulting from a conformational change in HA), which likely leads 
to release of the liposomes or peptide polymer NP into the cytoplasm and a potential 
MHC class I presentation. Therefore, even though this was not investigated in this 
thesis, it may be that HA itself enhances its own delivery into the cells, leading a 
potent immune response. 
7.2.3 – Need for a better understanding of the NP’s adjuvant mechanisms 
The immunogenicity of HA was notably improved by the use of DC-Chol 
liposomes. Although the presence of cholesterol does induce specific interaction of 
the liposome with the biological systems, it remains unknown whether the presence 
of the cholesterol backbone was also the reason for the superior immunogenicity of 
HA/DC-Chol:DPPC liposomes and, if so, by which mechanism. In Chapter 5, the use 
of DC-Chol liposomes loaded with HA in a mouse model increased the antibody 
responses, both the IgG1 and IgG2 a/c antibody responses, which is consistent with 
the results obtained in previous studies where DC-Chol lipids administered with 
hepatitis B surface antigen [6] or monovalent split inactivated influenza vaccine 
(H1N1) resulted in improved immune responses in animal models [7].  
Studies to elucidate the mechanisms by which DC-Chol liposomes act as 
adjuvants have suggested a role for the chemokine CCL2, secreted by epithelial cells 
and involved in Langerhans cell recruitment [8] and complement activation [9]. 
Another mechanism may be the ability of DC-Chol liposomes to associate with 
antigen and initiate a depot-effect [10]. The raise of chemokine secretion probably 
leads to DC migration and local inflammation. It would be interesting to study the 
role of plain DC-Chol liposomes, by injecting separately the liposomes and the 
antigen at the same site of injection, which should preclude the antigen depot effect 
and enable the monitoring of the potential recruitment of the APCs and 
macrophages, and the activation of the NLRP3 inflammasome pathway. Finally, 
despite the concern about eventual cytotoxicity of cationic liposomes, DC-
cholesterol has already been tested in the clinic with an HIV recombinant gp160 






Following the work achieved in this thesis, the future of the peptide polymer NP 
as adjuvant system shou 
 
ld be addressed. Our studies showed some efficacy for their use in vaccine 
formulations with strong adjuvant and vaccine carrier abilities, allowing co-delivery 
of the antigen with a TLR -9 ligand (CpG). Insights into the liposome adjuvant 
mechanism could partially be extended to these new systems, which could notably 
be explained by a depot effect. However, more investigations should be carried out 
in order to get a better understanding of their adjuvant mechanism, and the 
influence of the formulation. Different immune stimulators could be either added or 
incorporated to further enhance the immunogenicity. Since vesicles composed of 
polypeptide-b-designed peptides can be easily functionalized, it is expected that 
these peptide-based NP will be able to act as delivery vehicles to specific targets in 
the body. Furthermore, their peptide sequence could be designed to modulate the 
immune response. For instance, the IC31® adjuvant [12], currently in phase II 
clinical trials, is based on the cationic peptide KLKL5KLK with successful results 
with the tuberculosis antigen Ag85B [13] [14]. 
 
Finally, an ideal vaccine should contain a sufficient amount of immune 
modulators for the activation of the innate immune response and alert the immune 
system, but at the same time without causing hyper-immunostimulation (which may 
result in anaphylactic shock or local tissue damage by excess of inflammatory 
mediators). The immune modulator(s) should also stay associated with the antigen 
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De beste vorm van bescherming tegen griep is vaccinatie, zowel qua effectiviteit om 
individuen te beschermen als qua vermindering van de sociale gevolgen van een 
epidemie op onze samenleving. Hoofdstuk 1 van dit proefschrift beschrijft de 
huidige verkrijgbare griepvaccins en hun gebrek aan doeltreffendheid, en de huidige 
vraag naar nieuwe op adjuvantia gebaseerde formuleringen voor griepvaccins. 
Ziekteverwekkers zoals griepvirussen kunnen beschouwd worden als deeltjes. Het 
formuleren van antigenen in nanodeeltjes resulteert in systemen die 
ziekteverwekkers nabootsen wat betreft grootte en die bovendien de opname van 
antigenen door dendritische cellen (DCs) kunnen bevorderen. Het voornaamste doel 
van het in dit proefschrift beschreven onderzoek was er achter te komen hoe 
nanodeeltjessystemen kunnen fungeren als een adjuvans voor subunit-griepvaccins 
(d.w.z. griepvaccins die gebaseerd zijn op onderdelen, subunits, van het griepvirus). 
Hiertoe werden twee soorten nanodeeltjes onderzocht: op polypeptide gebaseerde 
nanodeeltjes en kationische liposomen. Er werden drie sub-doelen gedefinieerd: 
• het ontwerpen van verschillende nanodeeltjessystemen om de 
immunogeniciteit van een subunit-griepvaccin te moduleren; 
• het bestuderen van de gevolgen van de samenstelling, lading en 
bereidingsmethode van deze systemen op hun adjuvanseffect; 
• het onderzoeken van de gecombineerde toediening van het gezuiverde 
virale membraaneiwit hemagglutinine (HA) en immuunmodulatoren, 
verpakt in nanodeeltjessystemen. 
 
Als eerste werd de potentie van op polypeptide gebaseerde nanodeeltjes als 
adjuvans voor een vaccin tegen seizoensgebonden griep bestudeerd (hoofdstuk 2-
4). Hiertoe werd gebruikgemaakt van poly(-benzyl L-glutamaat)-E (PBLG-E), de 
eerste van een nieuwe klasse van peptiden: de polypeptide-blok-peptiden. Deze 
verbindingen zijn veelzijdig wat betreft hun ketenlengte en functionaliteit. Er zijn 
verschillende methoden beschikbaar om nanodeeltjes die op polypeptiden 
gebaseerd zijn te produceren, maar elk van hen heeft beperkingen en is mogelijk 
niet geschikt voor de toediening van vaccins. Daarom hebben we een nieuwe 
methode ontwikkeld voor het produceren van nanoblaasjes (ook bekend als 
polymeersomen) uit polypeptide-blok-peptiden PBLG36-E (waarbij het getal 36 het 
gemiddeld aantal benzyl L-glutamaat-residuen per  PBLG-E molecuul weergeeft), 
gebruikmakend van een detergens- verwijderingsmethode die al vele tientallen 
jaren gebruikt wordt om liposomen te produceren (hoofdstuk 2). De methode werd 
aangepast voor PBLG-E, dat andere assemblage-eigenschappen heeft dan lipiden. De 
op detergens gebaseerde polymeersoombereiding maakt gebruik van 
detergensmoleculen (natriumcholaat) die het PBLG-E solubiliseren in een waterige 




Tijdens de verwijdering van het detergens wordt het solubilisatie-effect verminderd 
waardoor de PBLG-E moleculen zich organiseren in polymeersomen. Deze methode 
heeft als voordeel dat er geen organisch oplosmiddel of hoge energie (zoals bij 
sonicatie) aan te pas komt – factoren waarvan bekend is dat ze biomoleculen 
kunnen denatureren. 
Hoofdstuk 3 beschrijft een studie van het adjuvanseffect van polymeersomen 
beladen met een subunitvaccin tegen seizoensgebonden griep (HA afkomstig van de 
H3N2 A/Wisconsin-stam). Het bouwmateriaal voor de polymeersomen was het 
PBLG50-K polypeptide-blok-peptide en de watertoevoegings-
oplosmiddelverdampingsmethode werd gebruikt om de polymeersomen te 
produceren. Het PBLG50-K werd opgelost in tetrahydrofuraan (THF) en de oplossing 
werd snel toegevoegd aan een waterige oplossing, zodat de THF binnen enkele 
minuten verdampte en polymeersomen met een gemiddelde diameter van 250 nm 
en een negatieve zeta-potentiaal gevormd werden. Vervolgens werden verschillende 
hoeveelheden van het antigeen (HA) gemengd met de nanodeeltjes, resulterend in 
een verhoging van de gemiddelde grootte en polydispersiteit. De fysieke associatie 
van HA en polymeersomen werd bevestigd door transmissie-elektronenmicroscopie 
(TEM). De door de polymeersomen geïnduceerde immuunrespons werd onderzocht 
in een muismodel. De polymeersomen slaagden erin om zowel de totale serum igG- 
als de hemagglutinatie-inhibitie (HI)-titers significant te verhogen ten opzichte van 
antigeen zonder adjuvans. De polymeersoomformulering induceerde echter een 
hoge IgG1-respons en een lage IgG2a/c-respons, wat op een sterke Th2-respons 
duidt, terwijl de Th1-respons vrij laag was. 
Om de werkzaamheid van de op polypeptiden gebaseerde nanodeeltjes richting een 
Th1-respons te optimaliseren werden twee belangrijke veranderingen doorgevoerd, 
zoals beschreven in hoofdstuk 4: ten eerste werd een nieuw polypeptide-blok-
peptide (PBLG30-TAT) ontwikkeld, gebaseerd op de aminozuurvolgorde afgeleid van 
het celpenetrerende TAT-peptide; ten tweede werd een immuunmodulator (CpG) 
verpakt in de nanodeeltjes. Na een uitgebreide fysisch-chemische karakterisering 
van deze nieuwe systemen werd de immunogeniciteit in vitro getest in menselijke 
DCs, waaruit bleek dat de formuleringen een verhoogde afgifte van 
maturatiemarkers (MHC-II en CD86) konden induceren wanneer ze samen met CpG 
werden toegediend (nanodeeltjes/HA+CpG). Verder induceerde de 
nanodeeltjes/HA+CpG formulering na intramusculaire toediening aan muizen 
sterkere HI-titers in vergelijking met nanodeeltjes/HA zonder adjuvans en HA 
geadjuveerd met Alhydrogel [Al(OH)3]. Daarnaast wekte de nanodeeltjes/HA+CpG 
formulering aanzienlijk meer IgG2a/c-antilichamen op dan alle andere 
formuleringen, hetgeen wijst op een verhoogde Th1-respons. 
 
Hoofdstukken 5 & 6 beschrijven het onderzoek naar het adjuvansmechanisme van 
kationische liposomen, waarbij HA als modelantigeen werd gebruikt. De 
verschillende door kationische liposomen geïnduceerde immunologische effecten 




ten grondslag ligt aan hun werking als adjuvans. In eerdere studies werden echter 
liposomen gebruikt die onderling niet direct vergelijkbaar waren (door gebruik van 
verschillende antigenen, andere toedieningsroutes, etc.). Daarom bestudeerden we 
hoe de samenstelling en fysisch-chemische eigenschappen van de positief geladen 
component het adjuvanseffect van kationische liposomen beïnvloedt (hoofdstuk 5). 
Om de invloed van de liposoomsamenstelling te onderzoeken werden kationische 
liposomen bereid met verschillende kationische componenten (DDA, DPTAP, 
eDPPC) maar met vergelijkbare fysisch-chemische eigenschappen (grootte, zeta-
potentiaal, vloeibaarheid van de bilaag). De liposomen werden beladen met HA door 
middel van adsorptie. We namen op DC-Chol gebaseerde liposomen ook op in onze 
vergelijking, erkennende dat de eigenschappen van DC-Chol verschillen van die van 
de andere kationische componenten wat betreft zowel de hydrofiele kopgroep als de 
waterafstotende steroïdstructuur. HA met de DC-Chol/DPPC-liposomen als adjuvans 
wekte significant hogere totale anti-HA-antilichamen- (IgG1 en IgG2a/c) en HI-titers 
op in een muismodel dan de andere liposomale HA-formuleringen en HA zonder 
adjuvans. Het was echter niet duidelijk of de waterafstotende steroïdstructuur of de 
tertiaire amine-kopgroep van DC-Chol hiervoor verantwoordelijk was. 
Daarom werd de invloed van cholesterol in de bilaag van kationische liposomen op 
de immunogeniciteit van geadsorbeerd HA bestudeerd (hoofdstuk 6). Hiertoe 
werden liposomen bestaande uit neutrale lipiden (DPPC of cholesterol) en 
kationische componenten (DDA of eDPPC) bereid en gekarakteriseerd. Over het 
algemeen lieten ze een vergelijkbare grootteverdeling, zeta-potentiaal en HA-
belading zien. Verder lieten in vitro studies met monocyt-afgeleide menselijke DCs 
en immunisatiestudies in C57BL/6-muizen zien dat de incorporatie van cholesterol 
in de bilaag van kationische eDPPC-liposomen de cellulaire opname en ook hun 
adjuvanseffect in vivo verhoogt. Om de immunogeniciteit van HA-beladen DC-Chol-
liposomen verder te verbeteren, werden ze bovendien beladen met CpG of 
imiquimod. Waar belading met imiquimod geen invloed op de immuunrespons leek 
te hebben, verbeterde de verpakking van CpG in DC-Chol-liposomen aanzienlijk de 
IgG2a/c-titers tegen geadsorbeerd HA in vergelijking met HA geadsorbeerd aan DC-
Chol-liposomen zonder adjuvans of HA geformuleerd met Alhydrogel. Bovendien liet 








1H-NMR, 1H Nuclear magnetic resonance 
ANOVA, Analysis of variance 
APC, Antigen-presenting cell 
BCA, Bicinchoninic acid protein assay 
BSA, Bovine serum albumin 
Chol, Cholesterol 
CMC, Critical micelle concentration 
Con A, Concanavalin A 
CpG, Cytosine phosphodiester guanine oligomer 
CTL, Cytotoxic T lymphocyte 
DC, Dendritic cell 
DC-Chol, Dimethylaminoethane-carbomyl cholesterol 
DCM, Dichloromethane 
DDA Dimethyldioctadecylammonium bromide 
Dh, Hydrodynamic diameter 
DLS, Dynamic light scattering 
DMEM, Dulbecco’s minimum essential medium 
DMF, Dimethylformamide  
DMF, N,N Dimethylformamide 
DMPG, Dimyristoyl-phospoglycerol 
DMSO, Dimethyl sulfoxide  




DSC, Differential scanning calorimetry  
E, Glutamic acid 
eDOPC, Dioleoyl-glycero-ethylphosphocholine 
eDPPC, Dipalmitoyl-glycero-ethylphosphocholine 
ELISA, Enzyme-linked immunosorbent assay 
EM, Electron microscopy 
FACS, Fluorescence-activated cell sorting 
FCS, Fetal calf serum  
FITC, Fluorescein isothiocyanate 
Fmoc, Fluorenylmethoxycarbonyl 
G, Glycine 
GM-CSF, Granulocyte-macrophage colony-sitmulating factor 
GPC, Gel permeation chromatography 
HA, Hemagglutinin 




HEPES, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid 
HI, Hemagglutination inhibition  
HPLC,High-performance liquid chromatography  
HRP, Horseradish peroxidase 
I, Isoleucine 
IgG, Immunoglobulin G 
IL, Interleukin 
INFɣ, Interferon gamma 
K, Lysine 
L, Leucine 
LC-MS, Liquid chromatography–mass spectrometry 
LPS, Lipopolysaccharide 
MALDI-TOF, Matrix-assisted laser desorption-ionization time-of-flight 
MHC I/II, Major histocompatibility complex class I/II 
MPL, Monophosphoryl lipid A 
MS, Mass spectrometry 
MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NA, Neuraminidase 
NCA, N-carboxyanhydride 
NMP, Nitroxide-mediated polymerization 
NP, Nanoparticle 
O/W, Oil-in-water (emulsion) 
OVA, Ovalbumin 
PAMP, Pathogen associated molecular pattern 
PBLG, poly(ɣ-benzyl L-glutamate) 
PbP-A, polypeptide-b-peptide amphiphile 
PBS, Phosphate buffered saline 
PC, Phosphatidyl choline 
PDI, Polydispersity index 
PEG, Poly(ethylene glycol) 
PRR, Pattern recognition receptor 
PTA, Phosphotungstic acid 
R, Arginine 
RNA, Ribonucleic acid 
ROP, Ring-opening polymerization 
RP-HPLC, Reversed-phase high-pressure liquid chromatography 
S, Serine 
s.c, Subcutaneous 
SEM, Scanning electron microscopy 
TCR, T cell receptor 
TDB, Trehalose 6,6’-dibehenate 
TEM, Transmission electron microscopy 




Tg, Glass transition temperature 
Th, T helper cell 
THF, Tetrahydrofuran 
TLR, Toll like receptor 




WIV, Whole inactivated virus 
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